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 Hybrid nanomaterials composed of synthetic and biological building blocks 
possess high potential for the design of nanomedicines. We propose a new therapeutic 
approach that mimics the mechanism of immune effector cells to crosslink surface 
receptors of target cells and induce apoptosis. The receptor crosslinking is mediated by 
biorecognition of high-fidelity natural binding motifs (antibody fragments or 
oligonucleotides) that are grafted to the side chains of synthetic polymers. This approach 
features the absence of low-molecular-weight cytotoxic compounds. Thus, we name it 
“drug-free macromolecular therapeutics.” 
 This dissertation describes the development and preclinical evaluation of two 
drug-free macromolecular therapeutic platforms. The designed therapeutics were tested 
against B-cell malignancies that highly express the surface antigen CD20. 
 In the first design,	   a multivalent conjugate comprising high-molecular-weight, 
linear copolymer of N-(2-hydroxypropyl)methacrylamide (HPMA) grafted with multiple 
Fab' fragments of an anti-CD20 antibody was synthesized. Exposure of human non-
Hodgkin lymphoma (NHL) Raji B-cells to the multivalent construct resulted in 
crosslinking of CD20 receptors and commencement of apoptosis. 
 In the second design, two hybrid conjugates were produced: (1) an anti-CD20 
Fab' attached to an oligonucleotide1, and (2) a linear HPMA copolymer grafted with 
multiple complementary oligonucleotide2. We showed that the two conjugates self-
	  iv 
assembled via oligonucleotide hybridization at the surface of CD20+ B-cells, which 
crosslinked CD20 antigens and initiated apoptosis. When tested in a mouse xenograft 
model, the two conjugates, either administered consecutively or as a premixture, 
eradicated Raji cells and produced long-term survivors. 
 The consecutive administration approach was chosen for further studies where a 
two-step pretargeting strategy was employed. We showed that the time lag between 
administering the two conjugates can be optimized based on pharmacokinetics and 
biodistribution of the Fab'-oligonucleotide1 conjugate. Using the optimized treatment 
regimen, the designed nanomedicine achieved superior anti-lymphoma efficacy to 
rituximab, a clinically used drug for NHL. We also evaluated the nanomedicine in patient 
mantle cell lymphoma and chronic lymphocytic leukemia cells. The treatment 
demonstrated potent apoptosis-inducing activity. 
 In summary, we have developed novel nanotherapeutics that may constitute 
potent treatments for NHL and other B-cell malignancies. The verified concept can be 
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 Macromolecular therapeutics, also referred to as polymeric nanomedicines, are a 
diverse group of drugs characterized by their large molecular weight (MW), including 
polymer-drug conjugates, polymeric micelles, polymer-modified liposomes, etc. The 
advantages of macromolecular therapeutics when compared to low-molecular-weight 
compounds are reviewed elsewhere.1–3 In particular, water-soluble polymeric drugs (MW 
> 40 kDa)	  attain prolonged plasma half-lives and achieve tumoritropic accumulation due 
to the enhanced permeability and retention (EPR) effect.4,5 Conventional polymeric 
nanomedicines utilize polymers as delivery vehicles to carry anticancer therapeutic 
agents. Many of these approaches are under clinical development.6–12 Increasingly the 
role of nanomedicine is not only to deliver a given drug to diseased tissues efficiently but 
also to trigger or improve therapeutic effects through innate biological responses.13,14 The 
design of macromolecular therapeutics has extended towards a unique paradigm where 
biomimetic strategies are employed to incite or control specific cellular activities.15–17 For 
instance, receptor coupling (or clustering) can be used to sensitize diseased tissues to a 
therapeutic agent.18–21 In this dissertation, we describe a novel paradigm in the 
1This chapter is adapted from the following publication: T.-W. Chu and J. Kopeček. Drug-free 
macromolecular therapeutics – a new paradigm in polymeric nanomedicines. Biomater Sci.	  2015; 3(7): 
908–922. Adapted by permission of The Royal Society of Chemistry. 
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nanomedicine research area – drug-free macromolecular therapeutics. This approach was 
firstly proposed by our laboratory in 2010.21 The basic idea is to induce apoptosis by 
crosslinking of cell-surface noninternalizing receptors mediated by the biorecognition of 
high-fidelity natural binding motifs, such as antiparallel coiled-coil peptides or 
complementary oligonucleotides. The general design concept of drug-free 
macromolecular therapeutics is shown in Figure 1.1. An important feature of these 
designs is the absence of low-molecular-weight cytotoxic compounds (thus named “drug-
free”). This chapter introduces recent developments in this exciting new area, which 
mainly includes research performed in our laboratory using B-cell malignancies as a 
disease model and the CD20 receptor as a pharmacological target, as well as relevant 
approaches reported by other researchers. 
 
1.1 B-Cell Lymphoma and CD20 
 Non-Hodgkin’s lymphoma (NHL) is a prevalent cancer with over a half-million 
individuals having a history in the United States and an estimated 70,800 new cases 
diagnosed in 2014.22 Over the past 3 decades, the incidence of NHL has continuously 
increased (doubled since 1980). NHL has a high mortality rate; from 2006 to 2010, there 
were 18,990 deaths for every 100,000 patients in the U.S.22 The disease is comprised of a 
diverse and heterogeneous group of lymphatic malignancies, which makes the treatment 
challenging. About 85% of NHLs are cancers originating from B-cells; the remaining 
diseases are mostly of T-cell origin.23 This dissertation focuses mainly on designs and 
developments of novel therapeutics against B-cell lymphomas (or B-NHLs), including 
Burkitt’s, diffuse large B-cell, follicular, immunoblastic large cell, precursor B-
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lymphoblastic, and mantle cell lymphomas. These malignancies are generally classified 
as either indolent or aggressive, which then dictates the type of therapy the patient may 
receive.23,24 Besides conventional chemotherapy and radiotherapy, which are usually 
accompanied by severe adverse reactions, monoclonal antibodies (mAbs) targeted to the 
B-cell surface antigen CD20 have become common treatments.25 Such 
“immunotherapies” have revolutionized the field. The current standard of B-NHL 
treatment is rituximab (the most commonly used anti-CD20 mAb) in combination with 
chemotherapy.26,27 However, large populations of patients exist who do not respond or 
develop resistance to these therapies. For example, the overall response rates for the 
treatment of relapsed/refractory low-grade or follicular NHL typically ranged from 40 to 
50% (complete response 6, 3, 17, 3, and 14%; overall response 48, 46, 47, 39, and 43% in 
five different clinical trials).28 The nonresponsiveness and/or resistance have been 
attributed to the inability of immune effector cells (e.g., macrophages, natural killer cells) 
to hypercrosslink ligated mAbs,29,30 and Fc receptor (FcR)-mediated endocytosis31 or 
“trogocytosis”32 of CD20 antigens. These clinical obstacles create the need for new, 
improved therapeutic strategies. 
 CD20 is a 35–37 kDa integral membrane protein highly expressed on more than 
95% of B-cell lymphomas.33,34 Free CD20 antigen is not present in serum, and there is no 
known natural ligand of CD20. When bound by antibodies, CD20 has a very low 
intracellular internalization rate;35,36 it is often considered a noninternalizing receptor. 
Studies suggest that CD20 functions as a store-operated calcium channel and a cell cycle 
regulator.37–39 It is one of the most reliable biomarkers of B-lymphocytes, thus providing 
an ideal target for treatment of B-NHL.23,24 CD20 is also expressed on normal B-cells; 
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however, it is not expressed on stem cells or progenitor cells and mature or activated 
plasma cells.33 Therefore, the “B-cell depletion” therapeutic approach is considered safe; 
normal numbers of B-cells can be restored after treatment.25–27 The therapeutic efficacy 
of anti-CD20 mAbs is ascribed to three cellular events: antibody-dependent cellular 
cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and CD20-mediated 
apoptosis.40–42 All of these mechanisms require immune effector cells to function.41 In 
contrast, drug-free macromolecular therapeutics trigger direct and specific apoptosis of 
B-cell lymphomas without the help of effector cells. This is achieved by the design of 
synthetic effectors that reproduce the function of immune effector cells. The advantages 
of such an approach will be further discussed in this dissertation. 
 
1.2 Receptor Crosslinking and Apoptosis 
 Cell receptor clustering (crosslinking) is a natural process and driving force for 
numerous biological responses. For instance, the following cellular events have been 
reported to result from receptor clustering: hormone uptake,43 cell adhesion,44 cell 
activation45 and apoptosis.42,46 In particular, crosslinking of the surface antigen CD20 
induces apoptosis of B-cells. Research has shown that when CD20-bound antibodies are 
hypercrosslinked by FcR-expressing immune effector cells (or polyclonal secondary 
antibodies), CD20 receptors tend to cluster as dimers or tetramers, redistribute and 
become localized into lipid rafts.47 Such events mediate the interaction between clustered 
CD20 and Src-family kinases (which are also located in lipid rafts), and trigger apoptotic 
signaling.48,49 Without the hypercrosslinking, apoptosis initiated by ligated mAbs is 
limited.50–52 These mechanistic studies warranted various earlier designs of multivalent 
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mAb constructs. For example, Ghetie et al. synthesized a homodimer of rituximab by 
using a heterobifunctional crosslinker and showed that the mAb dimer potentiated 
apoptosis in human B-cell lymphomas, which synergized with a chemotherapeutic agent 
and an immunotoxin.51 Rossi et al. produced a hexavalent anti-CD20 antibody by 
covalently assembling 6 Fab' to 1 Fc.53 Anti-lymphoma efficacy of this hexavalent 
construct in mouse xenografts was comparable to that of the monovalent mAb, but it was 
independent of effector mechanisms such as CDC. Stein et al. used a monomeric Ab that 
lacks effector cell functions hypercrosslinked by a secondary Ab to specifically facilitate 
apoptosis.54 These previous research studies showed that approaches aimed at direct 
apoptosis induction via cell surface receptor clustering are becoming attractive. 
 
1.3 Origin of Drug-Free Macromolecular Therapeutics 
 The initial design of	  drug-free macromolecular therapeutics was inspired by our 
previous work on hybrid hydrogels self-assembled from synthetic polymers and coiled-
coil protein domains. We developed “smart” biomaterials composed of N-(2-
hydroxypropyl)methacrylamide (HPMA) copolymers grafted with biorecognition 
domains.55–58 The biorecognition	   of complementary grafts resulted in physical 
crosslinking of polymer chains and formation of 3D networks (hydrogels). In particular, a 
pair of oppositely charged pentaheptad peptides (CCE and CCK) that form antiparallel 
coiled-coil heterodimers were designed (Figure 1.2). Multiple copies of CCE or CCK 
were grafted to the HPMA polymer (P) backbones to produce P-(CCE)x and P-(CCK)y, 
respectively. Equimolar mixtures of P-(CCE)x and P-(CCK)y solutions self-assembled 
into hydrogels where the coiled-coil peptides served as macromolecular physical 
	  	  
6 
crosslinkers.58,59 The excellent CCE/CCK biorecognition was also employed by Lv et al. 
for the development of tandem modular protein-based hydrogels.60 On the other hand, our 
laboratory pioneered the design of HPMA copolymers as anticancer drug carriers,61,62 
which led to the development of PK1 (HPMA copolymer–doxorubicin conjugate), the 
first polymeric drug that entered clinical trials.63 HPMA copolymers are water-soluble,	  
biocompatible, and long circulating in the bloodstream.3,64 They have flexible (random-
coil) conformation in aqueous solutions; thus, targeting moieties or biorecognition motifs 
that are grafted to the side chains can be effectively presented.65 Based on these 
studies58,59 and the above-mentioned mechanism of receptor clustering mediated 
apoptosis, we hypothesized that the unique biorecognition of the CCE/CCK peptide 
motifs could be used to crosslink not only polymer chains but also cell surface receptors 
(e.g., CD20) to induce apoptosis of target cells (e.g., B-cell). Such an application of 
hybrid materials to biological systems to mediate specific cellular events (i.e., apoptosis) 
provides a bridge between the designs of functional biomaterials and novel 
nanomedicines. 
 Due to the specific intermolecular interactions and the high degree of structural 
control based on primary sequences, coiled-coil peptides have become attractive as a 
building block for nanomedicine design.66–68 Our laboratory pioneered the development 
of drug-free macromolecular therapeutics, which employed the coiled-coil forming 
peptides CCE and CCK as the biorecognition motif.21 Two macromolecular conjugates 
were synthesized: (1) CCE tethered to a Fab' fragment of an anti-CD20 mAb (Fab'-CCE); 
(2) an HPMA copolymer grafted with multiple CCK peptides (P-(CCK)y). Exposure of a 
CD20+ human B-NHL cell line (Raji) to the Fab'-CCE conjugate first decorated the cell 
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surfaces with CCE. Further treatment of the decorated cells with P-(CCK)y resulted in 
formation of antiparallel coiled-coils at cell surfaces, which crosslinked CD20 receptors 
and induced apoptosis. This concept has been successfully proven by Wu et al.21,69 In 
vitro apoptosis induction of Raji B-cells was achieved after co-treatment with Fab'-CCE 
and P-(CCK)y, either consecutively or as a premixture.21 In vivo anticancer efficacy was 
evaluated in mice bearing systemically disseminated B-cell NHL.69 Both the consecutive 
and the premixed treatments were able to eradicate lymphoma cells in the blood and in 
the bone marrow, which produced long-term survivors. 
 The biorecognition of the coiled-coil forming oligopeptides, CCE and CCK, in 
the “drug-free” system functioned well to induce cell apoptosis. However, to achieve a 
strong anticancer effect (produce tumor-free long-term survivors), we used a 1:25 molar 
ratio of CCE equivalent (in Fab'-CCE) to CCK equivalent (in P-(CCK)9).69 This is 
because the individual peptide sequences (CCE and CCK) do not have a pronounced 
secondary structure at pH 7 and are in a random coil conformation.58 Binding of 
oligopeptides to macromolecules increases their secondary structure only slightly.58,70 
Consequently, Fab'-CCE and P-(CCK)y interact first via hydrophobic and electrostatic 
interactions, and then the oligopeptides fold into a strong antiparallel coiled-coil 
heterodimer. Such relatively complex binding pattern likely results in inadequate 
interaction of polymer conjugates with Fab' conjugates when administered at the 1:1 
molar ratio condition. Therefore, in order to design improved therapeutic systems, it is 
essential to identify a biorecognition pair that possess a more direct and efficient binding 




1.4 Nucleic Acid Hybridization and Morpholino Oligonucleotide 
 Nucleic acid hybridization is a crucial biorecognition event in life. A DNA double 
helix is composed of Watson-Crick base paring, i.e., hydrogen bonding of A/T and C/G, 
between two single-stranded polynucleotides with complementary sequences. The 
conformation is further stabilized by base stacking, i.e., π-π interaction of neighboring 
bases on the same strand. Such a self-recognition property plays the central role for 
coding, storing and transferring of genetic information; it possesses a high fidelity 
feature. Since early 1980s, DNA has been used as building blocks for biomaterials 
design,71,72 and more recently, functional nanostructures for drug delivery.73,74 In 
particular, hybrid materials comprising oligonucleotides and synthetic polymers can be 
utilized to fabricate nanoconstructs with precise geometry and versatile functionality.75–77 
 Over the years, a variety of artificial oligonucleotides with chemically modified 
backbones have been synthesized.78 These nonphosphodiester backbones are nuclease 
resistant and stable in the body; thus, they are suitable for biopharmaceutical applications. 
We decided to pursue phosphorodiamidate morpholino (MORF) oligomers as the 
biorecognition motifs for the second-generation “drug-free” therapeutic design. The 
MORF oligos are charge neutral, resulting in significantly stronger binding than natural 
DNA and RNA.79 Hybridization of MORF pairs has well-defined binding specificity, 
which prevents potential off-target effects.80,81 In addition, MORF oligos have good 
aqueous solubility and favorable pharmacokinetics.82,83 Their base sequence can be 
designed to achieve optimal binding efficiency and minimal off-targets with human and 
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Figure 1.1  Drug-free macromolecular therapeutics for apoptosis induction. Crosslinking 
of cell surface noninternalizing receptors is mediated by the biorecognition of natural 
binding motifs. Two hybrid conjugates can be administered consecutively as pretargeting 










Figure 1.2  Helical wheel diagram of the CCE/CCK coiled-coil antiparallel heterodimer. 
The heptad repeat of each peptide is labeled a–f. Both CCE and CCK were modified with 
a YGG peptide spacer (to prevent steric hindrance of binding after grafted to polymer 







ANTI-CD20 MULTIVALENT HPMA COPOLYMER – FAB'  





 In this chapter, a hybrid biomimetic system comprising high-molecular-weight, 
linear copolymer of N-(2-hydroxypropyl)methacrylamide (HPMA) grafted with multiple 
Fab' fragments of anti-CD20 monoclonal antibody (mAb) was synthesized by reversible 
addition-fragmentation chain transfer (RAFT) polymerization followed by attachment of 
Fab' fragments via thioether bonds. Exposure of human non-Hodgkin’s lymphoma (NHL) 
Raji B-cells to the multivalent conjugates resulted in crosslinking of CD20 receptors and 
commencement of apoptosis. Five conjugates with varying molecular weight and valence 
(amount of Fab' per polymer chain) were synthesized. One of the copolymers contained 
enzyme degradable peptide sequences (GFLG) in the backbone. The multivalency led to 
higher avidity and apoptosis induction compared to unconjugated whole mAb. Time-
dependent studies showed that the cytotoxicity of conjugates exhibited a slower onset at 
shorter exposure times than mAb hyper-crosslinked with a secondary Ab; however, at 
longer time intervals the HPMA copolymer conjugates achieved significantly higher
1This chapter is adapted from the following publication: T.-W. Chu, J. Yang and J. Kopeček.           
Anti-CD20 multivalent HPMA copolymer – Fab' conjugates for the direct induction of apoptosis. 
Biomaterials. 2012; 33(29): 7174–7181. Elsevier. 
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biological efficacies. In addition, study of the relationship between the structure of 
conjugates and Raji B-cell apoptosis revealed that both valency and polymer molecular 
weight influenced biological activities, while insertion of peptide sequences into the 
backbone was not a factor in vitro. 
 
2.1 Background 
 The use of hybrid biomaterials composed of synthetic and biological 
macromolecules to design “smart” nanomedicines is an emerging field.1,2 The goals 
include precise targeting to diseased sites, enhancing therapeutic efficiency, reducing 
adverse effects, and minimizing drug resistance. In particular, water-soluble HPMA 
copolymers are extensively used as delivery vehicles to conjugate anticancer therapeutic 
agents (e.g., small molecule drugs) and targeting moieties (e.g., antibodies).3 HPMA 
polymer and copolymers have favorable physicochemical and pharmacokinetic properties 
to provide a well-defined safety profile, increase circulation half-life of therapeutics, and 
provide a flexible (random coil) conformation of the polymer backbone in solution.4 The 
design of macromolecular therapeutics has extended towards a unique paradigm where 
biomimetic strategies are used to trigger specific responses or facilitate therapeutic 
efficiency through innate biological processes.1,3,5,6 For instance, an HPMA-based hybrid 
system has been used as a “drug-free” macromolecular platform to induce apoptosis via 
biorecognition and receptor crosslinking at the cell surface; a clinically relevant 
therapeutic efficacy was demonstrated in vitro6 and in vivo7. 
 Non-Hodgkin’s lymphoma (NHL) is a prevalent cancer in the United States with 
a history of over a half-million incidences and projected 70,130 new cases diagnosed in 
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2012.8 Because about 85% of NHL is of B-cell origin and more than 95% of B-
lymphomas bear the CD20 surface antigen,9 immunotherapies using anti-CD20 
monoclonal antibodies (mAb) have revolutionized the treatment of NHL.10 However, the 
overall response levels to clinically used mAb, mainly rituximab (Rituxan®), for 
treatments of relapsed/refractory low-grade or follicular NHLs are less than 50%.11 Rare 
but lethal side effects such as progressive multifocal leukoencephalopathy (PML) and 
lung injuries observed in patients treated with rituximab or other anti-CD20 mAb also 
raised biocompatibility concerns.12–15 Therefore, new therapeutic strategies are needed. 
 The clinical nonresponsiveness and adverse effects of rituximab or other 
therapeutic mAb has been partly attributed to Fc fragment-related biological events.14,16–
18 The inactivity of effector cells to hyper-crosslink bound rituximab on B-cell surface via 
Fc results in failure of antibody-dependent cellular cytotoxicity (ADCC) and 
complement-dependent cytotoxicity (CDC), the main thrusts of anti-CD20 mAb’s 
therapeutic effect.16,18–20 In addition, Fc-mediated cellular events such as complement 
activation or the surge release of tumor necrosis factor-α (TNFα) upon mAb infusion are 
related to the severe side effects.12,14,17 Consequently, approaches aiming at direct 
apoptosis induction through cell surface receptor clustering are becoming attractive.21–25 
In these previous studies, either multimeric Abs covalently linked to each other,24,25 
bound to dextran,22 to lipid nanoparticles,23 or monomeric Ab lacking effector cell 
functions hyper-crosslinked by a secondary Ab21 were used to specifically enhance 
apoptosis. In particular, Rossi et al. developed a hexavalent anti-CD20 Ab by covalently 
assembling 6 Fab' to 1 Fc, and demonstrated that its antitumor efficacy in a murine model 
was comparable to mAb monomer (Veltuzumab), but without any sign of CDC.25 
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 We have reported a hybrid biomimetic system composed of branched HPMA 
copolymer and multiple Fab' fragments of the anti-CD20 mAb (1F5), which targets and 
crosslinks CD20 on the surface of B-cells.26,27 We hypothesized that the crosslinking 
would lead to clustering of (noninternalizing) CD20 antigens and induction of apoptosis 
via CD20-mediated signaling pathways. The design features the absence of Fc fragment 
and multimeric interactions with targets. Superior binding affinity26 and apoptosis 
induction27 when compared to unconjugated mAb were observed in several B-cell lines. 
Here, we aimed at improving this system using high-molecular-weight linear HPMA 
copolymers synthesized by controlled radical polymerization. This provided tailor-made 
multivalent conjugates with narrow molecular weight distribution, precise control of 
valences (Fab' content per polymer chain), well-defined and reproducible architectures, 
and potentially longer circulating half-lives. The improved design permitted the study of 
the relationship between the structure of conjugates and their biological activities, which 
facilitated the understanding of processes involved in CD20-crosslinking mediated 
apoptosis induction. 
 
2.2 Materials and Methods 
2.2.1 Materials 
 N-(3-Aminopropyl)methacrylamide hydrochloride (APMA) was purchased from 
Polysciences (Warrington, PA). 4,4'-azobis(4-cyanopentanoic acid) (V-501) was obtained 
from Wako Chemicals (Richmond, VA). Succinimidyl-4-(N-maleimidomethyl) 
cyclohexane-1-carboxylate (SMCC) and sulfo-SMCC were purchased from Soltec 
Ventures (Beverly, MA). o-Phthalic dicarboxaldehyde (OPA) and 3-mercaptopropionic 
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acid (MPA) were purchased from Sigma-Aldrich (St. Louis, MO). N-(2-
Hydroxypropyl)methacrylamide (HPMA)28 and 4-cyanopentanoic acid dithiobenzoate 
(CPDB)29 were prepared as previously described. All solvents were obtained from 
Sigma-Aldrich as the highest purity available. 
 
2.2.2 Cell Line, Hybridoma, and Fab' Fragment Preparation 
 Human Burkitt’s B-cell non-Hodgkin’s lymphoma Raji cell line (ATCC, 
Bethesda, MD) was used for biological evaluations. Cells were cultured in RPMI-1640 
medium (Sigma, St. Louis, MO) supplemented with 10% fetal bovine serum (Hyclone, 
Logan, UT) and grown at 37 °C in a humidified atmosphere with 5% CO2 (v/v). All 
experiments were performed using cells in exponential growth phase. Murine 1F5 anti-
CD20 IgG2a antibody was prepared from the hybridoma clone 1F5 in a CellMax 
bioreactor (Spectrum Laboratories, Rancho Dominguez, CA) according to the 
manufacturer’s instructions. Cells were initially cultured in aforementioned conditions 
and adapted to chemically defined, serum-free medium (Invitrogen, Carlsbad, CA). Anti-
CD20 mAb was purified on a Protein G Sepharose 4 Fast Flow column (GE Healthcare, 
Piscataway, NJ) from bioreactor harvest supernatant. Preparation of Fab' fragment from 
the whole Ab was achieved using a previously reported procedure.6, 26 Briefly, 1F5 mAb 
was digested into F(ab')2 with 10% (w/w) pepsin (Sigma, St. Louis, MO) in 0.1 M citric 
buffer (pH 4.0) and labeled with Rhodamine Red™-X succinimidyl ester (R6010) 
(Molecular Probes®, Invitrogen). Immediately before use, 5 mg/mL of F(ab')2 was 
reduced to Fab' with 5 mM tris(2-carboxyethyl)phosphine (TCEP) (Thermo Scientific, 
Waltham, MA) in 0.1 M phosphate buffered saline (PBS) (pH 6.5). 
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2.2.3 HPMA Copolymers and Polymer Precursors 
 Synthesis of HPMA copolymer with pendant amino groups (P-NH2) and its 
conversion into maleimide-derivatized polymer precursor (P-mal) are depicted in Figure 
2.1. P-NH2 was synthesized by reversible addition-fragmentation chain transfer (RAFT) 
copolymerization of HPMA and APMA in deionized (DI) water at 70°C using CPDB as 
chain transfer agent (CTA) and V-501 as initiator. For the backbone degradable polymer 
precursor, a bifunctional dithiobenzoate containing enzyme cleavable oligopeptide Gly-
Phe-Leu-Gly (GFLG) was synthesized29 and used as CTA (Nα,Nε-bis(4-cyano-4-
(phenylcarbonothioylthio)pentanoylglycylphenylalanylleucylglycyl)lysine, abbreviated 
peptide2CTA) (Figure 2.1A). A typical polymerization was as follows: HPMA (134.6 
mg, 0.94 mmol) and APMA (10.7 mg, 0.06 mmol) were added into an ampoule attached 
to a Schlenk-line. After three vaccum-nitrogen cycles to remove oxygen, 0.46 mL 
degassed DI H2O was added to dissolve monomers, followed by addition of CPDB 
solution (0.35 mg in 60 µL methanol) and V-501 solution (0.12 mg in 60 µL methanol) 
via syringe. The mixture was bubbled with nitrogen for 15 min before sealing the 
ampoule; the copolymerization was performed at 70°C for 20 h. The copolymer was 
isolated by precipitation into acetone and purified by dissolution-precipitation in 
methanol-acetone twice and dried under vacuum. Yield of P-NH2 was 127 mg (87.3%). 
The molecular weight (Mw) and molecular weight distribution (Mw/Mn) were 
determined by size-exclusion chromatography (SEC) on ÄKTA FPLC system (GE 
Healthcare, Piscataway, NJ) equipped with miniDAWN and OptilabREX detectors. 
Superose 6 HR10/30 column (GE Healthcare) was used with sodium acetate buffer (pH 
6.5) and 30% acetonitrile (v/v) as mobile phase. The content of amino groups in the 
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copolymer was determined by ninhydrin assay.30 
 After polymerization, P-NH2 copolymers were reacted with 2,2'-azobis(2,4-
dimethyl valeronitrile) (V-65) (Wako Chemicals) to remove the terminal (active) 
dithiobenzoate groups. Briefly, HPMA copolymer (45 mg, Mn = 105 kDa, 0.43 µmol) 
and V65 (20× excess, 2.13 mg, 8.57 µmol) were added into an ampoule. After three 
vacuum-nitrogen cycles to remove oxygen, 0.4 mL methanol was added. The solution 
was bubbled with nitrogen for 15 min, sealed and reacted at 50°C for 3 h. The end-
modified copolymer was purified by precipitation into acetone twice and then dried under 
vacuum (yield 42 mg). 
 The side chain amino groups of P-NH2 were converted to maleimides by reaction 
with SMCC or sulfo-SMCC in DMF in the presence of triethylamine (TEA). A mixture 
of 42 mg P-NH2 (12.6 µmol NH2) and SMCC (12.7 mg, 37.8 µmol) was dissolved in 0.5 
ml DMF followed by dropwise addition of TEA (ratio of [NH2]:[SMCC]:[TEA] = 1:3:3), 
then kept at room temperature overnight. The product was precipitated into acetone/ether 
(2:1, v/v), filtered, and redissolved in methanol, precipitated into acetone again, filtered 
and dried under vacuum. The amount of maleimide in copolymer was determined by a 
modified Ellman’s assay.31 The conversion of amine into maleimido groups was 54%–
59% with SMCC and > 80% when sulfo-SMCC was used. 
 
2.2.4 Preparation of Multivalent Conjugates 
 The polymer precursors P-mal were conjugated with reduced 1F5 Fab' fragments 
via thioether bonds following a previously established protocol.32 In brief, 10 mg of P-
mal were dissolved in 100 µL of DMSO, and the solution was added to Fab' (5 mg/mL) 
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in PBS (pH 6.5) (ratio of [mal]:[Fab'] = 5:1). The products were purified on a Superose 6 
HR16/60 column (GE Healthcare) to remove unbound Fab', if any. The HPMA 
copolymer–Fab' conjugates (P-Fab') containing varying amounts of Fab' per 
macromolecule were collected and analyzed on a Superose 6 HR10/30 column. Fab'-
equivalent concentration of conjugates was determined by UV spectroscopy, measuring 
absorbance at 280 nm on a Varian Cary 400 Bio UV-visible spectrophotometer, and 
confirmed by bicinchoninic acid (BCA) protein assay (Thermo Scientific). 
 
2.2.5 Determination of Valence and Effective Diameter 
 A modified amino acid analysis procedure was utilized to determine the 
concentrations of amino acid residues from Fab' as well as 1-amino-2-propanol derived 
from the HPMA polymer backbone. This enables the calculation of valence (number of 
Fab' per polymer chain) of P-Fab' conjugates. In practice, after hydrolysis in 6 N HCl 
(125 °C, 24 h), samples were precolumn derivatized with o-phthalic dicarboxaldehyde in 
the presence of 3-mercaptopropionic acid, and analyzed by HPLC (Agilent Technologies, 
Santa Clara, CA) equipped with an eclipse XDB-C8 column and fluorescence detector 
(excitation 229 nm, emission 450 nm). Free 1F5 Fab' and HPMA homopolymer were 
used for calibration, which was performed by a significant peak indicating glutamate (for 
Fab') and a significant peak indicating 1-amino-2-propanol (for HPMA polymers). 
 The effective diameters of HPMA copolymer–Fab' conjugates were analyzed by 
dynamic light scattering using a Brookhaven BI-200SM goniometer and BI-9000AT 
digital correlator equipped with a He-Ne laser (λ = 633 nm) at room temperature in PBS 
(pH 7.4). The scattering angle was 90°. Samples in PBS (1 mg/mL, Fab' equivalent 
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concentration) were filtered through a 0.45 µm filter before measurement. To rule out the 
possibility of aggregation of P-Fab' conjugates in solution, samples were also measured at 
lower concentrations (0.5, 0.25 mg/mL). P-NH2 polymer precursors, 1F5 mAb, and Fab' 
fragment were also analyzed. All measurements were performed in at least triplicate. 
 
2.2.6 Confocal Fluorescence Microscopy 
 Confocal fluorescence microscopy was used to detect the biorecognition of 
(rhodamine-labeled) P-Fab' conjugates at the surface of Raji B-cells. Cells at a density of 
2.5–5.0 × 105 per well were incubated with 0.5 mL of varying concentrations of 
conjugates (1, 2, 5, and 10 µM) in culture medium at 37 °C, 5% CO2 for 2 h prior to 
analysis. After incubation, media containing conjugates were discarded. The cells were 
washed twice with PBS, and then plated onto sterile 35 mm glass bottom dishes with 14 
mm microwells (MatTek Corporation, Ashland, MA) for live cell fluorescence imaging 
using Olympus laser scanning confocal microscope (FV 1000). As controls, cells 
incubated with FITC-labeled 1F5 mAb, rhodamine-labeled F(ab')2, and PBS were also 
examined. 
 
2.2.7 Apoptosis Evaluation 
 Apoptosis induction of Raji cells following exposure to the multivalent conjugates 
was evaluated by three assays: caspase-3 activation, annexin V binding, and TUNEL 
(terminal deoxynucleotide mediated-dUTP nick-end labeling) assay. Quantification of 
apoptotic activity was performed by flow cytometry, and presented as “apoptotic index” 
(% apoptotic cells). In all experiments, 1F5 mAb hyper-crosslinked with a goat 
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antimouse (GAM) secondary antibody (2° Ab) (KPL, Gaithersburg, MD) was used as a 
positive control (molar ratio 1F5:GAM = 3:1). Cells treated with: (a) free anti-CD20 Fab' 
fragments, (b) mixture of Fab' and P-NH2 (equivalent amounts to conjugates), and (c) 
culture medium only, were used as negative controls. 
 
2.2.7.1 Caspase-3 Activity 
 Caspase-3 activity was characterized by analysis of treated cells with the 
PhiPhiLux kit (OncoImmunin, Gaithersburg, MD). Prior to analyses, 2.5 × 105 Raji cells 
were suspended in 0.5 mL fresh growth medium with 2 µM of Fab' equivalent of 
conjugates. The cells were treated for 6 h in a humidified atmosphere at 37 °C and 5% 
CO2 and then analyzed for caspase-3 activation following the manufacturer’s protocol. 
For treatments using hyper-crosslinked mAb, cells were firstly incubated with 2 µM of 
1F5 mAb for 1 h, and then washed twice with PBS + 1% BSA, followed by re-
suspension in 0.5 mL of fresh growth medium with 100 µg per mL of GAM. The cells 
were incubated for another 5 h at 37 °C prior to staining. All experiments were carried 
out in triplicate. 
 
2.2.7.2 Annexin V Binding 
 Apoptotic activity was studied by treating Raji cells with conjugates followed by 
annexin V staining using the RAPID protocol provided by the manufacturer (Oncogene 
Research Products, Boston, MA). In addition, annexin V binding assay was chosen to 
further study the processes in time- and concentration-dependent manner. For each assay, 
2.5 × 105 cells were suspended in 0.5 mL of fresh growth medium with an appropriate 
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amount of conjugate (conjugates in Fab' equivalent ranged from 1 to 8 µM) and incubated 
for 20 h, 40 h, or 60 h. For positive controls, cells were treated with 1F5 mAb at 
concentrations from 1 to 8 µM in growth medium for 1 h. The cells were then washed 
and suspended in 0.5 mL of fresh growth medium with corresponding amounts of GAM 
antibody (from 50 to 400 µg per mL) (molar ratio 1F5:GAM = 3:1). The cells were 
treated for another 19 h, 39 h, or 59 h at 37 °C prior to staining. All experiments were 
carried out in triplicate. 
 
2.2.7.3 TUNEL Assay 
 Analysis of DNA fragmentation as characteristics of apoptosis was conducted 
using the TUNEL assay. In these experiments 7.5 × 105 Raji cells were treated with 2 µM 
of Fab' equivalent of conjugates in 0.5 mL of fresh growth medium and allowed to 
incubate for 20 h. Raji cells were treated with 2 µM of 1F5 mAb, and they were allowed 
to incubate for 1 h, and then washed twice with PBS + 1% BSA, followed by re-
suspension into 0.5 mL of fresh growth media with 100 µg/mL of GAM antibody. The 
cells were incubated for another 19 h. Prior to analysis, the cells were fixed with 2% 
paraformaldehyde in PBS for 1 h at room temperature. Cells were then permeabilized in 
70% ethanol overnight at 4 °C. Nick-end labeling was done using an Apo Direct TUNEL 
kit (Phoenix Flow Systems, San Diego, CA) following the manufacturer’s protocol. All 






2.2.8 Cell Viability Study 
 Viabilities of Raji cells after different treatment times were analyzed by 
propidium iodide (PI) binding. Quantification of cell viability was performed with flow 
cytometry. For these experiments, all treatment conditions were identical to those in the 
time-dependent annexin V binding assays except for selection of different time intervals 
for analysis. In brief, cells were incubated with 2 µM (Fab'-equivalent) of HPMA 
copolymer–Fab' conjugates (or 1F5 mAb) for 24 h, 48 h, or 72 h (or 1 h for 1F5 mAb 
followed by exposure to 100 µg/mL of GAM for 23 h, 47 h, and 71 h). All experiments 
were carried out in triplicate. 
 
2.2.9 Statistics 
 All quantified data were presented as means ± standard deviation (SD). Analyses 
were performed by the Student’s t-test, with p < 0.05 considered as statistically 
significant. 
 
2.3 Results and Discussion 
2.3.1 Synthesis of Multivalent HPMA Copolymer – Fab' Conjugates 
 Previously, we have demonstrated that attaching multiple Fab' fragments to 
soluble, branched HPMA copolymer resulted in antigen binding enhancement.26 
Multivalent HPMA copolymer–Fab' conjugates showed significant apoptotic activity 
initiated by crosslinking the B-cell antigen CD20.27 To further elucidate the relationship 
between the structure of HPMA copolymer–Fab' conjugates and their biological 
activities, a series of linear HPMA copolymers with variable chain lengths and different 
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contents of APMA comonomer (Fab' attachment points) was designed (Figure 2.1 and 
Table 2.1). Polymer precursor P1 with polymer backbone with average molecular weight 
100 kDa contained the lowest number of pendant amino groups per polymer chain; it 
served as a “control conjugate.” P2 had a double the backbone length (200 kDa) and 
identical amino group density with P1. P2a had a double the backbone length (200 kDa) 
but the same number of pendant amino groups as P1. Comparison of conjugates based on 
P1, P2, and P2a allowed evaluation of the impact of both valence and polymer chain 
length. P2b had polymer chain length (200 kDa) and pendant group numbers almost 
identical to P2; however, its backbone contained an enzyme cleavable oligopeptide 
(GFLG). Comparison of P2b with P2 will evaluate if the insertion of the peptide into 
polymer backbone would change the flexibility of polymer with potential influence on 
biorecognition by CD20 receptors. The degradability of the polymer backbone will be of 
utmost importance in future in vivo study. P3 possessed the longest polymer chain (300 
kDa) and the highest number of amino groups, and will be used to assess the impact of 
multivalency. 
 As described above, multivalent HPMA copolymer – (anti-CD20) Fab' conjugates 
(P-Fab') were prepared in a three-step process (Figure 2.1A). First, the copolymers of 
HPMA and APMA (P-NH2) were synthesized by RAFT copolymerization, which yielded 
copolymers with precisely designed molecular weight (Mw) and low polydispersity. This 
process is controllable; an excellent correlation between theoretical and experimental 
molecular weights was achieved (Table 2.1). This is an improvement over the synthesis 
using traditional radical polymerization.26,27 Previously, copolymerization of HPMA and 
APMA was performed in the presence of a small amount of tetraethyleneglycol 
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dimethacrylate and produced branched copolymers with high polydispersity. 
Consequently, fractionation was required to prepare narrowly dispersed polymer 
precursors.26 
 For the synthesis of biodegradable polymer precursor, a bifunctional chain 
transfer agent (peptide2CTA) was used. The monomers were incorporated at both 
dithiobenzoate groups of peptide2CTA with identical efficiency29 producing a diblock 
copolymer P2b with an enzyme degradable sequence (GFLG) in the middle of the 
polymer chain. Such diblock (or multiblock) HPMA polymers have demonstrated 
excellent backbone degradability in responses to papain and the lysosomal enzyme 
cathepsin B.29,33,34 
 After converting pendant amino groups to maleimido groups by reaction with 
heterobifunctional reagent, SMCC or sulfo-SMCC, HPMA copolymers (P-mal) were 
conjugated with freshly reduced Fab' fragments. Representative SEC profiles of P1 and 
P1-Fab' are shown in Figure 2.2; a significant shift of signal towards earlier elution time 
was observed which suggests successful attachment of Fab' to the polymer backbone. 
 For further characterization of the P-Fab' conjugates, dynamic light scattering 
(DLS) was used to determine the hydrodynamic effective diameters of the polymers 
before and after conjugation with Fab' (Table 2.2). To analyze the valence (number of 
Fab' fragments per polymer chain), a modified amino acid analysis (AAA) was 
performed (Table 2.2). The results of DLS on polymer precursors (P-NH2) and 
unconjugated Fab' fragment corresponded well with both published values35 and our 
previous observations26. For the conjugates, enlargement of the effective diameter was 
observed. To rule out aggregation, we measured the hydrodynamic volume at lower 
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concentrations of samples; no difference was found among different concentrations. The 
increased volume may be explained by dispersive forces between intrachain Fab' 
fragments, resulting in the expansion of the polymer coil. In addition, there is a slight 
possibility of a side reaction between residual amines from P-NH2 (or amines of Fab') 
with the maleimido groups resulting in the formation of interchain covalent crosslinks. 
Nevertheless, when compared to branched HPMA copolymer–Fab' conjugates of 
comparable Mw and valences,26 the effective diameters of linear P-Fab' are apparently 
larger. This could have significant impact on in vivo circulating half-life and 
biodistribution. 
 Several studies have demonstrated the positive correlation between hydrodynamic 
volumes of HPMA polymers, copolymers, or conjugates and their intravascular half-
lives.4,36–38 Thus, the P-Fab' conjugates presented here will very likely possess prolonged 
systematic circulation times. Previous studies on therapeutic mAb or multimeric Ab have 
pointed out the significant influence of unintended alteration of serum half-life after 
genetic engineering or physicochemical modification on in vivo therapeutic 
efficacy.22,23,25 For instance,	   Popov et al. reported the rapid elimination from blood 
circulation of multivalent rituximab lipid nanoparticles (Ritux-LNPs), and ascribed the 
observed absence of increase in in vivo therapeutic efficacies (when compared to 
rituximab) to the decreased circulating half-life.23 The recent design of backbone 
degradable HPMA copolymers29,33,34 will permit the use of high-Mw, long-circulating 
conjugates without impairment of therapeutic efficacy. 
 Confocal fluorescence microscopy (Figure 2.3) demonstrated the localization of 
(rhodamine-labeled) conjugates at the surface of Raji B-cell, corresponding to a high 
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expression level of noninternalizing CD20 surface antigen of this cell line. This result 
further illustrated the successful synthesis of conjugates with retained biological activity 
of anti-CD20 Fab' in order to target B-cells. 
 
2.3.2 Relationship Between Polymer Chain Length and Valence of 
P-Fab' Conjugates and Apoptosis Induction in Raji B-Cells 
 Previous studies demonstrated that crosslinking of noninternalizing CD20 
receptors on Raji B-cells results in receptor clustering with concomitant apoptosis 
induction. The evaluation of apoptosis initiation following Raji B-cell exposure to 
multivalent conjugates was performed by three distinct assays from differing 
perspectives: caspase-3 activation (gene expression due to CD20-mediated signaling), 
annexin V binding (cell membrane flipping as an early apoptotic event), and the TUNEL 
assay (DNA fragmentation as a late apoptotic event). Levels of apoptosis induction by the 
five conjugates (Table 2.2) were compared; results from the three assays were consistent 
and showed very similar trends (Figure 2.4). P1-Fab' designed as a “control conjugate” 
had the weakest apoptotic activity among the five, with only minimal effects detected 
when compared to the untreated group (culture medium only), unconjugated Fab', and 
Fab' + P-NH2 controls. Conjugate P2-Fab' with doubled backbone length and doubled 
valence (than P1-Fab') produced significant apoptotic levels as expected. Interestingly, 
P2a-Fab' with similar valence as P1-Fab' but a longer polymer chain seemed to have 
stronger apoptotic efficacy than P1-Fab' (but less than P2-Fab'), suggesting that in 
addition to valence, polymer chain length could also be a factor for apoptosis induction. 
This result is striking because, first, none of the previous literature on multimeric anti-
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CD20 mAb has published the positive influence of polymer length on apoptosis, and 
second, Rossi et al. suggested the need for clustering at least three CD20 to induce 
cytotoxicity25 (noting that the mean valence of P2a-Fab' is 1.3). Data reported here could 
be potentially explained by either an improved binding kinetics of the conjugate, or a 
better range of “reaching” to cluster neighboring CD20 as a result of the longer polymer 
chain, although further analysis is necessary. 
 Furthermore, P2b-Fab' had almost identical polymer chain length and valence as 
P2-Fab' but with a peptide (GFLG)-containing enzyme cleavable backbone. The similar 
degrees of apoptosis observed in P2b-Fab' and P2-Fab' indicate that the insertion of 
peptide segments into the polymer backbone does not have a noticeable impact on the 
flexibility of the macromolecule and on its potential to attach to multiple CD20 antigens 
on the surface of Raji B-cells. In addition, these biodegradable HPMA-based polymer 
carriers29,33,34 possess favorable properties for in vivo applications. They have long 
plasma circulation time, their biodegradability profiles can be easily manipulated, and 
they possess favorable pharmacokinetics and a favorable tumor-to-normal tissue 
accumulation ratio.4,39 Data presented here rationalize the future design of a 
biodegradable, multiblock P-Fab' system composed of HPMA copolymer blocks of 
molecular weight below the renal threshold (40–45 kDa). 
 The conjugate P3-Fab' was designed with the longest backbone and highest 
valence with the aim of achieving an optimal biological efficacy. Although the conjugate 
P3-Fab' produced the highest apoptotic level among the five conjugates, the enhancement 
of activity observed at the experimental conditions used (2 µM Fab'-equivalent 
concentration, 20 h incubation) was modest. We hypothesize that the combination of a 
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high valence (11.3) and a long polymer chain (336 kDa) might result in a solution 
conformation that renders some Fab' fragments less accessible (shielded) to interaction 
with CD20, thus limiting the targeting effect.40 This explanation was supported by results 
of DLS (Table 2.2); P3-Fab' had a mean hydrodynamic diameter of 97.3 nm – a modest 
increase when compared to the other conjugates. 
 
2.3.3 Impact of Exposure Time and P-Fab' Concentration on 
Apoptosis Induction and Cytotoxicity 
 A time-dependent cell viability study (Figure 2.5) was performed using propidium 
iodide (PI) and flow cytometry. PI is a fluorescent DNA-intercalating agent commonly 
used to bind and detect nonviable cells, or to distinguish late apoptotic cells depending on 
the experimental setup;41 here, we applied the former to stain and quantify all nonviable 
cells. The viability of Raji cells was analyzed at varying time intervals after exposure to 
multivalent conjugates at similar conditions as used in apoptosis assays described above. 
The cytotoxicity of conjugates demonstrated a slower onset at shorter exposure times (24 
h, 48 h) than the whole 1F5 mAb hyper-crosslinked with a secondary Ab (mAb + 2°Ab); 
however, at the longer time interval (72 h) the conjugates appeared to be more effective. 
For instance, at 72 h, conjugates P2-Fab' and P2b-Fab' showed comparable effects as the 
positive control (mAb + 2°Ab), while P3-Fab' achieved a significantly better efficacy. In 
the time-dependent apoptosis evaluation (Figure 2.6A) using annexin V assay, the onset 
patterns of apoptosis were the same as observed in the cytotoxicity assay. Both, P2-Fab' 
and P3-Fab' reached comparable levels of early apoptosis as the positive control at longer 
exposure times (40 h, 60 h). In particular, at 60 h, the apoptotic activity of P3-Fab' 
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exceeded that of the positive control (p < 0.05). Since the trends of cytotoxicity compared 
well with results of apoptosis, we speculate that the PI-positive cells primarily resulted 
from CD20 clustering (late apoptotic cells); however, the potential contribution of cell 
necrosis cannot be ruled out. These data and the previous observation that the therapeutic 
efficacy of anti-CD20 mAb may result in direct eradication of B-lymphomas10,11,18 bode 
well for the potential of P-Fab' conjugates as therapeutics for NHL. 
 The concentration (dose)-dependent apoptosis assay (Figure 2.6B) revealed an 
increase of apoptotic index with increasing concentration for all compounds tested. 
However, the dose-escalation effect was stronger in the positive control group (mAb + 
2°Ab) than in multivalent conjugates P2-Fab' and P3-Fab'. In addition, within the 
concentration range used (1–8 µM), saturation of apoptotic index at high concentrations 
was not observed in contrast to results obtained with branched polymer–Fab' 
conjugates.27 This suggests a better accessibility of Fab' fragments bound to linear 
polymer chains when compared to branched conjugates. This hypothesis is further 
supported by the comparison of effective diameters of conjugates; the linear P-Fab' 
conjugates possess larger hydrodynamic sizes than branched conjugates with equivalent 
Mw, polydispersity, and valency. 
 The data seem to suggest that to achieve enhanced biological activities, a long 
exposure time of linear P-Fab' was more important than a high Fab'-equivalent 
concentration. Two factors may contribute to this phenomenon: (a) shielding effect,40 and 
(b) different binding kinetics to CD20 between P-Fab' and mAb followed by 2° Ab. The 
impact of time corresponds well with the design of backbone degradable, long-circulating 
conjugates. Optimization of the structure of conjugates based on the best combination of 
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molecular weight and valency needs to be undertaken. 
 
2.4 Summary 
 A hybrid biomimetic system composed of RAFT-synthesized, linear, high-Mw 
HPMA copolymers grafted with multiple anti-CD20 Fab' fragments was designed. The 
preparation methods did not require fractionation by SEC, thus are well suited for scale-
up studies. The technique enabled synthesis of conjugates with low polydispersity and 
tailor-made properties to study the structure-activity relationship. The biorecognition of 
multivalent P-Fab' conjugates by CD20 receptors on the surface of Raji B-cells was 
visualized by confocal fluorescence microscopy. Crosslinking of CD20 receptors on the 
surface of Raji B-cells induced apoptosis as determined by caspase-3 activity, annexin V 
binding, and TUNEL assays. Both polymer chain length and valence (amount of Fab' per 
chain) were factors having an impact on apoptotic efficiency, whereas insertion of a 
peptide into the HPMA copolymer backbone was not. In addition, long exposure time of 
the conjugates with Raji B-cells resulted in enhanced apoptosis and higher cytotoxicity 
when compared to whole anti-CD20 mAb hyper-crosslinked by a secondary Ab; high 
dose (concentration) seemed to be less influential. The present system possesses ideal 
architecture (linear) and characteristics (suitable hydrodynamic size, as analyzed by DLS) 
to allow the further design of long-circulating biodegradable systems. Based on the 
presented data and the favorable characteristics of CD20 (noninternalizing, not present in 
serum under standard conditions, with no known natural ligand) as a target for B-
lymphoma, this study provides a potential strategy for the improved treatment of NHL 
and other B-cell malignancies through direct induction of apoptosis without Fc-related 
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mechanisms and side effects. 
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Figure 2.1  Synthesis of multivalent HPMA copolymer – Fab' conjugates. (A) Schemes 
for the synthesis of polymer precursors (P-NH2, P-mal) and multivalent conjugates (P-










Figure 2.2  SEC profiles of 1F5 mAb, F(ab')2, Fab', P-NH2 and P-Fab'. (A) SEC profiles 
of harvested 1F5 mAb, digested F(ab')2 and reduced Fab' fragments by ÄKTA FPLC 
(Superdex 200 HR10/30 column, PBS). Purity of all products from each step were > 
95%. (B) SEC profiles of representative P-NH2 (P1) and P-Fab' (P1-Fab') by ÄKTA 























Figure 2.3  Confocal fluorescence microscopic images of Raji B-cells. Cells were 
exposed to (A) PBS, (B) 1F5 mAb labeled with FITC, (C) F(ab')2 antibody fragment 
labeled with rhodamine, and (D) P-Fab' conjugate labeled with rhodamine. Raji cells (2.5 












Figure 2.4  Apoptosis induction of Raji B-cells analyzed by (A) caspase-3 activity, (B) 
annexin V binding, and (C) TUNEL assay. Quantification was performed by flow 
cytometry. All experiments were carried out in at least triplicate (data shown as mean ± 










Figure 2.5  Time-dependent cell viability study assessed by PI binding. Treatment 
conditions were identical to apoptosis assays. Quantification was performed by flow 
cytometry. Experiments carried out in triplicate (data shown as mean ± SD). (n) 















Figure 2.6  Cell apoptosis evaluated by annexin V binding in (A) time-dependent and (B) 
concentration-dependent assays. All experiments were carried out in triplicate (data 
shown as mean ± SD). Statistical analyses (unless otherwise indicated) performed by 
comparing each group with the corresponding shortest time interval or lowest 








Table 2.1  Synthesis and characterization of P-NH2 polymer precursors. 
*Modified CPDB containing enzyme cleavable peptide was used as chain transfer agent (CTA). 
a Conversion estimated by weight % polymer products. 
b Theoretical molecular weight of polymer calculated by the following equation: 
   Mwtheo.= [([M]0÷[CTA]0) × Conversion × Mean Mw of monomers] + Mw of CTA. 
c Average molecular weight and polydispersity determined by SEC. 



















*Degradable backbone containing GFLG oligopeptide. 
†	  Branched conjugates with polymer Mw=193 kDa.26 
a Fab' per polymer chain as determined by modified AAA. 









Fed     Found d 
Structure 
P1 800:1:0.33 87.3 102       105 1.09 6         4.31 Non-degradable 
P2 1600:1:0.33 89.4 208       207 1.07 6         4.13 Non-degradable 
P2a 1600:1:0.33 94.9 219       223 1.04 3         2.12 Non-degradable 
P2b* 1600:1:0.25 84.1 197       201 1.11 6         4.23 Degradable 
P3 3000:1:0.33 75.7 330       336 1.05 6         4.75 Non-degradable 
No. Valence a 
Effective Diameter b (nm) 
before conj.   after conj. 
 
P1-Fab' 1.7       12.4             36.2  
P2-Fab' 3.3       19.1             82.3  
P2a-Fab' 1.3       21.1             56.3  
P2b-Fab'* 3.4       21.6             74.3  
P3-Fab' 11.3       27.4             97.3  
Fab' – 4.5  






CELL SURFACE SELF-ASSEMBLY OF HYBRID NANOCONJUGATES 




 Hybrid nanomaterials composed of synthetic and biological building blocks 
possess high potential for the design of nanomedicines. The use of self-assembling 
nanomaterials as “bio-mimics” may trigger cellular events and result in new therapeutic 
effects. Motivated by this rationale, we designed a therapeutic platform that mimics the 
mechanism of immune effector cells to crosslink surface receptors of target cells and 
induce apoptosis. This platform was tested against B-cell lymphomas that highly express 
the surface antigen CD20. In this chapter, two nanoconjugates were synthesized: (1) an 
anti-CD20 Fab' fragment covalently linked to a single-stranded morpholino 
oligonucleotide (MORF1), and (2) a linear, synthetic copolymer of N-(2-hydroxypropyl) 
methacrylamide (HPMA) grafted with multiple copies of the complementary 
oligonucleotide MORF2. We show that the two conjugates self-assemble via MORF1-
MORF2 hybridization at the surface of CD20+ malignant B-cells, which crosslinks CD20 
antigens and initiates apoptosis. When tested in a murine model of human non-Hodgkin’s 
lymphoma, the two conjugates, either administered consecutively or as a premixture, 
1This chapter is adapted with permission from: T.-W. Chu, J. Yang, R. Zhang, M. Sima and J. Kopeček. 
Cell surface self-assembly of hybrid nanoconjugates via oligonucleotide hybridization induces 
apoptosis. ACS Nano. 2014; 8(1): 719–730. Copyright (2014) American Chemical Society. 
	  	  
49 
eradicated cancer cells and produced long-term survivors. The designed therapeutics 
contain no small-molecule cytotoxic compounds and are immune-independent, with the 
aim of a treatment improved over chemotherapy, radiotherapy and immunotherapy. This 
therapeutic platform can be applied to crosslink any noninternalizing receptor and 
potentially treat other diseases. 
 
3.1 Background 
 Molecular biorecognition is a fundamental feature of life – many biological 
processes are governed by the complex yet specific interactions between 
macromolecules, e.g., antibody-antigen binding and DNA base pairing. These high-
fidelity recognition motifs from nature can be employed to design self-assembling 
nanobiomaterials for applications in drug delivery,1–3 tissue engineering,4,5 bio-
detection,6–8 etc. A new direction of research is to use such precisely defined “smart” 
materials to incite or control cellular activities;9–11 in this case the materials alone, 
without any conventional drug, can provide therapeutic effects. Such biomimetic strategy 
translates molecular biorecognition into cellular responses to define new therapeutic 
entities with high functional specificity. 
 Non-Hodgkin’s lymphoma (NHL) is a prevalent cancer worldwide with a high 
mortality rate.12 Conventional chemotherapy and radiotherapy are accompanied by 
significant adverse reactions, particularly cytopenias leading to increased risk of infection 
and need for transfusions. Because most NHLs are of B-cell origin, immunotherapies 
using monoclonal antibodies (mAbs) targeted to the B-cell surface antigen CD20 have 
become common treatments.13 However, large populations of patients exist who are not 
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responsive to immunotherapies, especially in the relapse setting. For example, rituximab, 
the most commonly used anti-CD20 mAb, has a less than 50% overall response rate for 
relapsed/refractory NHL.14 This is largely attributed to the inactivity of immune effector 
cells to hyper-crosslink ligated mAbs.15,16 Moreover, mAb treatments cause rare but 
lethal side effects such as progressive multifocal leukoencephalopathy17 and lung 
injuries,18,19 which are due to Fc-mediated effector cellular events (e.g., complement 
activation).20 These clinical obstacles warrant new, improved therapeutic strategies. 
 We designed a biomimetic material platform composed of self-assembling hybrid 
nanoconjugates (Figure 3.1A) as a therapeutic system against B-cell lymphomas (Figure 
3.1B). It comprises an anti-CD20 Fab' antibody fragment, a pair of complementary 
phosphorodiamidate morpholino oligomers (MORF1 and MORF2), and a linear polymer 
(P) of N-(2-hydroxypropyl)methacrylamide (HPMA). We hypothesized that: (1) the 
exposure of malignant CD20+ B-cells to the conjugate of anti-CD20 Fab' and MORF1 
(Fab'-MORF1) decorates the cell surfaces with MORF1; and (2) further treatment of 
decorated B-cells with HPMA copolymer grafted with multiple copies of MORF2 (P-
MORF2) results in MORF1-MORF2 hybridization at the cell surface with concomitant 
CD20 crosslinking, which triggers apoptosis. The proposed mechanism of apoptosis 
induction is shown in Figure 3.1B. 
 This design is inspired by the fact that cell surface receptor clustering is a driving 
force for numerous cellular events, e.g., cell adhesion,21 cell proliferation,22 and hormone 
uptake.23 In particular, when CD20-bound antibodies are hyper-crosslinked by	   Fc 
receptor (FcR)-expressing immune effector cells (e.g., macrophages, natural killer cells),	  
CD20 clustering occurs within lipid rafts and induces apoptosis.24 We named the 
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designed platform “drug-free macromolecular therapeutics” due to the absence of low-
molecular-weight drugs that are often toxic (e.g., chemotherapeutic agents).9 
Furthermore, each component (Fab', morpholino oligo, HPMA polymer) of this system, 
when used individually, does not have any pharmacological effect. The apoptosis 
induction is direct (i.e., independent of immune function) and specific (i.e., targeted to 
CD20); thus, it has the potential to address the side effect problems of currently used 
immunotherapy, chemo- and radiotherapy. 
 The design is based on a pair of morpholino (MORF) oligonucleotides	   with 
complementary sequences. They form double helixes by Watson-Crick base pairing 
(hybridization) and serve as physical crosslinkers. MORF oligos have a charge-neutral 
phosphorodiamidate backbone resulting in much stronger binding affinity than DNA or 
RNA.25 More importantly, they are biocompatible and nuclease resistant; this ensures in 
vivo stability and safety.26 Due to these advantages, MORF oligos have been successfully 
used as macromolecular binders to enhance therapeutic delivery.2,27,28 The HPMA 
copolymers are water-soluble and long circulating in the bloodstream; they have well-
established safety profiles and are used extensively as therapeutic carriers.29 In aqueous 
solutions, linear HPMA copolymers have a random coil conformation and are able to 
effectively present targeting moieties that are grafted to the side chains.30 
 In this chapter, we show the development and preclinical evaluation of the 
proposed anti-lymphoma nanomedicine. Biorecognition of the two nanoconjugates (Fab'-
MORF1 and P-MORF2) was characterized. The therapeutic system was optimized to 
achieve efficient apoptosis induction of malignant B-cell lines. Excellent anticancer 
efficacy (100% survival without residual tumors) was demonstrated in a mouse model of 
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human NHL. These findings validate the concept of the designed therapeutic platform. 
 
3.2 Materials and Methods 
3.2.1 MORF1 and MORF2 
 The two complementary 3'-amine-derivatized 25-mer phosphorodiamidate 
morpholino oligomers were obtained from Gene Tools, LLC (Philomath, OR). MORF1: 
5'-GAGTAAGCCAAGGAGAATCAATATA-linker-amine-3' (MW: 8630.5 Da); 
MORF2: 5'-TATATTGATTCTCCTTGGCTTACTC-linker-amine-3' (MW: 8438.5 Da). 
Structure of the linker is shown in Figure 3.2. For the design of base sequences, sequence 
scrambling software (http://www.sirnawizard.com/scrambled.php) and sequence analysis 
software (http://www.basic.northwestern.edu/biotools/oligocalc.html) were used. 
 
3.2.2 Preparation of Fab'-MORF1 
 The 1F5 mAb was prepared from a murine hybridoma cell subclone 1F5 (ATCC, 
Bethesda, MD) in a CellMax® bioreactor (Spectrum Laboratories, Rancho Dominguez, 
CA). Antibodies were harvested from the culture media, and purified on a Protein G 
Sepharose 4 Fast Flow column (GE Healthcare, Piscataway, NJ). Preparation of Fab' 
from mAb followed a previously reported procedure.31 Briefly, mAb was digested into 
F(ab')2 with 10% (w/w) pepsin (Sigma, St. Louis, MO) in citric buffer (pH 4.0). 
Immediately before conjugation, F(ab')2 was reduced to Fab' by 10 mM tris(2-
carboxyethyl)phosphine (Thermo Scientific, Waltham, MA). To prepare the Fab'-
MORF1 conjugate, the MORF1 oligo containing a 3'-primary amine was reacted with 
succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) to introduce a 
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terminal (thiol-reactive) maleimide group. This produced MORF1 with 3'-maleimide 
(MORF1-mal). MORF1-mal was then conjugated to Fab' (containing a terminal thiol 
group) via a thioether bond to obtain Fab'-MORF1. The conjugates were purified using 
size exclusion chromatography (SEC) to remove free, unconjugated Fab' and MORF1. 
 A typical procedure was as follows: first, 200 nmol MORF1-NH2 was reacted 
with 0.67 mg (2 µmol) SMCC (Soltec Ventures, Beverly, MA) in 170 µL DMSO to 
produce the MORF1-mal. The reaction was performed at RT (room temperature) for 24 
h. The product was isolated by precipitation into 1.5 mL acetone, purified by dissolution-
precipitation in deionized water-acetone twice, and dried under vacuum. Second, 200 
nmol MORF1-mal was dissolved in 200 µL 10 mM PBS (pH 6.5), and then the solution 
was mixed with 200 nmol (~10 mg) freshly reduced Fab'-SH in 2 mL PBS (pH 6.5). The 
reaction was performed at 4 °C for 24 h. Finally, the Fab'-MORF1 conjugate was purified 
using SEC. An ÄKTA FPLC system (GE Healthcare, Piscataway, NJ) equipped with 
Sephacryl S-100 HR16/60 column (GE Healthcare) eluted with PBS (pH 7.2) was used. 
Alternatively, Fab'-MORF1 was labeled with 5–10 molar excess Rhodamine RedTM-X 
succinimidyl ester (R6010) (Molecular Probes®, Invitrogen, Carlsbad, CA) for imaging 
studies. The product was purified using a PD-10 desalting column (GE Healthcare). To 
determine Fab' equivalent concentration of the Fab'-MORF1 conjugate, a bicinchoninic 
acid (BCA) protein assay (Thermo Scientific Pierce, Rockford, IL) was used. The 
obtained values were compared to the MORF1 equivalent concentrations obtained from 
UV-visible spectroscopy (using a molar absorptivity of 278,000 M-1 cm-1). Such 




3.2.3 Preparation of P-MORF2 
 The multivalent P-MORF2 conjugates were prepared in two steps. First, the 
polymer precursors (P-TT), namely, copolymers of N-(2-hydroxypropyl)methacrylamide 
(HPMA), N-methacryloylglycylglycine thiazolidine-2-thione (MA-GG-TT), and 
optionally (for imaging studies only), N-methacryloylaminopropyl fluorescein thiourea 
(MA-FITC), were synthesized by RAFT copolymerization. Second, P-TT was reacted 
with MORF2-NH2 to produce the multivalent P-MORF2. 
 
3.2.3.1 Synthesis of P-TT 
 In the RAFT copolymerization, 2,2'-azobis[2-(2-imidazolin-2-yl)propane] 
dihydrochloride (VA-044) was used as the initiator, and 4-cyanopentanoic acid 
dithiobenzoate (CPDB) as the chain transfer agent. CPDB32 and monomers HPMA,33 
MA-GG-TT,34 and MA-FITC35 were synthesized as previously described. The reaction 
was carried out in methanol containing 0.3% (v/v) acetic acid (MeOH/H+). A typical 
procedure was as follows: HPMA (272 mg, 1.9 mmol) and MA-GG-TT (30.1 mg, 0.1 
mmol) were added into an ampoule attached to an Schlenk-line. After three vaccum-
nitrogen cycles to remove oxygen, 1 mL degassed MeOH/H+ was added to dissolve 
monomers, followed by addition of CPDB solution (0.43 mg in 50 µL MeOH/H+) and 
VA-044 solution (0.25 mg in 50 µL MeOH/H+) via syringe. The mixture was bubbled 
with nitrogen for 15 min before sealing the ampoule; the copolymerization was 
performed at 40 °C for 36 h. The copolymer was isolated by precipitation into acetone 
and purified by dissolution-precipitation in methanol-acetone twice and dried under 
vacuum. Yield of P-TT was 160 mg (53%). The number average molecular weight (Mn) 
	  	  
55 
and molecular weight distribution (polydispersity, Pd) of P-TT were determined by SEC, 
using ÄKTA FPLC equipped with miniDAWN and OptilabREX detectors (GE 
Healthcare). Superose 6 HR10/30 column (GE Healthcare) was used, with sodium acetate 
buffer (pH 6.5) and 30% acetonitrile (v/v) as mobile phase. To remove the terminal 
(active) dithiobenzoate groups, P-TT copolymers were reacted with 2,2'-azobis(2,4-
dimethyl valeronitrile) (V-65) (Wako Chemicals, Richmond, VA). Briefly, P-TT (39 mg, 
Mn = 92 kDa, ~0.42 mmol) and V-65 (20× excess, 2.1 mg, ~8.47 mmol) were added into 
an ampoule. After three vacuum-nitrogen cycles to remove oxygen, 0.4 mL MeOH/H+ 
was added. The solution was bubbled with nitrogen for 15 min, sealed and reacted at 50 
°C for 3 h. The end-modified copolymer was purified by precipitation into acetone twice 
and then dried under vacuum (yield 34 mg, or 86%). The content of TT groups in the 
copolymers was determined by UV absorbance at 305 nm (molar absorptivity = 10,900 
M-1 cm-1; in methanol).34 The content of FITC was determined by absorbance at 495 nm 
(molar absorptivity = 82,000 M-1 cm-1; in borate buffer pH 9.2 + 10% (v/v) DMF).35 
 
3.2.3.2 Attachment of MORF2-NH2 to P-TT to Produce P-MORF2 
 The P-TT described above was reacted with MORF2-NH2 to produce multivalent 
P-MORF2. A typical reaction was as follows: 10 mg P-TT (92 kDa; containing 3.83 
µmol TT groups) was mixed with 6.46 mg (766 nmol) MORF2-NH2 in 400 µL 10 mM 
PBS (pH 7.4). The solution mixture in an ampoule was stirred at RT for 24 h; then 1 µL 
1-amino-2-propanol (Sigma-Aldrich, St. Louis, MO) was added and stirred for another 15 
min to aminolyze unreacted TT groups on the polymer chains. After reaction, the solution 
was filtered through a 0.22 µm filter, and the conjugate was purified by SEC using 
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ÄKTA FPLC with Superose 6 HR16/60 column (GE Healthcare) eluted with PBS (pH 
7.2). P-MORF2 was characterized by UV absorbance at 265 nm after removal of 
unconjugated MORF2 (if any). To quantify the content of MORF2 and determine the 
valence (number of MORF2 per polymer chain), the fractionated P-MORF2 conjugates 
were freeze-dried and dissolved in 0.1 N HCl prior to UV-Vis analysis. A molar 
absorptivity of 252,000 (M-1 cm-1) was used for quantification of MORF2. The valences 
of the P-MORF2 conjugates were calculated based on the resulting MORF2 contents and 
the Mn of the polymer backbones (as previously determined by SEC). 
 
3.2.4 Analysis of Fab'-MORF1/P-MORF2 Self-Assembly by UV-Visible 
Spectroscopy and Dynamic Light Scattering (DLS) 
 Analysis of the hypochromic effect upon MORF1-MORF2 hybridization was 
performed using a Varian Cary 400 Bio UV-visible spectrophotometer (Agilent 
Technologies, Santa Clara, CA). MORF1 and MORF2 (or Fab'-MORF1 and P-MORF2) 
were firstly dissolved in 1 mL PBS (pH 7.4) each at a concentration of 2.5 µM (MORF 
equivalent) and then mixed in different ratios. The final concentrations of MORF oligos 
(MORF1 + MORF2) in every solution mixture were kept constant (2.5 µM). For 
example, the mixture containing 75% MORF1 (or 25% MORF2) was contained in a 0.75 
mL of 2.5 µM MORF1 solution and 0.25 mL of 2.5 µM MORF2 solution. Samples were 
placed in a 1-cm quartz cuvette for measurement. The optical density (OD) at 260 nm 
(contributed by bases) was recorded. All measurements were performed in triplicate. 
 The hydrodynamic effective diameters of the conjugates, Fab'-MORF1 and P-
MORF2, and their precursors, Fab'-SH and P-TT, were analyzed by DLS (dynamic light 
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scattering) using a Brookhaven BI-200SM goniometer and BI-9000AT digital correlator 
equipped with a He-Ne laser (λ = 633 nm) at RT in PBS (pH 7.4). The scattering angle 
was 90°. A NanosphereTM polystyrene bead with a standard diameter of 102 ± 3 nm 
(STD100nm) (Thermo Scientific, Waltham, MA) was used to measure in line. 
Conjugates and precursors at a concentration of about 1 mg/mL were filtered through a 
0.22 µm filter prior to measurement. All samples showed a polydispersity less than 0.2, 
and the mean particle diameters were recorded. Furthermore, DLS was used to 
characterize the change of particle size upon the binding of Fab'-MORF1 and P-MORF2. 
The analysis was performed at different times (10, 30 and 60 min) after mixing the two 
conjugates (at equimolar MORF1/MORF2 concentrations). All samples contained a 
major population of particles (polydispersity < 0.2) indicating the hybridized conjugates, 
as well as minor populations indicating unbound Fab'-MORF1 and P-MORF2. The mean 
effective diameter of the major population was recorded. All measurements were 
performed in triplicate. 
 
3.2.5 Circular Dichroism (CD) Spectrometry 
 An Aviv 62DS CD spectrometer with a thermoelectric temperature control system 
(Aviv Biomedical, Lakewood, NJ) was used. Regular measurements (excluding thermal 
melting analysis) were carried out at 25 °C where each sample was scanned from 200 to 
340 nm with 1 nm/step (bandwidth = 1 nm, each step = 2 sec). Samples were prepared in 
10 mM PBS (pH 7.4) at 50 µM MORF equivalent concentrations (Fab'-SH at 50 µM 
Fab'-eqv.). Prior to measurement, samples were filtered through a 0.22 µm filter and 
placed in a 0.1-cm path length quartz cuvette. The obtained spectra were subtracted from 
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the background (PBS, pH 7.4); data from three sequential scans were averaged. For 
thermal melting studies, the CD signal at 260 nm was recorded (n = 3). Fab'-MORF1 and 
P-MORF2 (or MORF1 and MORF2) were mixed in equimolar ratio (5 µM/5 µM 
MORF1/MORF2) in PBS for 1 h at RT. The solution mixtures were filtered and placed in 
a 1-cm path length quartz cuvette prior to measurement. Each sample first underwent a 
forward scan where the temperature increased from 25 to 95 °C at 2 °C/step. For each 
step, the sample was equilibrated for 2 min followed by 30 sec of data point averaging. 
Afterward, a reverse scan was performed where the temperature decreased from 95 to 25 
°C at -10 °C/step. For each step, the sample was equilibrated for 5 min followed by 30 
sec of data point averaging. 
 The measured ellipticity (θobs) was converted to molar ellipticity (θ) using the 
following equation: 𝜃 = 𝜃𝑜𝑏𝑠/(𝑙 ∗ 𝑐) where l is the cuvette’s optical path length and c is 
MORF-equivalent molar concentration. To analyze melting temperature (Tm) of 
MORF1-MORF2 hybridization, θ (at 260 nm) was plotted against temperature (T), and 
the data were fitted to a thermo-melting curve by nonlinear regression (GraphPad Prism 5 
software) using the following four-parameter logistic function: 𝜃 = 𝜃𝑚𝑖𝑛 + (𝜃𝑚𝑎𝑥 − 𝜃𝑚𝑖𝑛)/[1+ (𝑇/𝑇𝑚)^𝐻  ] 
where θmin is the minimal molar ellipticity (at 260 nm) in the curve, θmax is the maximal 
molar ellipticity (at 260 nm) in the curve, and H is the Hill slope. 
 
3.2.6 Confocal Fluorescence Microscopy 
 Human Burkitt’s B-cell non-Hodgkin’s lymphoma Raji cell line (ATCC, 
Bethesda, MD) was cultured in RPMI-1640 medium (Sigma, St. Louis, MO) 
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supplemented with 10% fetal bovine serum (Hyclone, Logan, UT) at 37 °C in a 
humidified atmosphere with 5% CO2 (v/v). All experiments were performed using cells 
in exponential growth phase. For the consecutive treatment, cells at a density of 106 per 
well were incubated with 0.4 mL Fab'-MORF1-RHO (0.4 µM Fab' equivalent) in culture 
medium at 37 °C for 1 h; then the cells were washed twice with PBS prior to incubation 
with 0.4 mL of P-MORF2-FITC (0.4 µM MORF2 equivalent) in culture medium for 
another 1 h. For the premixed treatment, Fab'-MORF1-RHO and P-MORF2-FITC were 
firstly mixed in culture medium in equimolar concentrations (0.4 µM) for 1 h; then cells 
at the same density were incubated with 0.4 mL of the premixture solution for 1 h. After 
incubation, the cells were washed twice with PBS (to discard the media that contained the 
conjugates), and then plated onto sterile 35-mm glass bottom dishes with 14-mm 
microwells (MatTek Corporation, Ashland, MA) for imaging, using Olympus laser 
scanning confocal microscope (FV 1000). For control studies, concentrations of all 
corresponding components were kept consistent; excess amounts of P-FITC and P-
dsMORF were used. Prior to analysis, cells incubated with FITC-labeled 1F5 mAb, 
rhodamine-labeled F(ab')2, and PBS were used to adjust channel setting and confirm 
CD20 binding. 
 
3.2.7 In Vitro Apoptosis Evaluation 
 Apoptosis of human NHL B-cells was evaluated by three methods: caspase-3 
activation assay, annexin V/propidium iodide (PI) binding assay, and terminal 
deoxynucleotide mediated-dUTP nick-end labeling (TUNEL) assay. These assays 
evaluated apoptosis from different aspects – levels of caspase-3 activation represented 
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apoptotic protein expression; annexin V/PI binding characterized cell membrane flipping 
as an early apoptotic event; TUNEL assay analyzed genomic DNA fragmentation as a 
late apoptotic event. Quantification of apoptotic activity (% apoptotic cells) was 
performed by flow cytometry. In all experiments, 1F5 mAb hyper-crosslinked with a goat 
antimouse (GAM) secondary antibody (2° Ab) (KPL, Gaithersburg, MD) was used as a 
positive control (molar ratio 1F5:GAM = 2:1). Untreated cells (in culture media) were 
used as negative controls. The procedures of each assay are described below. 
 
3.2.7.1 Caspase-3 Activity 
 A Phi-PhiLux kit (OncoImmunin, Gaithersburg, MD) was used. For the 
consecutive treatment, 2 × 105 Raji cells were suspended in 0.4 mL fresh growth medium 
containing 0.5 µM Fab'-MORF1. The cells were incubated for 1 h in a humidified 
atmosphere at 37 °C with 5% CO2, and then washed twice with PBS + 1% bovine serum 
albumin (BSA), followed by resuspension in 0.4 mL medium containing 0.5 or 5 µM 
(MORF2-eqv.) P-MORF2. The cell suspension was incubated for 6 or 24 h. For the 
premixed treatment, first, 0.5 µM Fab'-MORF1 was mixed with 0.5 or 5 µM (MORF2-
eqv.) P-MORF2 in culture medium at RT for 1 h, and then 2 × 105 Raji cells were 
suspended in 0.4 mL of the premixed solution. The cell suspension was incubated for 6 or 
24 h. For the positive control, cells were firstly incubated with 0.4 mL 0.5 µM of 1F5 
mAb in culture medium for 1 h, and then washed twice with PBS + 1% BSA, followed 
by resuspension in 0.4 mL of fresh growth medium containing 0.25 µM GAM. The cells 
were incubated for another 6 or 24 h at 37 °C. After the treatments, cells were washed 
twice with PBS and analyzed for caspase-3 activity following the manufacturer’s 
	  	  
61 
protocol. All experiments were carried out in triplicate. 
 
3.2.7.2 Annexin V/PI Binding 
 Annexin V-FITC and PI staining were performed following the RAPIDTM 
protocol provided by the manufacturer (Oncogene Research Products, Boston, MA). For 
the consecutive treatment, 2 × 105 Raji or DG75 (CD20 negative; control) cells were 
suspended in 0.4 mL fresh growth medium containing 0.5, 1, 2 or 5 µM Fab'-MORF1. 
The cells were incubated for 1 h in a humidified atmosphere at 37 °C with 5% CO2, and 
then washed twice with PBS + 1% bovine serum albumin (BSA), followed by 
resuspension in 0.4 mL culture medium containing 0.5, 1, 2 or 5 µM (MORF2-eqv.) of P-
MORF2. The cell suspension was incubated for 24 or 48 h. For the premixed treatment, 
first, 0.5, 1, 2 or 5 µM Fab'-MORF1 was mixed with 0.5, 1, 2 or 5 µM (MORF2-eqv.) P-
MORF2 in culture medium at RT for 1 h, and then 2 × 105 Raji or DG75 cells were 
suspended in 0.4 mL of the premixed solution. The cell suspension was incubated for 24 
or 48 h. For the positive control, cells were firstly incubated with 0.4 mL 0.5, 1, 2 or 5 
µM of 1F5 mAb in culture medium for 1 h, and then washed twice with PBS + 1% BSA, 
followed by resuspension in 0.4 mL of fresh growth medium containing 0.25, 0.5, 1 or 
2.5 µM GAM. The cells were incubated for another 24 or 48 h at 37 °C. Prior to staining, 
cells were washed twice with PBS. All experiments were carried out in triplicate. 
 
3.2.7.3 TUNEL Assay 
 An Apo Direct TUNEL kit (Phoenix Flow Systems, San Diego, CA) was used. 
For the consecutive treatment, 106 Raji cells were suspended in 0.5 mL fresh growth 
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medium containing 0.5 µM Fab'-MORF1. The cells were incubated for 1 h in a 
humidified atmosphere at 37 °C with 5% CO2, and then washed twice with PBS + 1% 
bovine serum albumin (BSA), followed by resuspension in 0.5 mL medium containing 
0.5 or 5 µM (MORF2-eqv.) P-MORF2. The cell suspension was incubated for 24 or 48 h. 
For the premixed treatment, first, 0.5 µM Fab'-MORF1 was mixed with 0.5 or 5 µM 
(MORF2-eqv.) P-MORF2 in culture medium at RT for 1 h, and then 106 Raji cells were 
suspended in 0.5 mL of the premixed solution. The cell suspension was incubated for 24 
or 48 h. For the positive control, cells were firstly incubated with 0.5 mL 0.5 µM of 1F5 
mAb in culture medium for 1 h, and then washed twice with PBS + 1% BSA, followed 
by resuspension in 0.5 mL of fresh growth medium containing 0.25 µM GAM. The cells 
were incubated for another 24 or 48 h at 37 °C. After the treatments, cells were washed 
twice with PBS and fixed with 2% paraformaldehyde in PBS for 1 h at RT. Cells were 
then permeabilized in 70% ethanol overnight at 4 °C. Prior to analysis, nick-end labeling 
was performed following the manufacturer’s protocol. All experiments were carried out 
in triplicate. 
 
3.2.8 Animal Model and Evaluation of In Vivo Anticancer Efficacy 
 Female C.B-17 SCID mice (Charles River Laboratories, Wilmington, MA) at 
about 7 weeks of age were intravenously injected with 4 × 106 Raji cells in 200 µL saline 
via the tail vein (day 0). This animal model represents dissemination, infiltration and 
growth of lymphoma cells in various organs, including the spinal cord which leads to 
hind-limb paralysis and subsequent animal death.36–38 The conjugates, Fab'-MORF1 (57.5 
µg/20 g; 1 nmol MORF1) and P-MORF2/v10 (22 µg/20 g; 1 nmol MORF2), were 
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dissolved in 100 µL PBS and injected via tail vein either consecutively (1-h interval) or 
as a premixture (mixed 1 h prior to treatment). The inoculated mice were divided into 
seven groups: (1) negative control (injected with 200 µL PBS), (2) single administration 
of the consecutive treatment (Cons ×1), (3) single administration of the premixed 
treatment (Prem ×1), (4) consecutive treatment administered three times (Cons ×3), (5) 
premixed treatment administered three times (Prem ×3), (6) single administration of the 
consecutive treatment but with 5× excess P-MORF2/v10 (110 µg/20 g; 5 nmol MORF2) 
to Fab'-MORF1 (Cons (1:5) ×1), and (7) positive control injected with three doses (75 
µg/20 g; 1 nmol Fab'-equivalent per dose) of 1F5 mAb via tail vein. For single-dose 
groups, conjugates were administered on day 1 (24 h after injection of cancer cells); for 
multiple-dose groups, conjugates (or mAb) were given on days 1, 3 and 5. 
 Posttreatment monitoring of the animals was performed twice a day. Body weight 
of mice was recorded every other day. Major aspects of the mice closely assessed 
included: hind-limb paralysis, food/water consumption, vital signs of abnormal 
mobility/activity (e.g., licking, biting, scratching a particular area, vocalizing), and 
physical appearance (e.g., failure to groom, unkept appearance, abnormal resting/hunched 
posters, piloerection). Animals were sacrificed in the following scenarios (whichever 
showed up first): (1) at the onset of (hind-limb) paralysis, and (2) body weight loss 
exceeding 20% of the baseline (one day before the injection of cancer cells). Animals 
without any aforementioned signs were kept until 125 days (after the injection of cancer 
cells) and sacrificed for further analysis. These procedures adhered to the Institutional 
Animal Care and Use Committee (IACUC) protocol #12-11004 of the University of 
Utah. Animals without signs of paralysis/sickness were kept until 125 days and 
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considered long-term survivors. 
 
3.2.9 Magnetic Resonance Imaging (MRI) of Mice 
 To monitor disease progression and treatment efficacy, mice (2–4 per group) were 
scanned by T1-weighted MRI on weeks 4, 5, and 16 after tumor inoculation. Gadobenate 
dimeglumine (MultiHance®; Bracco SpA, Milan, Italy) was used as a contrast agent for 
imaging. Precontrast images were also acquired (for comparison). A typical procedure 
was as follows: first, mice were anesthetized with 1%–2.5% isoflurane (IsoFlo®, Abbott 
Laboratories, Abbott Park, IL) in oxygen from a precision vaporizer, and then mice were 
placed in the prone position at the coil center. A 7-Tesla Bruker BioSpec MRI scanner 
(Bruker Biospin, Billerica, MA) with a 30-cm wide cylindrical bore and a 12-cm gradient 
insert was used. Precontrast images were firstly acquired, and then mice were injected 
with gadobenate dimeglumine via tail vein at 0.3 mmol/kg (100 µL, in physiological 
saline). Twenty minutes after the injection, postcontrast images were acquired. During 
the scanning, mouse body temperature was maintained at 37 °C using a warm-air 
circulation system (SA Instruments, Stony Brook, NY). Respiration was monitored 
continuously. Scanning was performed under the ParaVision® 5.1 software environment. 
Acquisition parameters were as follows: T1-weighted FLASH sequence with 
retrospective gating to suppress breathing artifacts, echo time (TE) 2.9 ms, repetition time 
(TR) 43.2 ms, flip angle 50°, 6 sagittal plane slice with thickness 0.5 mm, matrix 256 × 
256, field-of-view (FOV) 3 cm × 3 cm, 50 repetitions. After the scanning, images were 




3.2.10 Flow Cytometry Analysis of Residual Raji Cells 
 After mice were sacrificed, the following organs/tissues were analyzed by flow 
cytometry for residual Raji cells: bone marrow (femur), mesenteric and inguinal lymph 
nodes, spinal cord, and spleen. Two fluorescently labeled antibodies, R-phycoerythrin 
(PE)-labeled mouse anti-human CD10 (IgG1, κ isotype) and allophycocyanin (APC)-
labeled mouse anti-human CD19 (IgG1, κ isotype) (BD Biosciences, San Jose, CA), were 
used to stain Raji B-cells.39 Single-cell suspensions were prepared from the organs/tissues 
using the following procedures. For bone marrow, fresh femurs were purged with 1 mL 
PBS to obtain cell suspensions. Cells were resuspended in 5 mL red blood cell (RBC) 
lysis buffer and incubated at RT for 5 min. Cells were then washed with 5 mL PBS and 
centrifuged to remove debris, followed by resuspension in 400 µL cold washing buffer 
and equally divided into four tubes: (1) nonstained control, (2) CD10 singly-stained, (3) 
CD19 singly-stained, and (4) CD10/CD19 doubly-stained cells. For the staining, 20 µL of 
each antibody was added to 100 µL cell suspension containing about 106 cells. Cells were 
incubated for 30 min at 4 °C in the dark, and washed with 1.5 mL washing buffer prior to 
analysis. For lymph nodes, spinal cord and spleen, a mechanical method was used. 
Tissues were gently disaggregated with the help of tweezers in a Petri dish containing 1 
mL PBS. The suspensions were passed through a 70-µm FalconTM cell strainer (BD 
Biosciences) to remove large clumps and debris, and then cells were centrifuged and 
resuspended in 5 mL RBC lysis buffer. The rest of the procedures were the same as 





3.2.11 Pathological and Histopathological Examinations 
 Immediately after mice were sacrificed, the following organs/tissues were 
harvested for pathological evaluation: brain, heart, lung, liver, spleen, kidneys, spinal 
cord and lymph nodes. These organs/tissues were fixed in 10% formalin overnight at RT, 
and then transferred and preserved in 70% ethanol. Histopathological examination was 
performed by a blinded veterinary pathologist at ARUP Laboratories (Salt Lake City, 
UT). Sections were cut at 4-µm thickness, mounted on glass slides, and stained by 
hematoxylin and eosin (H&E). 
 
3.2.12 Statistical Analysis 
 All experiments in this study were at least triplicated. Quantified data were 
presented as mean ± standard deviation (SD). Statistical analyses were performed by 
Student’s t-test to compare between two groups, or one-way analysis of variance 
(ANOVA) to compare three or more groups (with p value < 0.05 indicating statistically 
significant difference). Animal survival analysis was performed with the log-rank test 
using the GraphPad Prism 5 software. 
 
3.3 Results and Discussion 
 To verify the concept of hybridization-mediated drug-free macromolecular 
therapeutics, we selected CD20 as a pharmacological target. CD20 is a noninternalizing 
receptor expressed on most NHL malignant B-cells as well as on normal B-cells.40 
However, it is not expressed on plasma cells (effector B-cells) and stem cells. 
Consequently, humoral immunity of patients is not severely affected, and normal 
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numbers of B-cells can be restored after treatment.41,42 Here, we employed an anti-CD20 
Fab' fragment in the therapeutic system and used NHL as a disease model to demonstrate 
the first example of the designed platform. 
 
3.3.1 Design of MORF1 and MORF2 
 The MORF oligos used in this study were 25 bp and about 8.5 kDa (see structure 
in Figure 3.2 and base sequence in Subsection 3.2.1). Their 3' termini were modified with 
a primary amine used for conjugation. The A/T/C/G content was selected to achieve 
optimal binding efficacy and specificity (GC = 35–65%),26 maintain aqueous solubility 
(G < 36%),26 and potentially provide favorable pharmacokinetics (number of C < 7 to 
avoid rapid kidney uptake).27 After the base composition was determined, the sequences 
were generated by a scrambling software to minimize off-target binding with human and 
murine mRNA and further optimized to prevent self-complementarity. 
 
3.3.2 Synthesis and Characterization of Fab'-MORF1 and P-MORF2 
 To prepare the Fab'-MORF1 conjugate (Figure 3.2A), the Fab' fragment from a 
mouse anti-human CD20 IgG2a mAb (1F5)43 was tethered to the 3' end of MORF1 via a 
thioether bond. Optionally, the conjugates were labeled with rhodamine (RHO) for 
imaging studies. Fab'-MORF1 was successfully synthesized as confirmed by HPLC 
(Figure 3.2B) and size	   exclusion chromatography (SEC) (Figure 3.3A); the coupling 
reaction followed a 1:1 stoichiometry as characterized by MALDI-ToF mass 
spectrometry (Figure 3.3B) and UV-visible spectroscopy (Figure 3.3C). The molecular 
weight (MW) of Fab'-MORF1 was about 57.5 kDa. 
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 To prepare the multivalent P-MORF2 conjugates (Figure 3.2C), we first 
synthesized HPMA copolymers containing glycyl-glycine (GG; spacer) side-chains 
terminated in (amine-reactive) thiazolidine-2-thione (TT) groups. These polymer 
precursors (P-TT) were synthesized by reversible addition-fragmentation chain transfer 
(RAFT) polymerization. A polymerizable fluorescein isothiocyanate (FITC) derivative 
was optionally added for imaging studies. Using RAFT polymerization, polymer 
backbones with narrow MW distribution (polydispersity index ≤ 1.15, as determined by 
SEC) were reproducibly synthesized. Furthermore, the amine-derivatized MORF2 oligos 
(MORF2-NH2) were grafted via stable amide linkage to the side chains of the HPMA 
copolymers to produce multivalent P-MORF2. The conjugates were purified and 
characterized by SEC (Figure 3.2D). Three different P-MORF2’s with varying backbone 
MW and valences (number of MORF2 per polymer chain) were synthesized; see Figure 
3.4 for details. The backbone number average molecular weights (Mn) of these 
conjugates ranged from 70 to 136 kDa. Valences of the three P-MORF2 conjugates were 
2, 3 and 10, respectively. 
 
3.3.3 In Vitro Hybridization of Fab'-MORF1 and P-MORF2 
 Hybridization of the two conjugates via MORF1-MORF2 biorecognition was first 
evaluated by UV-visible spectroscopy. The two conjugates were mixed in different ratios, 
and the optical density at 260 nm (contributed by bases) was measured. Upon mixing 
Fab'-MORF1 and P-MORF2, a “hypochromic effect” was observed (Figure 3.5A); the 
OD260 nm reached a minimum when a molar ratio of 1:1 (MORF1:MORF2) was used. 
Such decrease was due to hydrogen bonding between complementary bases that limited 
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the resonance of the aromatic rings. This method was also used to determine 
hybridization of the free, unconjugated MORF1 and MORF2, and the same 
hypochromicity was observed. These results indicated that the function of MORF1-
MORF2 hybridization was preserved after conjugation to Fab' or polymers. 
 Furthermore, the binding of Fab'-MORF1 and P-MORF2 was characterized by 
dynamic light scattering (DLS) (Figure 3.5B). As shown in Figure 3.5B, a significant and 
rapid increase of hydrodynamic size upon mixing the two conjugates (at equimolar 
MORF1/MORF2) was revealed. The fast attainment of stable diameter (~40 nm) 
reflected a fast binding kinetics (< 10 min) of MORF1-MORF2 hybridization of the 
conjugates. Such rapid binding is in agreement with the literature; for example, Mang’era 
et al. reported that a pair of 15-mer complementary MORF oligomers reached near-
maximal binding within 2–5 min.28 This characteristic is favorable for the design of drug-
free macromolecular therapeutics. 
 Circular dichroism (CD) spectroscopy was used to determine the melting 
temperature (Tm) of the Fab'-MORF1/P-MORF2 complex in physiological conditions 
(PBS pH 7.4) (Figure 3.5C). First, a pronounced optical signature (maximum at 260 nm, 
minimum at 210 nm) indicating A-form double helixes44 was obtained upon mixing the 
two conjugates; a similar CD profile was observed when unconjugated MORF1 and 
MORF2 were mixed (Figure 3.6). Second, a thermal melting study was performed to 
analyze the mixture of Fab'-MORF1 and P-MORF2. Data showed that the 
aforementioned CD signature no longer existed at 95 °C; the positive band at 260 nm 
underwent a significant bathochromic shift that produced a peak centered around 275 nm 
(Figure 3.7). The thermo-melting curves shown in Figures 3.5C and 3.7B demonstrate 
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that the signal at 260 nm decreased in a sigmoidal pattern as temperature increased. 
Results of nonlinear regression indicated a Tm value of about 57 to 62 °C. The Tm is 
well above body temperature, suggesting in vivo stability of the binding. 
 
3.3.4 Biorecognition of Fab'-MORF1 and P-MORF2 at B-Cell Surface 
 Human B-cell lymphoma Raji cell line (CD20+)40,45 was used to study the 
biorecognition of Fab'-MORF1 and P-MORF2 at the cell surface. This study was 
performed by confocal fluorescence microscopy. First, exposure of Raji cells to 
rhodamine-labeled Fab'-MORF1 resulted in cell surface red signal (RHO) decoration due 
to Fab'-MORF1 binding to CD20; cells exposed to only FITC-labeled P-MORF2 did not 
show any fluorescent signal (Figure 3.8A). Second, when Raji cells were exposed to both 
fluorescently labeled conjugates (Fab'-MORF1 + P-MORF2), either consecutively or as a 
premixture, the red and the green (FITC) signals were well colocalized at the surfaces of 
B-cells (Figure 3.8B). This observation indicated successful MORF1-MORF2 
hybridization at the cell surface. Figure 3.8C shows the microscopic images obtained 
from two control groups: (1) cells exposed to the premixture of Fab'-MORF1(-RHO) and 
an HPMA copolymer carrying FITC dye but without MORF2 (P-FITC); (2) a 
“preblocking” control achieved by exposing cells consecutively to Fab'-MORF1(-RHO) 
followed by a mixture of P-MORF2(-FITC) with an excess of unconjugated MORF1 (this 
produced HPMA copolymers grafted with double-stranded MORF; P-dsMORF). As 
expected, both control treatments resulted in only the red signal at cell surfaces (Figure 
3.8C) due to absence of a biorecognition pair. Results of these controls confirmed that the 
cell surface biorecognition of Fab'-MORF1 and P-MORF2 was indeed mediated by 
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MORF1-MORF2 hybridization. 	  
3.3.5 Apoptosis Induction of Human NHL B-Cells 
 Apoptosis induction of human B-cell lines (Raji and DG75) was evaluated by 
three methods: caspase-3 activation assay, annexin V/propidium iodide (PI) binding 
assay, and terminal deoxynucleotidyl transferase dUTP nick end-labeling (TUNEL) 
assay. Throughout these studies, anti-CD20 1F5 mAb hyper-crosslinked with a goat anti-
mouse secondary Ab (2° Ab) was used as a positive control	   to imitate the function of 
FcR+ immune effector cells.45 This control partly reflects the therapeutic efficacy of anti-
CD20 mAbs. Results showed that cotreatment with Fab'-MORF1 and P-MORF2, either 
consecutively or as a premixture, effectively induced apoptosis of Raji B-cells (Figure 
3.9). In contrast, single-component treatments with either Fab'-MORF1 or P-MORF2 
failed to initiate apoptosis. A series of control experiments validated the hypothesis that 
MORF1-MORF2 hybridization with concomitant crosslinking of CD20 antigens is 
responsible for the apoptosis induction. Raji cells were exposed to: (1) a mixture of Fab'-
MORF1 and the polymer precursor P-TT; (2) a mixture of Fab' and P-MORF2; (3) 
“preblocked” conjugates whose MORF1 or MORF2 binding sites were blocked by excess 
unconjugated complementary MORFs prior to treatment. None of these treatments 
induced apoptosis (Figure 3.10A), due to absence of MORF1-MORF2 hybridization. 
Furthermore, the apoptosis of a negative control B-cell line (DG75) that does not (or 
minimally) express CD20 was evaluated.46 The levels of apoptosis after cotreatment with 
two conjugates were very low, and similar to that of the untreated cells (Figure 3.10B). 
This result indicated that CD20 binding is a necessary event for apoptosis induction. 
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3.3.6 Optimization of Apoptosis Induction 
 To optimize the therapeutic system, several factors and their impact on apoptosis 
of Raji B-cells were examined, including concentration of conjugates, ratio between two 
conjugates, valence of P-MORF2, and exposure time. We started with a P-MORF2 
containing about 3 oligos per polymer chain (P-MORF2/v3). Results of annexin V/PI 
staining assay indicated that 1 µM Fab'-MORF1 and equimolar P-MORF2/v3 
(MORF1:MORF2 = 1:1) induced about 40% of apoptotic cells (more than 4 fold 
compared to untreated) (Figure 3.9A). When all conditions were kept identical except 
different concentrations of Fab'-MORF1 (and corresponding P-MORF2/v3), a 
concentration-dependent apoptosis induction was observed (Figure 3.9B). Data suggested 
that increasing concentrations of the conjugates from 0.5 µM to 2 and 5 µM (Fab' 
equivalent) resulted in higher levels of apoptosis. The dose-dependent trends were 
observed in both consecutive and premixed treatment regimens as well as in the positive 
control (mAb + 2° Ab). At the highest concentration tested (5 µM), apoptosis induction 
by drug-free macromolecular therapeutics (Fab'-MORF1 + P-MORF2/v3) reached about 
7 fold compared to untreated controls. In addition, the percentage of the apoptotic cells 
induced by mAb + 2° Ab seemed to saturate when the concentration of 1F5 mAb was 
increased from 2 to 5 µM; however, such saturation was not observed in the 
nanomedicine groups. This difference was likely due to P-MORF2 having multimeric 
interactions with targets, in contrast to mAbs with only two binding sites. 
 Furthermore, we examined the influence of the valence of P-MORF2 and the ratio 
between Fab'-MORF1 and P-MORF2 on apoptosis induction of Raji B-cells. A “high-
valence” P-MORF2 containing 10 oligos per chain (P-MORF2/v10) was compared with 
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P-MORF2/v3 (3 oligos per chain). Results showed that when all treatment conditions 
were identical (0.5 µM Fab', MORF1:MORF2 = 1:1 or 1:10), the P-MORF2/v10 
conjugate induced about 2-fold higher levels of apoptosis compared to P-MORF2/v3 
(Figure 3.9C). It is noteworthy that the consecutive treatment of Fab'-MORF1 and P-
MORF2/v10 induced apoptosis more effectively than the positive control (consecutive 
treatment of mAb and 2° Ab). The superior apoptosis induction observed here was likely 
due to multivalency of P-MORF2/v10 resulting in higher avidity to B-cells, as well as 
more effective CD20 clustering.47–49 Interestingly, when Raji cells were exposed to the 
same concentration of Fab'-MORF1 (0.5 µM), whereas a 10-time excess P-MORF2 was 
used (MORF1:MORF2 = 1:10), we did not observe significantly enhanced apoptotic 
levels compared to the treatment with equimolar MORF1/MORF2 (Figure 3.9C). 
Apparently, the MORF1 binding sites on the surfaces of the Fab'-MORF1-decorated cells 
were saturated, which suggests good accessibility of MORFs on the polymer chain for 
hybridization (minimal steric hindrance effect by the polymer chain). The same trends of 
apoptosis induction were observed at different exposure times (6, 24 and 48 h) and from 
different apoptosis assays (caspase-3, annexin V/PI, TUNEL). 
 
3.3.7 Preclinical Evaluation in a Murine Model of Human NHL 
 In vivo therapeutic efficacy of the hybridization-mediated drug-free 
macromolecular therapeutics was evaluated in SCID (C.B-17) mice bearing systemically 
disseminated Raji B-cells. This animal model has a near 100% tumor engraftment rate,36 
and the hind-limb paralysis-free survival time after treatment accurately reflects 
anticancer efficacy.37,38 The conjugates, Fab'-MORF1 and P-MORF2/v10, were injected 
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via the tail vein of mice either consecutively or as a premixture. Mice divided into 
different groups (n = 6–7) received either one or three doses of the nanomedicine, starting 
at 24 h after tumor injection. Doses and treatment regimens were based on literature37,38 
and our previous study with peptide conjugates.50 The animal survival curve is shown in 
Figure 3.11. The negative control mice treated with PBS (n = 8) developed hind-limb 
paralysis in 17–35 days after injection of cancer cells; the median survival time was 24 
days. This observation was in agreement with the literature.38,50 A single administration 
of the consecutive treatment (Cons ×1; MORF1:MORF2 = 1:1) substantially extended 
the animal survival (median survival time: 81 days). A single premixed dose (Prem ×1; 
MORF1:MORF2 = 1:1) had similar efficacy as the consecutive treatment, resulting in a 
median survival of 78 days. When the same dose of Fab'-MORF1 (57.5 µg/20 g) was 
given but followed by 5-times the excess P-MORF2/v10 (MORF1:MORF2 = 1:5), the 
efficacy significantly improved over the treatment with equimolar MORF1/MORF2. A 
single administration of such treatment (Cons (1:5) ×1) produced a 67% survival rate (4/6 
long-term survivors; 125 days). The discrepancy between in vivo and in vitro data (Figure 
3.9C), when excess P-MORF2 was used, can be explained by blood dilution of the 
conjugates, which interferes with binding saturation. 
 Excellent therapeutic efficacy was observed with the groups of mice that received 
three consecutive administration doses (Cons ×3; n = 7) or three premixed administration 
doses (Prem ×3; n = 7). All mice survived until the experimental endpoint (day 125). The 
positive control group (n = 7) that received three equivalent doses of 1F5 mAb (i.v.) had 
an 86% survival rate. Although the difference to the three-dose nanomedicine groups is 
not statistically significant, the anticancer activity of the nanomedicine, unlike mAbs, is 
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independent of immune effector mechanisms such as	   antibody-dependent cellular 
cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).45 These data 
indicated that the direct apoptosis induction strategy can be as effective as the 
immunotherapy while simultaneously reducing the concerns of side effects that are 
mostly associated with ADCC and CDC.20,51 The preclinical evaluation here 
demonstrated the in vivo anticancer efficacy of the hybridization-mediated drug-free 
macromolecular therapeutics and suggested that the therapeutic efficacy can be further 
improved by increasing the number of treatments and/or the dose of the second, 
therapeutically active conjugate (P-MORF2). 
 
3.3.8 Analysis of In Vivo Anti-Lymphoma Efficacy 
 Using the above-mentioned animal model, eradication of Raji cells in SCID mice 
after treatment with Fab'-MORF1 and P-MORF2 was confirmed by MRI, flow cytometry 
and histology. MRI with gadolinium-based contrast at 4–5 weeks after injection of cancer 
cells showed that the control mice treated with PBS developed tumors in the lumbar 
spinal cord, whereas three doses of the nanomedicine prevented tumor development 
(Figure 3.12A). The surviving mice treated with Cons ×3 or Prem ×3 were imaged again 
on week-16; no relapse of the disease was observed. After the mice were sacrificed, flow 
cytometry was performed to analyze residual Raji cells (human CD10+ CD19+) in the 
femoral bone marrow (Figure 3.12B). Two fluorescently labeled antibodies, PE-labeled 
mouse anti-human CD10 and APC-labeled mouse anti-human CD19, were used for flow 
cytometry analysis.39 Results indicated that the paralyzed animals (PBS-treated) bore 
significant amounts of Raji cells in the bone marrow, while all long-term survivors in the 
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therapy groups (Cons ×3 and Prem ×3) were tumor free (Figure 3.12C). Flow cytometry 
also confirmed Raji cells in the spinal cord of paralyzed mice (PBS-treated), but not in 
the long-term survivors (Figure 3.13), which was in agreement with MRI data. 
Furthermore, histological examination disclosed lymphoma dissemination in the liver, 
lung and brain of PBS-treated mice (Figure 3.14). In contrast, no tumors were found in 
the long-term survivors. Importantly, histology suggested no toxicity caused by the 
treatments in any of the tissues evaluated; this corresponded to a stable body weight 
growth of the treated animals. In conjunction these results indicated that the 




 Data presented here validate the proposed concept of hybridization-mediated cell 
surface antigen crosslinking and apoptosis induction. A unique bio-inspired nanomaterial 
system has been demonstrated where extracellular hybridization of oligonucleotide 
analogues translates into innate biological responses. The cellular event (apoptosis) is 
triggered by specific biorecognition defined from the molecular level (i.e., base pairing), 
suitable for the design of precisely targeted therapeutics. The proposed two-step 
(consecutive) treatment offers the opportunity of pretargeting.52–54 This is an advantage 
over the premixed treatment and other single-component anti-CD20 constructs, such as 
rituximab polymers55 and multivalent anti-CD20 Fab'-functionalized polymers.47–49 For 
example, the timing of administration of the crosslinking dose (P-MORF2) can be 
optimized based on biodistribution of the pretargeting dose (Fab'-MORF1), in order to 
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achieve maximal tumor-to-tissue accumulation in individual patients and enable more 
efficient treatment. This approach would also limit potential adverse reactions associated 
with off-target binding, thus being beneficial for the treatment of solid tumors as well as 
disseminated diseases. For blood-based cancers, the pharmacokinetics of Fab'-MORF1 
and the binding kinetics of Fab'-MORF1 to diseased cells can be further studied to 
determine the best timing for P-MORF2 administration. 
 The presented work offers a new strategy in lymphoma treatment by immune-
independent apoptosis induction. This is a potential improvement over currently used 
immunotherapies with type I anti-CD20 mAbs (e.g., rituximab).14,16 Comparing to type II 
anti-CD20 mAbs (e.g., obinutuzumab) that may also induce direct apoptosis,56 our 
nanomedicine approach still possesses two advantages: (1) superior targeting of B-cells 
due to multivalency, and (2) potential for decreased side effects that are associated with 
immune functions. Previously our lab has designed and developed a pilot anti-CD20 
drug-free macromolecular therapeutic system using a pair of pentaheptad peptides that 
formed antiparallel coiled-coil heterodimers as the biorecognition moieties.9,50 The 
binding of CCE and CCK served as the driving force for CD20 clustering and 
concomitant apoptosis induction in malignant B-cells. When the cell surface 
biorecognition and apoptosis were evaluated on Raji cells (using conditions similar to this 
study), we found that a 25-time excess of the second peptide (CCE:CCK = 1:25) was 
required in order to achieve significant efficacy in vitro9 and in vivo50. In contrast, for the 
hybridization-mediated system (Fab'-MORF1/P-MORF2), the treatment with equimolar 
MORF1/MORF2 was sufficient for biorecognition and apoptosis induction (Table 3.1). 
Results of the animal experiments showed that at equivalent doses, a single treatment of 
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Fab'-MORF1 + P-MORF2 (1:1) was significantly more effective than a single treatment 
of Fab'-CCE + P-CCK (1:25) in preventing lymphoma dissemination (Table 3.1). In 
conjunction these data suggested superior binding and accessibility of the MORF oligos 
on the HPMA polymer chains as compared to the coiled-coil forming peptides. In 
addition, for the MORF1-MORF2 hybridization, a rapid binding kinetics was observed 
(~10 min as characterized by DLS; Figure 3.5B in the main article). On the contrary, the 
CCE-CCK coiled-coil formation required a much longer time (~60 min).9 The 
comparison of CCs vs. MORFs clearly indicates that the hybridization system is 
advantageous for the design of drug-free macromolecular therapeutics. Other advantages 
of the MORF oligos include: (1) specific binding due to a well-defined hydrogen bonding 
pattern (i.e., base pairing), (2) charge-neutral property that prevents potential off-target 
effects, and (3) water solubility due to good base-stacking property resulting in favorable 
pharmacokinetics.26 
 Besides lymphomas, the therapeutic conjugates developed here can be used for 
other B-cell-associated diseases such as rheumatoid arthritis, multiple sclerosis, and 
chronic lymphocytic leukemia. The designed platform can be applied to crosslink any 
non- or slowly internalizing receptor (e.g., CD45,57 prostate stem cell antigen58) and 
control different cellular activities.21–23 In addition, other targeting moieties (e.g., aptamer 
instead of Fab')54 can be used to construct various self-assembling antigen crosslinkers. 
Therefore, this work constitutes a new paradigm of nanomaterial-based therapeutics with 
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Figure 3.1  Self-assembling hybrid nanoconjugates for apoptosis induction. (A) General 
design concept of the therapeutic platform. Two nanoconjugates that self-assemble via 
biorecognition can be administered consecutively as pretargeting and crosslinking doses, 
or premixed to form a multivalent construct and used as a single dose. (B) Apoptosis 
induction of B-cells by crosslinking of the CD20 antigens that is mediated by 





Figure 3.2  Synthesis of Fab'-MORF1 and P-MORF2. (A) Scheme of Fab'-MORF1 
synthesis. *SMCC: succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate 
heterobifunctional linker. (B) HPLC analysis of the Fab' fragment (Fab'-SH) of 1F5 mAb 
and the Fab'-MORF1 conjugate; Agilent Zorbax 300SB-C18 column (4.6 x 250 mm) 
eluted with a gradient of buffer A (H2O + 0.1% trifluoroacetic acid v/v) and buffer B 
(acetonitrile + 0.1% trifluoroacetic acid v/v). (C) Scheme of the synthesis of polymer 
precursors (P-TT) and multivalent conjugates (P-MORF2). MA-GG-TT: N-
methacryloylglycylglycine thiazolidine-2-thione (MA-GG-TT). (D) SEC analysis of 
representative P-TT and P-MORF2 (valence = 3); Superose 6 HR10/30 column (acetate 





Figure 3.3  Characterization of Fab'-MORF1. (A) Size exclusion chromatography (SEC) 
analysis of the Fab' fragment (Fab'-SH) of 1F5 mAb and the Fab'-MORF1 conjugate 
using Sephacryl S-100 HR16/60 column eluted with PBS. The profile of Fab'-MORF1 
demonstrates the process of purification by ÄKTA FPLC – the first peak (eluted at 53 
mL) represents the conjugate (collected during purification); the second peak (eluted at 
70 mL) indicates unconjugated MORF1 (removed). Fab'-MORF1 was characterized by 
an earlier elution volume compared to Fab'-SH (56 mL). (B) MALDI-ToF mass spectrum 
of Fab'-MORF1. The major fraction shows that the molecular weight is about 57.5 kDa 
(Fab': ~48.8 kDa, MORF1: ~8.6 kDa); a small fraction of unconjugated Fab' was 
observed. (C) UV-Vis spectra of the purified Fab'-MORF1, unconjugated MORF1, and 
Fab' fragment. Concentrations of all components were 2.5 µM. The Fab'-MORF1 
conjugate was characterized by a combination of absorbance at 260 nm (contributed by 





Figure 3.4  Characterization of P-MORF2. (A) UV-Vis spectra of the SEC-purified P-
MORF2 conjugate (1 mg/mL), unconjugated MORF2 (2.5 µM), and HPMA polymers (P) 
(1 mg/mL). The multivalent P-MORF2 conjugates were characterized by UV absorbance 
at 260 nm (contributed by MORF2). (B) Physicochemical properties of different P-
MORF2 conjugates and their polymer precursors (P-TT) that were synthesized and used 
in this study. Number average molecular weight (Mn) and polydispersity (Pd) were 
determined by SEC. Number of thiazolidine-2-thione (TT) groups per polymer chain 
(TT/P) was determined by UV absorbance at 305 nm; number of FITC per chain 
(FITC/P) was determined by absorbance at 495 nm; number of MORF2 oligo per chain 
(MORF2/P) was determined by UV absorbance at 260 nm. (C) Size exclusion 
chromatography (SEC) analysis of P-MORF2 #3 and its P-TT polymer precursor by 
ÄKTA FPLC; Superose 6 HR10/30 column (acetate buffer pH 6.5 + 30% acetonitrile 




Figure 3.5  In vitro hybridization of Fab'-MORF1 and P-MORF2. (A) Hypochromic 
effect upon hybridization of Fab'-MORF1 and P-MORF2 as analyzed by UV-Vis. The 
optical density (OD) at 260 nm decreased when the two conjugates were mixed (in 
different ratios). (B) Effective hydrodynamic diameters of the two conjugates and their 
mixture (equimolar MORF1/MORF2; tested at different times after mixing) as 
characterized by dynamic light scattering. The valence of P-MORF2 was 3. Statistics, 
unless otherwise indicated, was performed by comparing the mixture with P-MORF2 (* p 
< 0.05; ** p < 0.005; n.s., no significant difference). (C) CD thermal melting curve of the 
hybridized Fab'-MORF1/P-MORF2. The molar ellipticity (θ) at 260 nm underwent a 
sigmoidal decrease as temperature increased. The melting temperature (Tm) resulted 
from fitting the data to a logistic function using nonlinear regression (GraphPad Prism 5 
software). All experiments were performed at physiological conditions (PBS, pH 7.4). 

















Figure 3.6  CD spectra of free, unconjugated MORFs, the conjugates, and their mixtures. 
All components were dissolved in PBS (pH 7.4) at 50 µM MORF equivalent 
concentration. The y-axis shows molar ellipticity (θ). (A) Free MORF1, MORF2, and the 
equimolar mixture of both. When mixed, an optical signature (maxima at 260 nm, 
minima at 210 nm) indicates that A-form double helixes were formed. (B) Comparison of 
P-MORF2 (valence = 3) with free MORF2. An identical spectrum was observed. (C) 
Comparison of the Fab'-MORF1 conjugate with free Fab' fragment and free MORF1. The 
conjugate appears to have the combined optical signatures of Fab' and MORF1. (D) 
Mixing P-MORF2 with either free MORF1 or Fab'-MORF1 (equimolar MORF1/MORF2 
concentrations) shifted the CD spectrum from that of the single-stranded MORF2 to that 
indicating A-form double-stranded oligos. Such spectral shift suggested that the function 








Figure 3.7  Analysis of melting temperature (Tm) of the Fab'-MORF1/P-MORF2 
hybridization by CD spectroscopy. (A) CD spectra of the mixture of Fab'-MORF1 (5 µM 
MORF1-eqv.) and P-MORF2/v3 (5 µM MORF2-eqv.; valence = 3) in PBS (pH 7.4) at 
different temperatures. When temperature increased from 25 °C to 60 and 95 °C, the 
positive band at 260 nm underwent a bathochromic shift that produced a peak centered 
around 275 nm. Molar ellipticity (θ) at 260 nm was used in the following thermal melting 
studies. (B) CD thermal melting curve of the hybridized Fab'-MORF1/P-MORF2. A 
sigmoidal decrease of θ at 260 nm was observed as temperature increased. Data are 
presented as mean ± SD (n = 3). These data were fitted to a logistic function to obtain 
Tm; results of nonlinear regression indicated Tm = 60–62 °C. The forward scan 
(increasing temperature) analysis as shown here gave similar results as the reverse scan 






Figure 3.8  Biorecognition of Fab'-MORF1 and P-MORF2 at the B-cell surface. Confocal 
microscopic images of Raji B-cells (CD20+) exposed to Fab'-MORF1 (labeled with 
rhodamine; red) and P-MORF2 (labeled with FITC; green; valence = 2) are shown. 
Trans: images acquired under transmitted light, R: red channel, G: green channel. (A) 
Cells exposed to only Fab'-MORF1 (0.4 µM) or P-MORF2 (0.4 µM, MORF2 equivalent). 
(B) Cells exposed to the mixture of Fab'-MORF1 (0.4 µM) and P-MORF2 (0.4 µM, 
MORF2 equivalent) (Premixed), or Fab'-MORF1 first, followed 1 h later by P-MORF2 
(Consecutive). (C) Control studies: (left panel) cells exposed to a premixture of Fab'-
MORF1 (0.5 µM) and polymer precursors labeled with FITC (P-FITC; excess amount); 
(right panel) cells exposed consecutively to Fab'-MORF1 (0.5 µM) and P-MORF2 









Figure 3.9  Apoptosis induction of Raji B-cells. Percentage of apoptotic cells were 
analyzed by annexin V/PI binding and quantified by flow cytometry. Incubation time was 
48 h. (A) Untreated: cells in culture medium; mAb + 2° Ab: 1F5 mAb (1 µM) followed (1 
h later) by goat anti-mouse secondary Ab (0.5 µM); Fab'-MORF1: single-component at 1 
µM; P-MORF2: single-component of P-MORF2/v3 at 1 µM (MORF2-eqv.); 
Consecutive: Fab'-MORF1 (1 µM) followed (1 h later) by P-MORF2/v3 (1 µM); 
Premixed: premixture of Fab'-MORF1 (1 µM) and P-MORF2/v3 (1 µM). Statistics, 
unless otherwise indicated, were performed by comparing each group with untreated (*** 
p < 0.0001; n.s., no significant difference). (B) Treatments with different concentrations 
of Fab'-MORF1 (as indicated) and corresponding P-MORF2/v3 (at equimolar 
MORF1/MORF2). ** p < 0.005; n.s., no significant difference. (C) Treatments with 
different valences of P-MORF2 (3 or 10 MORF2 per polymer chain) and different 
MORF1:MORF2 molar ratios (1:1 or 1:10). Cons: consecutive treatment of two 
conjugates; Prem: premixture of two conjugates. Concentration of Fab'-MORF1 was 0.5 
µM. P-MORF2: single-component treatment with P-MORF2/v3 or P-MORF2/v10 at 5 
µM (MORF2 equivalent); mAb + 2° Ab: 1F5 mAb (0.5 µM) followed by goat anti-mouse 
secondary Ab (0.25 µM). Statistics, unless otherwise indicated, were performed by 
comparing each “high-valence” group with the corresponding “low-valence” group (** p 





























Figure 3.10  Control studies of in vitro apoptosis by annexin V/PI binding assay. (A) 
Apoptosis induction of Raji B-cells (high levels of CD20 expression). Incubation time 
was 48 h. (B) Apoptosis induction of DG75 B-cells (minimal or no CD20 expression). 
Incubation time was as indicated. The following indications apply to both figures – 
Untreated: cells in culture medium; mAb + 2° Ab: 1F5 mAb (0.5 µM) followed (1 h later) 
by goat anti-mouse secondary Ab (0.25 µM); Fab'-MORF1: single-component at 0.5 µM; 
P-MORF2: single-component of P-MORF2/v3 at 0.5 µM (MORF2 equivalent); 
Consecutive: Fab'-MORF1 (0.5 µM) followed (1 h later) by P-MORF2/v3 (0.5 µM 
MORF2-eqv.); Premixed: premixture of Fab'-MORF1 (0.5 µM) and P-MORF2/v3 (0.5 
µM MORF2-eqv.); Fab'-MORF1 + P-TT: premixture of Fab'-MORF1 (0.5 µM) and the 
polymer precursor P-TT #2 (1 mg/mL); Fab'-SH + P-MORF2: premixture of free Fab' 
(0.5 µM) and P-MORF2 (0.5 µM MORF2-eqv.); Fab'-MORF1 + P-dsMORF: 
consecutive treatment (1-h interval) of Fab'-MORF1 (0.5 µM) and “preblocked” P-
MORF2 (~1 mg/mL) whose MORF2 binding sites were blocked by excess free MORF1 
(1 h before treatment); Fab'-dsMORF + P-MORF2: consecutive treatment (1-h interval) 
of “preblocked” Fab'-MORF1 (0.5 µM) whose MORF1 binding sites were blocked by 
excess free MORF2 (1 h before treatment) and P-MORF2 (0.5 µM MORF2-eqv.). 
Apoptotic cells percentage was quantified by flow cytometry. Data are presented as mean 









Figure 3.11  Therapeutic efficacy of the nanomedicine against systemic lymphoma in 
mice. Four million Raji B-cells were injected via tail vein on day 0; incidence of hind-
limb paralysis or survival of mice was monitored until day 125. One-dose treatment on 
day 1; three-dose treatment on days 1, 3, and 5. PBS: mice injected with PBS (n = 8); 
Cons ×1: consecutive treatment of Fab'-MORF1 and P-MORF2/v10, one-dose (n = 7); 
Prem ×1: premixture of Fab'-MORF1 and P-MORF2/v10, one-dose (n = 7); Cons (1:5) 
×1: consecutive treatment, MORF1:MORF2 = 1:5, one-dose (n = 6); Cons ×3: three 
doses of consecutive treatment (n = 7); Prem ×3: three doses of premixture (n = 7); 1F5 
mAb ×3: three doses of 1F5 mAb (n = 7). The paralysis-free survival of mice is presented 
in a Kaplan-Meier plot. Numbers of long-term survivors in each group are indicated (if 






Figure 3.12  Eradication of Raji cells in mice. Mice i.v. injected with 4 × 106 Raji B-cells 
on day 0 were exposed to different treatments – PBS: mice injected with PBS; Cons ×3: 
consecutive treatment of Fab'-MORF1 and P-MORF2/v10 on days 1, 3 and 5; Prem ×3: 
three doses of the premixture of Fab'-MORF1 and P-MORF2/v10 on days 1, 3 and 5. (A) 
Postcontrast T1-weighted sagittal MRI focusing on the lumbar spine of mice. A 
heterogeneous appearance and irregularly shaped masses indicating tumor nodules (red 
arrows) were observed in the spinal cord of control mice (PBS, n = 4), but not in the 
treated mice (Cons ×3 and Prem ×3, n = 4). (B) Flow cytometry analysis of residual Raji 
cells in the bone marrow (BM) of the PBS-treated, paralyzed mice (PBS) and the 
nanomedicine-treated, surviving mice (Cons ×3, Prem ×3). Bone marrow cells isolated 
from the femur of mice and Raji cells from culture flasks (upper right panel) were stained 
with PE-labeled mouse anti-human CD10 and APC-labeled mouse anti-human CD19 
antibodies. (C) Quantitative comparison of % Raji cells (human CD10+ CD19+) in the 
bone marrow of control mice (PBS, n = 6) and the nanomedicine-treated mice (Cons ×3 
and Prem ×3, n = 7 per group) as analyzed by flow cytometry. Each data point represents 
an individual mouse; mean % is indicated. Statistics were performed by Student’s t-test 









Figure 3.13  Flow cytometry analysis of residual Raji B-cells in different organs/tissues. 
(A) Cells isolated from the inguinal and mesenteric lymph nodes (LN) of mice. (B) Cells 
isolated from the spinal cord (SC) of mice. These cells were stained with PE mouse anti-
human CD10 and APC mouse anti-human CD19 antibodies; upper right quadrant (CD10+ 
CD19+) represents Raji cells. Results indicated that the PBS-treated, paralyzed mice 
(PBS) bore Raji cells in both LN (n = 6) and SC (n = 3), while the long-term survivors in 





Figure 3.14  Histopathological examination. (A) Control mice that were injected with 
Raji cells and treated with PBS developed metastatic tumors in the liver (2 mice found 
with tumors/4 mice examined), lung (3/4), and brain (1/4), as demonstrated by invasion 
of monomorphic lymphoma cells (red asterisks) and disruption of normal tissue 
architecture. (B) Three doses of the consecutive treatment of Fab'-MORF1 and P-
MORF2 (Cons ×3) resulted in no evidence of lymphoma invasion (0/3, for all organs). 
(C) Three doses of the premixed treatment (Prem ×3) prevented lymphoma dissemination 
(0/3, for all organs). Hematoxylin and eosin (H&E)-stained tissue specimens were 
examined by a blinded veterinary pathologist. No toxicity of the treatment was suggested 









Table 3.1  Comparison of anti-B-NHL efficacies (coiled-coil vs. morpholino). 
In Vitro – Apoptotic Index* 
 CCE/CCK MORF1/MORF2 
Consecutive 
(1 µM, valence=9) (0.5 µM, valence=3) (1 µM, valence=3) (0.5 µM, valence=9) 
12% 23% 37% 50% 
Premixed 
(1 µM, valence=9) (0.5 µM, valence=3) (1 µM, valence=3) (0.5 µM, valence=9) 
16% 17% 39% 43% 
In Vivo – Median Survival Time† 
 CCE/CCK MORF1/MORF2 
Consecutive 
(1 nmol, 1:25) (1 nmol, 1:1) 
50 days 81 days 
Premixed 
(1 nmol, 1:25) (1 nmol, 1:1) 
55 days 78 days 
*Apoptotic index (%) of Raji cells assessed by annexin V assay. Concentrations of Fab' and 
valences of polymer conjugates are listed; comparison at time intervals corresponding to 
maximum apoptosis. 









A TWO-STEP PRETARGETED NANOTHERAPY FOR CD20 
CROSSLINKING MAY ACHIEVE SUPERIOR ANTI- 




 The use of rituximab, an anti-CD20 mAb, in combination with chemotherapy is 
the current standard for the treatment of B-cell lymphomas. However, because of a 
significant number of treatment failures, there is a demand for new, improved 
therapeutics. We designed a nanomedicine that crosslinks CD20 and directly induces 
apoptosis of B-cells without the need for toxins or immune effector functions. The 
therapeutic system comprises a pretargeting component (anti-CD20 Fab' conjugated with 
an oligonucleotide1) and a crosslinking component (HPMA copolymer grafted with 
multiple complementary oligonucleotide2). Consecutive treatment with the two 
components resulted in CD20 clustering on the cell surface and effectively killed 
malignant B-cells in vivo. Here, to enhance therapeutic efficacy, a two-step pretargeting 
approach is employed. We show that the time lag between the two doses can be 
optimized based on pharmacokinetics and biodistribution of the Fab'-oligonucleotide1 
conjugate. In a mouse model of human non-Hodgkin lymphoma (NHL), increasing the
1This chapter is adapted from the following publication: T.-W. Chu, R. Zhang, J. Yang, M. P. Chao,     
P. J. Shami and J. Kopeček. A two-step pretargeted nanotherapy for CD20 crosslinking may achieve 
superior anti-lymphoma efficacy to rituximab. Theranostics. 2015; 5(8): 834–846. Ivyspring. 
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time lag from 1 h to 5 h resulted in dramatically improved tumor growth inhibition and 
animal survival. When the 5 h interval was used, the nanotherapy was more efficacious 
than rituximab and led to complete eradication of lymphoma cells with no signs of 
metastasis or disease recurrence. We further evaluated the nanomedicine using patient 
mantle cell lymphoma cells; the treatment demonstrated more potent apoptosis-inducing 
activity than rituximab hyper-crosslinked with secondary antibodies. In summary, our 
approach may constitute a novel treatment for NHL and other B-cell malignancies with 
significant advantages over conventional chemo-immunotherapy. 
 
4.1 Background 
 Non-Hodgkin lymphoma (NHL) is a prevalent cancer with an around 70,000 
projected new cases in 2014 in the United States.1 Approximately 85% of NHLs arise 
from B-lymphocytes, and the rest are of T-cell origin. Rituximab, an anti-CD20 
monoclonal antibody (mAb), was approved in 1997 for the treatment of B-cell NHL and 
remains one of the best-characterized antibodies in cancer immunotherapy.2 The current 
standard for the treatment of most B-cell NHLs is rituximab in combination with 
chemotherapy. However, in spite of significant success with this approach, primary 
resistance and relapse remain a problem.3 This has been attributed to the inability of 
immune effector cells to hyper-crosslink ligated mAbs,4,5 and Fc receptor (FcR)-mediated 
endocytosis6 or “trogocytosis”7 of CD20 antigens. These clinical problems warrant the 
development of new, improved therapeutic strategies. 
 CD20 is one of the most reliable biomarkers of B-lymphocytes. It is a 
noninternalizing8 or slowly internalizing9,10 receptor, highly expressed on the surfaces of 
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most malignant B-cells, as well as normal B-cells. However, CD20 is not expressed on 
stem cells and mature plasma cells.11 Consequently, therapeutics targeting CD20 are safe 
because normal B-cells can be restored after treatment. It is a well-established fact that 
crosslinking of CD20 at the surface of B-cells induces apoptosis.12 One widely accepted 
model suggests that when CD20-bound antibodies are hyper-crosslinked by FcR-
expressing immune effector cells (e.g., macrophages, natural killer cells), the clustered 
CD20 tend to redistribute at the cell surface and become localized to lipid rafts.13 Such 
events mediate the interaction of CD20 with Src-family kinases that are also located in 
lipid rafts, and trigger apoptotic signaling.14 Without hyper-crosslinking, apoptosis 
initiated by ligated mAbs is very limited.15 
 Based on the above-mentioned mechanism, we designed a biomimetic therapeutic 
system (Figure 4.1) that crosslinks CD20 and directly induces apoptosis of lymphoma B-
cells without the need for chemotherapeutic agents, toxins or immune effector functions. 
The therapeutic system is composed of two macromolecular conjugates: (1) Fab'-
MORF1: anti-CD20 Fab' attached to a morpholino oligonucleotide, MORF1, and (2) P-
MORF2: a linear N-(2-hydroxypropyl)methacrylamide (HPMA) polymer (P) backbone 
grafted with multiple copies of the complementary oligonucleotide, MORF2. We have 
previously shown that exposure of the human NHL B-cell line Raji to the first conjugate 
(Fab'-MORF1) decorated the cell surface with MORF1 via CD20 binding; further 
treatment of the cells with the second conjugate (P-MORF2) resulted in MORF1/MORF2 
hybridization at the cell surface, which mediated CD20 crosslinking and induced 
apoptosis in vitro and in vivo.16 We named the designed platform “drug-free 
macromolecular therapeutics” because it does not contain small-molecule cytotoxic 
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compounds (e.g., chemotherapeutics) and the individual components do not have 
apoptosis-inducing activity.17,18 This new therapeutic approach aims to selectively target 
B-cells for direct apoptosis induction. It has the potential to improve outcomes currently 
obtained with conventional chemo-immunotherapy. 
 A significant advantage of the designed “two-step” therapeutics (i.e., consecutive 
administration of Fab'-MORF1 followed by P-MORF2) is the opportunity of 
pretargeting. Pretargeting is an approach used in cancer radio-immunotherapy, by which 
targeting functionality and therapeutic modalities are separated in order to achieve 
desirable pharmacokinetic (PK) goals and reduce adverse side reactions.19 With the help 
of modern nanotechnology, the concept of pretargeting has been expanded in recent years 
and applied in such strategies as amplified therapeutic delivery20 and universal targeting 
of different tumor ligands.21 In the work presented here, Fab'-MORF1 and P-MORF2 are 
used as a pretargeting dose and a crosslinking dose (effector), respectively. We 
hypothesized that the time lag between the two doses could be optimized based on PK 
and biodistribution of the first dose (Fab'-MORF1), in order to achieve maximal tumor-
to-tissue accumulation in individual patients. This approach would enable more efficient 
treatment and limit potential side effects associated with off-target binding. 
 In this chapter, we show the development and preclinical evaluation of drug-free 
macromolecular therapeutics for B-cell lymphomas. In vivo therapeutic efficacy was 
evaluated in mice using a luciferase-based imageable model of human B-cell NHL. The 
two-step pretargeting approach was employed where the time lag was optimized after 
determining the PK and biodistribution of Fab'-MORF1. The designed therapeutic system 
was compared with rituximab in mouse xenografts and against patient NHL cells in order 
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to test its potential for clinical translation. 
 
4.2 Materials and Methods 
4.2.1 Preparation of Fab'-MORF1 and P-MORF2 
 A pair of 25 bp morpholino oligonucleotides (MORF1 and MORF2) with 3' 
primary amine modification was purchased from Gene Tools. MORF1 was modified with 
succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) and then 
conjugated to the Fab' fragment of the 1F5 mAb (IgG2a) via thiol-ene reaction. The 
second conjugate was obtained in two steps: The polymeric precursor was first 
synthesized by reversible addition-fragmentation chain transfer (RAFT) 
copolymerization of HPMA and N-methacryloylglycylglycine thiazolidine-2-thione 
(MA-GG-TT). Then, the complementary MORF2 was grafted to the copolymer backbone 
via amide linkage. Both conjugates were purified by size exclusion chromatography.16 
For detailed procedures, see Chapter 3, Subsections 3.2.1 and 3.2.2. 
 
4.2.2 Cell Lines 
 Burkitt’s B-lymphoma cell line Raji was purchased from the American Type 
Culture Collection (ATCC). ATCC confirmed this line tested positive for the presence of 
Epstein Barr viral DNA sequences via PCR. Luciferase-expressing Raji cell line (Raji-
luc) was generated as previously described.22 Raji-luc harbors a dual reporter gene L2G 
(Luc-2A-eGFP) containing a modified firefly luciferase gene joined to eGFP at the 3' 
end. The L2G construct was ligated into the pCDH-CMV-MCS lentiviral cDNA 
expression vector (System Biosciences). 
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4.2.3 Confocal Fluorescence Microscopy 
 Raji cell line was cultured in RPMI-1640 medium (Sigma) supplemented with 
10% fetal bovine serum (HyClone) at 37 °C in a humidified atmosphere with 5% CO2 
(v/v). Experiments were performed using cells in exponential growth phase. Cells at a 
density of 105 per well were incubated with 0.5 mL rhodamine-labeled Fab'-MORF1 (1 
µM) in culture medium at 37 °C for 1 h; then, the cells were washed twice with PBS prior 
to incubation with 0.5 mL of FITC-labeled P-MORF2 (1 µM, MORF2 equivalent) or 
FITC-labeled P-scMORF2 (1 or 5 µM, MORF eqv.) for another 1 h. Conjugates P-
MORF2 and P-scMORF2 were prepared from the same polymer backbone and had a 
similar valence (~5 oligos/chain). After the incubation, cells were washed twice with 
PBS, and plated onto sterile 35-mm glass bottom dishes with 14-mm microwells (MatTek 
Corporation) for imaging. An Olympus laser scanning confocal microscope (FV 1000) 
was used. Please note that all other experiments (except confocal microscopy) were 
performed with P-MORF2 containing 9 oligonucleotides/chain. For the CD20 
preblocking control studies, all conditions were kept the same, except that the cells were 
pretreated for 1 h with excess amounts of a mouse anti-human CD20 mAb, 1F5.23 
 
4.2.4 Pharmacokinetics and Biodistribution Studies 
4.2.4.1 Radiolabeling of Fab'-MORF1 
 Iodine-125 labeling of the Fab'-MORF1 conjugate was performed immediately 
before use. Na125I (PerkinElmer) was reacted with Fab'-MORF1 in 10 mM PBS (pH 7.4) 
in a precoated iodination tube (Thermo Scientific). The reaction mixture was gently 
stirred at room temperature for 10 min, followed by purification with a Sephadex PD-10 
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column (GE Healthcare) and then a Millipore® ultrafiltration tube (30 kDa cut-off). The 
specific radioactivity of the hot samples was in the range of 1.6–2.2 mCi/mg. 
 
4.2.4.2 Pharmacokinetics 
 Female C.B-17 SCID mice (6- to 8-week-old; 18–20 g; Charles River 
Laboratories) were used in all the following animal experiments in this chapter. Mice (n 
= 5) were intravenously injected with 125I-labeled Fab'-MORF1 (20 µCi per mouse; 1 
nmol Fab' equivalent; 58 µg). At predetermined time intervals, 10 µL blood samples were 
collected from tail vein, and the radioactivity of each sample was measured with a 
Gamma Counter (Packard). The blood pharmacokinetic parameters were analyzed using 
a two-compartment model with WinNonlin 5.0.1 software (Pharsight). 
 
4.2.4.3 Biodistribution 
 Mice were intravenously injected with 4 × 106 Raji cells (in 200 µL PBS) via the 
tail vein. At day 1 or 7 postinoculation, mice were i.v. administered with 125I-Fab'-
MORF1 (20 µCi; 58 µg). Healthy mice (without Raji cells injected) were also given the 
same dose of 125I-Fab'-MORF1 as controls. At 1 h or 5 h postadministration of 
conjugates, mice (n = 4 per group) were sacrificed. Various organs and tissues were 
harvested, weighed, and counted for radioactivity with a Gamma Counter. Uptake of 
conjugates was calculated as the percentage of the injected dose per gram of organs or 





4.2.5 Fluorescence Molecular Tomography (FMT) Imaging 
 Raji cells were stained with 10 µM DiR (1,1'-dioctadecyl-3,3,3',3'-tetramethyl 
indotricarbocyanine iodide) (PerkinElmer) at 37 °C for 20 min. Following staining, cells 
were washed twice with cold PBS. Four million DiR-labeled Raji cells (in 200 µL PBS; 
used immediately after stained) were injected into mice (n = 4) via the tail vein. At 24 h 
postinoculation, the mice were sacrificed, and various organs and tissues were harvested. 
The fluorescence signals of these organs and tissues were measured using an FMT 
camera (PerkinElmer) equipped with a 745 nm laser. Total signal intensities 
(count/energy) of each organ or tissue were quantified. Healthy mice (without tumor) 
were used as controls (n = 4). 
 
4.2.6 In Vivo Anti-Lymphoma Efficacy Study 
 Mice were injected via the tail vein with 4 × 106 Raji-luc cells. One week later, 
the inoculated mice were divided into groups (n = 6 or 7) and administered via the tail 
vein with three doses of different treatments (in 100 µL PBS) every other day. These 
treatments were: (1) PBS (100 µL), (2) Rituxan® (Genentech/Biogen Idec; 75 µg/20 g), 
(3) 1F5 mAb (75 µg/20 g), (4) Fab'-MORF1 (58 µg/20 g; 1 nmol MORF1) followed by 
P-MORF2 (119 µg/20 g; 5 nmol MORF2), 1 h interval, and (5) same as (4) but with 5 h 
interval. Mice were sacrificed at the onset of paralysis or when the body weight dropped 
below 80% of the baseline; otherwise, the mice were maintained until 125 days and 





4.2.7 Bioluminescence Imaging 
 Imaging of luciferase-expressing Raji lymphoma was performed in vivo and ex 
vivo, as previously described.22 Female C.B-17 SCID mice (6- to 8-week-old; 18–20 g; 
Charles River Laboratories) were intravenously engrafted with 4 × 106 Raji-luc cells via 
the tail vein and underwent different treatments as above-mentioned. In vivo imaging was 
performed twice per week on weeks 1–4 and once per week on weeks 5–7. Mice were 
anesthetized with 2% (v/v) isoflurane gas (IsoFlo®, Abbott Laboratories) in oxygen from 
a precision vaporizer and intraperitoneally injected with 3 mg firefly D-luciferin 
(Biosynth). At 15 min postinjection of luciferin (a predetermined time interval, with 
maximal luciferase signal intensity), mice were scanned in the prone position. Xenogen 
IVIS® Spectrum (Perkin Elmer) was used, with 1 min exposure time, medium binning, 
and 1 f/stop. Images were acquired and analyzed under the Living Image® (Perkin Elmer) 
software environment. Region of interest (ROI) was selected by drawing contours to 
include the whole mice. Luciferase light unit was quantified in average radiance 
(photons/sec/cm2/sr). For ex vivo analysis, mice were injected with 3 mg luciferin 12 min 
prior to being sacrificed. Various organs and tissues (heart, liver, spleen, kidney, lung, 
intestine, stomach, muscle, brain, spinal cord, femur, tibia, and mesenteric and inguinal 
lymph nodes) were harvested for imaging. Acquisition parameters were as follows: 1 min 
exposure time, small binning, and 1 f/stop. 
 
4.2.8 Microcomputed Tomography (MicroCT) Imaging 
 In vivo microCT imaging of mice was performed on week 10 after tumor 
implantation. Mice were anesthetized with 2% (v/v) isoflurane gas in oxygen and 
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positioned left lateral on the scanner bed. The hind limbs of mice were scanned using a 
high-resolution microCT Quantum FX system (Perkin Elmer) at 90 keV and 160 mA, 
with a field of vision (FOV) of 24 mm. The acquisition time was 4.5 min. Three-
dimensional (3D) reconstruction of bone architecture was performed under a Quantum 
FX viewer 1.3.0 software environment (Perkin Elmer). All above animal experiments 
were performed according to the protocol approved by the Institutional Animal Care and 
Use Committee (IACUC) of the University of Utah. 
 
4.2.9 Flow Cytometry Analysis of Femoral Bone Marrow Cells 
 After mice were sacrificed, fresh femurs (from both hind limbs) were purged with 
1 mL PBS to obtain bone marrow cells. The suspension was passed through a 70-µm 
FalconTM cell strainer (BD Biosciences), followed by centrifugation (200 g, 5 min) and 
resuspension in 5 mL red blood cell lysis buffer. The suspension was incubated at room 
temperature for 5 min and washed/resuspended in cold PBS. Allophycocyanin (APC)-
labeled mouse anti-human CD19 antibody (IgG1, κ isotype; BD Biosciences) (10 µL) 
was added to 100 µL single-cell suspension containing about 106 cells.24 Cells were 
incubated for 45 min at 4 °C in the dark, and washed with 1.5 mL PBS prior to analysis. 
For flow cytometry, data of 5 × 105 cells were recorded. 
 
4.2.10 Patient Samples Analysis and Apoptosis Assay 
 Leukocytes were isolated from four previously untreated mantle cell lymphoma 
(MCL) patients following ammonium chloride lysis. Two isolates were from lymph node 
biopsies (patients 1 and 2) and two were from the peripheral blood (patients 3 and 4). The 
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isolated cells harbor the t(11;14) chromosomal translocation, a typical MCL phenotype. 
Specimens were collected after informed consent under a protocol approved by the 
University of Utah Institutional Review Board. Primary cells (2 × 105) were suspended in 
0.4 mL RPMI-1640 medium (Sigma) supplemented with 10% fetal bovine serum 
(Hyclone) and treated consecutively (1 h or 5 h interval) with Fab'-MORF1 and P-
MORF2 (at equimolar MORF1/MORF2 concentrations). Untreated cells in the culture 
medium were used as negative controls. For positive controls, cells were treated 
consecutively (identical time intervals) with anti-CD20 mAbs (1F5 or rituximab) and a 
goat anti-mouse secondary antibody (KPL) (molar ratio mAb:2°Ab = 2:1). Incubation 
was carried out for 24 h at 37 °C in a humidified atmosphere with 5% CO2. All 
experiments were conducted in duplicate or triplicate wells. After treatments, cells were 
washed twice with PBS prior to staining by propidium iodide (PI) and FITC-labeled 
annexin V. Staining was performed following the RAPIDTM protocol provided by the 
manufacturer (Oncogene Research Products). Percentage of total apoptotic cells (annexin 
V+ PI+ + annexin V+ PI-) was quantified by flow cytometry where data of 104 cells were 
recorded. 
 
4.2.11 Statistical Analysis 
 Statistics were performed by Student’s t-test to compare two groups, or one-way 
analysis of variance (ANOVA) to compare three or more groups (with p value < 0.05 
indicating statistical significance). Animal survival analysis was performed with the log-





4.3.1 Conjugates Fab'-MORF1 and P-MORF2 were Successfully 
Synthesized 
 The morpholino oligonucleotide pair, MORF1 and MORF2 (Figure 4.1), were 25 
bp and both about 8.5 kDa. Their base sequences were designed to achieve optimal 
binding and solubility, and to avoid self-complementarity and off-target binding with 
human and murine mRNA.16 The 3'-primary amine was used for conjugation to Fab' or 
the polymer backbone. The Fab' fragment was from a mouse anti-human CD20 mAb, 
1F5.23 MORF1 was tethered to the terminal thiol of Fab' via a thioether bond. This site-
specific conjugation would prevent undesirable impact on antigen binding. The coupling 
reaction followed a 1:1 stoichiometry; molecular weight of the conjugate was 57.5 kDa 
(see Chapter 3, Subsection 3.3.2). The hydrodynamic effective diameter of Fab'-MORF1 
was 9 nm, as characterized by dynamic light scattering (Figure 4.2). 
 To prepare the multivalent P-MORF2 conjugate, we first synthesized a copolymer 
of HPMA with MA-GG-TT by RAFT polymerization.25 The copolymer contained 
multiple side chains terminated in (amine-reactive) thiazolidine-2-thione groups and 
possessed a narrow distribution of molecular weights as determined by size exclusion 
chromatography (number average molecular weight, Mn = 136 kDa; polydispersity, Pd = 
1.15). Then, the MORF2 oligonucleotides (containing a 3'-primary amine) were attached 
to the HPMA copolymer side chains via amide bonds. The valence (i.e., number of 
oligonucleotide grafts per polymer chain) of the P-MORF2 was 9. The hydrodynamic 





4.3.2 Fab'-MORF1 and P-MORF2 Self-Assembled on the Surface 
of NHL B-Cells 
 We have previously shown that the MORF1–MORF2 hybridization was fast (< 10 
min) and stable (Tm = 59 °C) after conjugation to Fab' and the polymer.16 When the two 
conjugates were mixed at equimolar MORF1/MORF2 concentration, a near 100% 
binding between Fab'-MORF1 and P-MORF2 was observed (Figure 4.3). This indicated 
highly efficient in vitro self-assembly of the two conjugates. We further determined the 
cell surface biorecognition of the two conjugates by confocal microscopy (Figure 4.4). In 
these experiments, Fab'-MORF1 was labeled with rhodamine (red), and P-MORF2 was 
labeled with FITC (green). Results showed that Fab'-MORF1 successfully decorated the 
surfaces of Raji cells (a human NHL B-cell line) via CD20 binding (Figure 4.4A). 
Preblocking of the CD20 receptors at cell surfaces with an excess amount of 1F5 mAb 
resulted in no red signal decoration after the Fab'-MORF1 treatment. Furthermore, 
consecutive exposure of Raji cells to Fab'-MORF1 followed by P-MORF2 led to both the 
red and green signal decoration at the cell surface (Figure 4.4B). This was mediated by 
the MORF1/MORF2 hybridization, as confirmed by controls using an HPMA copolymer 
labeled with FITC and grafted with multiple copies of a scrambled sequence of MORF2 
(scMORF2). The polymer (P)–scMORF2 control conjugate, even in excess amounts, 
failed to bind to the surfaces of the MORF1-decorated B-cells, due to absence of the 
biorecognition pair. These data suggested that Fab'-MORF1 and P-MORF2 self-assemble 






4.3.3 PK and Biodistribution Suggested an Optimal Time Lag of 5 
Hours for Efficient Tumor Pretargeting 
 We planned to employ the two-step pretargeting strategy in the in vivo therapy 
experiments. Therefore, we analyzed the PK and biodistribution of the pretargeting dose, 
Fab'-MORF1, in order to determine the optimal time lag. The blood radioactivity versus 
time profile of the 125I-labeled Fab'-MORF1 conjugate in mice is illustrated in Figure 
4.5A, and the PK parameters are summarized in Figure 4.5B. Results showed that Fab'-
MORF1 had a terminal plasma half-life of about 5 h, which was longer than the half-lives 
of other Fab' fragments of IgG antibodies.26 This was possibly due to the attachment of 
MORF1 since the PK of antibody fragments without Fc is molecular weight (MW)-
dependent.27 Importantly, at about 5 h after intravenous injection, Fab'-MORF1 reached a 
plateau or steady blood concentration, indicating a suitable timing for P-MORF2 
administration. At that point, most Fab'-MORF1 were cleared from the blood or 
distributed to tumors and tissues. Consequently, at this time point there were minimal 
free conjugates in the blood (unbound to B-cells) that would interfere with the 
hybridization when P-MORF2 is administered. Based on this result, we hypothesized 
that, by using a time lag of 5 h, the pretargeting and second-step targeting can be more 
effective, and the therapeutic efficacy of drug-free macromolecular therapeutics can be 
improved over our previous experimental conditions that used a 1 h interval.16 
 To further support this hypothesis, we compared the biodistribution of Fab'-
MORF1 at 1 h and 5 h (Figure 4.5C). The studies were performed in healthy SCID mice 
(no tumor), as well as SCID mice bearing systemically injected Raji B-cells (tumor). We 
first used fluorescence molecular tomography (FMT) imaging to determine the “hot 
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spots” of Raji lymphoma dissemination (Figure 4.5D); tumors were found abundantly in 
the tibiae, femora, spine, and lymph nodes, which is in agreement with previous reports.28 
Results of biodistribution showed that 5 h after intravenous injection, Fab'-MORF1 
indeed had a better tumor pretargeting efficiency when compared to 1 h postinjection. As 
shown in Figure 4.5C, at 5 h, significantly more conjugates were found in the tibiae, 
femora, and lymph nodes of the tumor-engrafted mice, when compared to 1 h 
postinjection. These organs with substantially more uptake of Fab'-MORF1 matched with 
the Raji lymphoma tumor sites (as determined by FMT; Figure 4.5D). Furthermore, in 
order to define tumor-specific uptake of Fab'-MORF1 (Figure 4.5E), the mean 
radioactivity (125I) in each organ of healthy mice (no tumor; background) was subtracted 
from the radioactivity of corresponding organs of the tumor-bearing mice. The increase 
from the background indicated tumor-specific uptake of the conjugates. This analysis 
suggested significantly more Fab'-MORF1 tumor uptake at 5 h, when compared to 1 h. 
Differences were statistically significant (5 h vs. 1 h) for all lymphoma hot spots (tibia, 
femur, spine, and lymph node) (p < 0.05), but not for organs without tumors (e.g., brain, 
muscle, and intestine). These data confirmed that, in this animal model, an optimal time 
lag of 5 h was suitable for tumor pretargeting of Fab'-MORF1. 
 Interestingly, we observed less accumulation of Fab'-MORF1 at 5 h (vs. 1 h) in 
several major organs, including the liver, kidneys, and lungs (Figure 4.5C), suggesting a 
lower chance of off-target binding after the administration of P-MORF2 (effector). This 
observation further strengthens the rationale of using 5 h as an optimal time lag. The 
biodistribution results were concordant with the PK data, which confirmed significant 
blood clearance of Fab'-MORF1 conjugates from 1 h (~18% ID/g) to 5 h (~5% ID/g for 
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healthy mice). In addition, at 5 h, mice bearing tumors had more conjugates in the blood 
(~10% ID/g) when compared to mice without tumors (~5% ID/g). This phenomenon 
likely resulted from Fab'-MORF1 targeting to the circulating lymphoma B-cells in the 
blood. The biodistribution study was performed on day 7 after tumor inoculation of mice; 
similar trends were also observed at day 1 after tumor inoculation. However, the tumor 
pretargeting efficiency was apparently better on day 7 (Figure 4.5C) when compared to 
day 1, presumably due to more pronounced tumor dissemination and infiltration on day 7. 
 
4.3.4 Pretargeted Nanotherapeutics Showed In Vivo Anti-Lymphoma 
Efficacy that is Superior to Rituximab 
 We used an imageable mouse model of systemically disseminated human B-cell 
lymphoma for preclinical evaluation of drug-free macromolecular therapeutics (Figure 
4.6). Luciferase-labeled Raji cells (Raji-luc) were engrafted intravenously into adult 
SCID mice, which have functional macrophages, natural killer cells and complement. 
One week after tumor inoculation, mice were administered three doses of different 
treatments every other day. Administration time and doses were based on a preliminary 
experiment (Figure 4.7) and our previous studies.16,29 In this animal model, the hind-limb 
paralysis-free survival time reflects the therapeutic efficacy.28–30 Luciferase imaging can 
be performed in vivo to determine tumor engraftment, dissemination, and 
growth/inhibition.22 Here, we employed the two-step pretargeting strategy where Fab'-
MORF1 and P-MORF2 were administered (via the tail vein) consecutively, using 1 h or 5 
h as an interval. These two nanomedicine groups (Cons 1h, Cons 5h) were compared 
side-by-side with the immunotherapy control (1F5 mAb) and a clinically used anti-CD20 
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mAb, rituximab. The animal survival curve is shown in Figure 4.6A. Data showed that 
mice in the placebo group (PBS) rapidly developed hind-limb paralysis within 4 weeks 
after tumor injection; the median survival time was 25 days (0% survival). The designed 
nanomedicine using the 1 h interval (Cons 1h) substantially prolonged animal survival, 
resulting in a median survival of 55 days (14% survival; p = 0.003 compared to PBS). 
The therapeutic efficacy of Cons 1h was comparable to a Fab'-equivalent dose of 
rituximab, which had a median survival of 72 days (17% survival; p = 0.772 compared to 
Cons 1h). Importantly, when the 5 h interval (previously optimized time lag) was used, 
the nanomedicine achieved a significantly improved anticancer efficacy over the 1 h 
treatment (p = 0.008). This optimized treatment regimen (Cons 5h) produced an 83% 
animal survival, which was comparable to the immunotherapy control (1F5 mAb; p = 
0.317) and was significantly better than rituximab (p = 0.009). 
 The in vivo tumor imaging studies (Figures 4.6B and 4.6C) were in agreement 
with the animal survival. Bioluminescent images of mice (on day 25) are shown in Figure 
4.6B. These images demonstrate B-cell lymphoma dissemination in various organs, 
including the spine, femora and tibiae. Furthermore, whole-body bioluminescent 
intensities of mice were quantified to compare groups; the averaged tumor signal versus 
time profiles are illustrated in Figure 4.6C. The negative control mice (PBS) showed a 
rapid progression of tumor burden after 10 days. At day 25, the luciferase signals in the 
PBS group reached saturation. Our drug-free nanotherapeutic using the 1 h interval (Cons 
1h) had a moderate effect of tumor inhibition, which was comparable to rituximab. The 
progression of lymphoma in these two groups (Cons 1h, Rituximab) was significantly 
delayed when compared to the placebo group. When the 5 h interval was used, the 
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nanomedicine (Cons 5h) showed a substantial improvement over the 1 h treatment, 
leading to complete elimination of tumor load in 5 (out of 6) animals. At day 49, the 
average luciferase signal of Cons 5h was similar to the background and was significantly 
lower than Cons 1h (p = 0.004). Although there is no difference between Cons 5h and 
1F5 mAb in tumor inhibition and animal survival, the anti-lymphoma efficacy of the 
designed nanotherapeutic, unlike mAbs, is independent of immune effector mechanisms, 
such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent 
cytotoxicity (CDC),31 and is a direct result of only apoptosis. 
     We also performed three-dimensional microcomputed tomography (3D microCT) 
imaging on the mice that bore Raji-luc lymphoma xenografts and underwent different 
treatments (Figure 4.8). These images were focused on the lumbar spine and hind limbs 
(hot-spots of B-cell NHL metastasis). Results revealed extensive bone destruction in the 
rituximab-treated mice and moderate bone lesions in the mice administered drug-free 
nanotherapeutics using the 1 h interval (Cons 1h). Observed bone heterogeneity was 
extensive in the femur, and in some cases, the proximal tibia (close to the knee joint), 
indicating abnormal osteoclast activation (bone remodeling) stimulated by lymphoma 
metastases.32 However, no signs of bone remodeling were found in mice treated with 
Cons 5h. Taken together, superior anti-lymphoma efficacy was achieved using the 5 h 
interval treatment, when compared to the 1 h treatment and rituximab. These results 
validate our hypothesis that 5 h is optimal for efficient pretargeting/2nd-step targeting in 





4.3.5 Optimized Nanotherapy Completely Eradicates Lymphoma Cells 
in 83% of Mice 
 Ex vivo luciferase imaging was performed to examine tumors in multiple organs 
and tissues (Figure 4.9A). Results were concordant with in vivo imaging and showed that 
Raji-luc lymphoma cells readily infiltrated in the femora, tibiae and lymph nodes of the 
negative control mice (PBS). Extensive infiltration of the spinal cord was also seen in the 
control animals, likely accounting for the occurrence of hind-limb paralysis.28 However, 
most of the surviving mice (5 out 6) that were treated with the nanomedicine using a 5 h 
interval (Cons 5h) were completely tumor-free. Furthermore, we used flow cytometry to 
quantitatively analyze residual lymphoma B-cells in the femoral bone marrow (BM) of 
mice (Figures 4.9B and 4.9C). Raji-luc cells harbor a dual reporter expressing both 
luciferase and green fluorescence protein (GFP).22 We additionally stained the cells with 
an anti-human CD19 antibody24 and analyzed the percentage of GFP+ CD19+ cells. 
Results showed that the negative control mice (PBS) harbored substantial amounts of 
Raji-luc cells in the bone marrow (average 6.4%). The mice treated with the 
nanomedicine using a 1 h interval (Cons 1h) demonstrated significant improvement 
(average 2.7%). In the group that was treated using optimized treatment conditions (Cons 
5h), all mice, including 5 long-term survivors and 1 animal sacrificed on day 105 due to a 
large abdominal tumor, had 0% lymphoma B-cells in the bone marrow. Histopathological 
examination further confirmed that the long-term surviving mice were tumor-free and 
suggested no acute or chronic toxicity caused by drug-free macromolecular therapeutics 
in any of the tissues evaluated, which corresponded to a stable body weight growth. 
These results demonstrate excellent anti-NHL efficacy of the nanotherapeutics with the 
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two components (Fab'-MORF1 and P-MORF2) administered at an optimal interval of 5 
h. A low dose (58 µg × 3) of the pretargeting agent with a 5× excess of effectors was able 
to completely eradicate lymphoma B-cells in mice and was not toxic to normal tissues. 
 
4.3.6 Drug-Free Nanotherapeutic Showed Higher Potency than 
Rituximab in NHL Patient Specimens 
 To further evaluate the clinical potential of the designed nanomedicine, primary 
cells were isolated from 4 mantle cell lymphoma (MCL) patients. MCL is an aggressive 
and incurable subtype of B-cell NHL. We treated the cells consecutively with Fab'-
MORF1 and P-MORF2, as well as rituximab (or 1F5 mAb) hyper-crosslinked with 
secondary antibodies. The purpose of using secondary antibodies is to reproduce the 
function of FcR+ immune effector cells, which partly reflects the in vivo therapeutic 
efficacy of anti-CD20 mAbs.12 Results showed that the designed nanomedicine 
effectively induced apoptosis of MCL cells from all 4 patients (Figure 4.10). The percent 
of apoptotic cells was increased by about 2 fold when compared to the untreated cells. 
When compared to mAbs, the nanomedicine demonstrated superior apoptosis-inducing 
activity to rituximab in all 4 patient samples, and to 1F5 mAb in 1 sample (patient 1). In 
patient 3, we observed an increase of apoptotic index with increasing concentration for all 
compounds tested. The efficacy of 1F5 and rituximab seemed maximized at 1 µM, 
whereas the nanomedicine reached maximal apoptosis induction at a lower concentration 
(0.5 µM). In patient 4, we employed two different time intervals (1 h and 5 h) between 
the treatments. Data showed that, when the time lag was increased from 1 h to 5 h, there 
was no change in efficacy for the nanomedicine. However, for both mAbs, the apoptosis-
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inducing activity dropped when the longer time interval was used. This phenomenon can 
be attributed to Fc-mediated endocytosis of the mAb/CD20 complex, which was 
observed elsewhere by other investigators.6 These results highlight the potential of drug-




 Data presented here validated the proposed concept and showed that the anti-
lymphoma efficacy of the designed nanomedicine was significantly better than rituximab, 
the most frequently used anti-CD20 mAb in the clinic, while also being comparable to 
1F5. In mice, the better efficacy of 1F5 (mouse mAb) when compared to rituximab 
(human/mouse hybrid mAb) was likely due to stronger binding of the Fc region of 1F5 
by (mouse) immune effector cells.33 It will be interesting to compare our approach with 
type II anti-CD20 mAbs (e.g., obinutuzumab) that can also induce direct apoptosis.34 It is 
worth noting that drug-free macromolecular therapeutics depleted tumors by a single, 
well-defined mechanism (apoptosis), whereas the efficacy of mAbs is related to apoptosis 
as well as other effector mechanisms, e.g., ADCC and CDC.31 We believe that the 
superior efficacy of our therapeutic results from the multivalent effect, i.e., the P-MORF2 
conjugate has multimeric interactions with targets, in contrast to mAbs with only two 
binding sites. Our laboratory has previously shown that the multivalency of anti-CD20 
constructs can magnify binding affinity and apoptosis induction by several fold, when 
compared to their monovalent or divalent counterparts.35–37 We have also reported that, in 
addition to valence, the polymer MW had a positive influence on CD20 clustering and 
	  	  
121 
apoptosis.37 Thus, it is possible to further improve the efficacy by using P-MORF2 with a 
higher valence and/or a larger polymer backbone, together with a higher dose of the 
pretargeting agent. 
 This research offers a unique new strategy in lymphoma treatment by direct 
apoptosis induction; no small-molecule toxic drug or immune activation is involved. This 
approach avoids the severe side effects associated with conventional chemo- and 
radiotherapy. It has potential to treat or sensitize chemoresistant malignancies.38 
Compared to immunotherapies using anti-CD20 mAbs, the designed nanomedicine kills 
B-cells without the need for effector cells. This allows us to target diseases that are not 
responsive to immunotherapy, which constitute about half of all NHL patients.3 In the 
clinic, a large population of rituximab nonresponders harbors polymorphism in the IgG 
Fc receptor (FcR) gene,4,5 resulting in failure of effector cells to hyper-crosslink ligated 
mAbs (via Fc–FcR binding). Many other cases of mAb nonresponsiveness or resistance 
are due to CD20 downregulation.5–7 For instance, repeated treatment of mAbs may lead 
to CD20 internalization, which is mediated by the inhibitory FcR expressed on the target 
B-cells themselves.6 In contrast, once the Fc region was removed, Fab' of the same 
antibody was found to be noninternalizing.9 More recently, resistance to rituximab has 
been attributed to “trogocytosis” (shaving of CD20 antigens from the surfaces of B-cells 
by macrophages via the regulatory FcR).7 It is noteworthy that all these mechanisms 
accounting for the nonresponsiveness/resistance are mediated by Fc–FcR recognition 
between mAbs and immune effector cells. Since our design does not contain Fc 
fragments, it may circumvent these mechanisms and benefit patients who do not respond 
to immunotherapy. Furthermore, our nano-sized therapeutic conjugates likely have better 
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mobility and more rapid tumor penetration when compared to immune effector cells, 
which is advantageous to target solid tumors that are commonly seen in lymphoma 
patients. 
 This preclinical study demonstrated the possibility of optimizing the designed 
two-step therapeutics based on PK and biodistribution of the pretargeting dose (Fab'-
MORF1). The optimized time lag was 5 h after i.v. administration (in female SCID 
mice); at this time, most Fab'-MORF1 was cleared from the blood and reached a steady 
plasma concentration (Figure 4.5A) and was efficiently distributed to the tumors (Figure 
4.5E). This approach, in combination with imaging methods or with predetermined 
clinical characteristics of individual patients, can potentially be applied for personalized 
therapy to enhance therapeutic efficacy. Studies have shown that the pharmacokinetic 
profile of rituximab differs between responders and nonresponders.39 Therefore, a two-
step pretargeted platform, which offers flexibility to individualize the PK of therapeutic 
effectors, may benefit patients with inadequate response to mAbs treatment by 
overcoming the pharmacokinetic limitations. For clinical application, the pretargeting 
parameters can be more precisely determined with the aid of mathematical modeling.40 
Our approach may constitute a novel personalized nanotherapy for lymphomas and 
potentially other cancers. 
 Our approach will ultimately require validation and confirmation in properly 
conducted clinical trials. Nonetheless, the selection of CD20 as a pharmacological target 
is validated by extensive prior experience. Our therapeutic effector P-MORF2 will likely 
result in prolonged B-cell depletion compared to mAbs, due to a long blood circulation 
time of the HPMA polymer backbone.41,42 The plasma half-life of P-MORF2 can be 
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further increased using multiblock backbone degradable HPMA copolymers.25,43,44 
Before translation to the clinic, one major issue to be addressed is potential 
immunogenicity of the conjugates. Here, the preclinical evaluation was performed in 
SCID mice, which are severely immunocompromised. It will be important to conduct 
immunogenicity studies using immunocompetent animals. The HPMA polymer is 
nonimmunogenic.45,46 Its safety has been proven in clinical trials.47 Moreover, 
conjugation of immunogens to HPMA copolymers reduces the immunogenicity.45 
Therefore, we anticipate that the P-MORF2 conjugate will have a favorable safety 
profile. Indeed, in the animal experiment performed here, mice were administered three 
doses of the designed therapeutic containing a total of about 18 mg/kg P-MORF2, and no 
toxicity has been observed. In the reported system, we used Fab' from a mouse 1F5 
mAb;23 it is likely that when tested in humans, this system will trigger immune responses 
due to foreign, murine-derived protein fragments (e.g., production of anti-mouse 
antibodies and the associated allergic or hypersensitivity reactions). Such concerns can be 
addressed by switching to a humanized anti-CD20 mAb, e.g., ofatumumab, veltuzumab. 
Alternatively, we shall develop a humanized 1F5 mAb to address this issue. 
 Besides lymphomas, the therapeutic conjugates developed in this study can also 
be used for autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, and 
systemic lupus erythematosus, as well as chronic lymphocytic leukemia (CLL). All these 
diseases have been treated by anti-CD20 mAbs.48,49 Recently, we evaluated the designed 
therapeutics in patient CLL cells, including high-risk patients with the 17p13 deletion.50 
Results showed that our treatment effectively induced apoptosis of CLL B-cells and led 
to subsequent cell death, and was more potent than 1F5 mAb. In summary, we have 
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developed a novel two-step pretargeted nanotherapy for treatments of B-cell 
malignancies. This approach is more direct and effective than type I anti-CD20 mAbs and 
possesses significant advantages over conventional chemo-, radio-, and immunotherapy. 
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Figure 4.1  Drug-free macromolecular therapeutics by a two-step pretargeting approach. 
Two macromolecular conjugates, Fab'-MORF1 and P-MORF2, are administered 
consecutively as the pretargeting dose and the crosslinking dose to induce apoptosis of 
malignant B-cells. 
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Figure 4.2  Hydrodynamic effective diameters of the two conjugates (Fab'-MORF1 and 
P-MORF2) and their precursors (Fab' and P) as characterized by DLS. Samples were 
dissolved in PBS (pH 7.4) and measured at room temperature. NanosphereTM polystyrene 
beads with a diameter of 102 ± 3 nm (STD100 nm) were used as the size standard. Data 
are presented as mean ± SD (n = 3). 
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Figure 4.3  SDS-PAGE analysis of the two conjugates and their mixture. Lane 1, 1F5 
mAb (1.5 µg). Lane 2, protein ladder. Lane 3, Fab' fragment of 1F5 (1.5 µg). Lane 4, 
Fab'-MORF1 conjugate (0.3 µg, 5 pmol). Lane 5, mixture of Fab'-MORF1 (5 pmol) and 
P-MORF2 (5 pmol MORF2 equivalent). Lane 6, P-MORF2 conjugate (5 pmol MORF2 
equivalent). Samples were incubated with 1× Laemmli buffer without reducing reagents 
at 37 °C for 30 min prior to loading; 8–16% polyacrylamide gel. Fab'-MORF1 and P-
MORF2 were mixed in PBS (pH 7.4) at room temperature for 1 h. When mixed, the Fab'-
MORF1 band completely disappeared from the gel, indicating an efficient binding 














Figure 4.4  Biorecognition of Fab'-MORF1 and P-MORF2 at the surface of Raji B-cells. 
Fab'-MORF1 was labeled with rhodamine (red) and P-MORF2 with FITC (green). Trans: 
images under transmitted light, R: red channel, G: green channel. (A) Top panel, Fab'-
MORF1 (1 µM) bound to the surfaces of B-cells. Bottom panel, pretreatment with 1F5 
mAb (10 µM) followed by Fab'-MORF1 (1 µM). (B) Top panel, consecutive exposure to 
Fab'-MORF1 (1 µM) and P-MORF2 (1 µM; MORF eqv.). Bottom panel, polymer grafted 
with scrambled MORF2 (P-scMORF2; 5 µM MORF eqv.) failed to bind to the surfaces 
of the MORF1-decorated cells; scMORF2: 5'-GTATCCTTATTCCACGTTCATTTGT-
3'. Note: P-MORF2 and P-scMORF2 used in this experiment only contained ~5 















Figure 4.5  Optimization of tumor pretargeting time lag by PK and biodistribution. (A) 
The blood radioactivity–time profile of 125I-labeled Fab'-MORF1 in healthy SCID mice 
(n = 5). The closed circles represent the mean radioactivity, expressed as the percentage 
of the injected dose per gram of blood (% ID/g). (B) Two-compartment plasma 
pharmacokinetic (PK) parameters of Fab'-MORF1 in mice. T1/2, α, initial half-life; T1/2, β, 
terminal half-life; AUC, total area under the blood concentration versus time curve; CL, 
total body clearance; MRT, mean residence time; Vss, steady-state volume of 
distribution. (C) Biodistribution of Fab'-MORF1 in healthy SCID mice (no tumor) and 
SCID mice bearing human B-cell lymphoma xenografts (n = 4 per group). Raji cells were 
injected from the tail vein of mice 7 days prior to the study. Mice were sacrificed at 1 h or 
5 h after i.v. injection of 125I-Fab'-MORF1. (D) Fluorescence molecular tomography 
(FMT) analysis of lymphoma B-cells dissemination in mice. Four million Raji cells were 
stained with the DiR dye and injected via the tail vein to SCID mice (n = 4). At 24 h after 
tumor inoculation, organs were harvested for ex vivo imaging. L.N., lymph node. (E) 
Tumor-specific uptake of Fab'-MORF1. Mean radioactivity in each organ of healthy mice 
(no tumor; n = 4) is defined as the background. Tumor-specific uptake was analyzed by 
subtracting the background from the radioactivity of corresponding organs of the tumor-
bearing mice (n = 4 per group). Negative values are shown as zero. All data are presented 





























Figure 4.6  In vivo therapeutic efficacy against systemic B-cell lymphoma. SCID mice 
were injected with luciferase-expressing Raji cells (4 × 106) via the tail vein on day 0. 
Three doses of each treatment were administered on days 7, 9, and 11. PBS: mice injected 
with PBS (n = 6); Cons 1h: consecutive treatment of Fab'-MORF1 and P-MORF2, 1 h 
interval (n = 7); Cons 5h: consecutive treatment of Fab'-MORF1 and P-MORF2, 5 h 
interval (n = 6); Rituximab (n = 6); 1F5 mAb (n = 6). (A) Paralysis-free survival of mice 
presented in a Kaplan-Meier plot. Numbers of long-term survivors in each group are 
indicated. Statistics were performed with log-rank test (* p < 0.05; ** p < 0.005; n.s., no 
significant difference). (B) In vivo bioluminescence images at 25 days after tumor 
injection. Mice were intraperitoneally injected with 3 mg firefly D-luciferin 15 min prior 
to imaging. (C) Whole-body bioluminescence intensity of mice. Data are shown as mean 
± SEM (n = 6 or 7). Statistics were performed by Student’s t-test (** p < 0.005). Black 










Figure 4.7  Preliminary in vivo therapy experiments. SCID mice were injected with 
luciferase-expressing Raji cells (4 × 106) via the tail vein on day 0. Fab'-MORF1 (57.5 
µg/20 g; 1 nmol) and P-MORF2 (119 µg/20 g; 5 nmol MORF2) were i.v. administered 
consecutively, using a 1 h interval. U.T.: Untreated mice (n = 3). D14: Mice given three 
doses of treatments on days 14, 16, and 18 (n = 2). D7: Mice given three doses of 
treatments on days 7, 9, and 11 (n = 2). (A) Whole-body bioluminescence intensity of 
mice. Mice were intraperitoneally injected with 3 mg firefly D-luciferin 15 min prior to 
imaging. Data are shown as mean ± SD. (B) Body weight charts. Data are shown as mean 
± SD. (C) Kaplan-Meier analysis of animal survival. Incidence of hind-limb paralysis or 
survival of mice was monitored until day 125. 
 






































Figure 4.8  Three-dimensional microcomputed tomography (microCT) analysis. Mice 
were intravenously injected with Raji-luc cells and exposed to different treatments as in 
Figure 4.6. Imaging was performed on day 70 and focused on the lumbar spine and hind 
limbs (n = 2 per group). Bone destruction, as a result of lymphoma metastasis, is 
indicated by the red arrow. Bioluminescence images (day 35) of the same mice are shown 














Figure 4.9  Eradication of lymphoma B-cells by drug-free macromolecular therapeutics. 
Mice i.v. injected with Raji-luc cells were exposed to different treatments as indicated in 
Figure 4.6. (A) Representative ex vivo bioluminescent images of the control mice (PBS) 
and the mice treated consecutively with Fab'-MORF1 and P-MORF2 using 5 h as an 
interval (Cons 5h). In vivo images of the same mice are shown alongside. bra: brain, hea: 
heart, lun: lung, liv: liver, spl: spleen, kid: kidney, s.c.: spinal cord, l.n.: lymph node, tib: 
tibia, fem: femur, mus: muscle, sto: stomach, int: intestine. (B) Flow cytometry analysis 
of residual Raji-luc cells in the bone marrow (BM) of mice. BM cells isolated from 
mouse femur and Raji-luc cells (with GFP expression) from culture flasks were stained 
with an APC-labeled mouse anti-human CD19 antibody. (C) Comparison of % 
lymphoma cells in the bone marrow of control mice (PBS) and the nanomedicine-treated 
mice (Cons 1h and Cons 5h) as analyzed by flow cytometry. Each data point represents 
an individual mouse (n = 6 per group); mean % is indicated. Statistics were performed 







Figure 4.10  Drug-free macromolecular therapeutics induce apoptosis of patient MCL 
cells. Two samples were from lymph node biopsies (patients 1 and 2) and two from the 
peripheral blood (patients 3 and 4). Percent apoptotic cells was analyzed by annexin V 
binding and quantified with flow cytometry. Nanomedicine, Fab'-MORF1 followed by P-
MORF2; Rituximab, rituximab followed by goat anti-mouse secondary Ab; 1F5 mAb, 
1F5 followed by goat anti-mouse secondary Ab. Time interval between treatments was 1 
h (unless otherwise indicated). Incubation time was 24 h. Fab' equivalent concentrations 
of treatments were 0.5 µM (for patients 1, 2 and 3) and 1 µM (for patients 3 and 4). Data 
are presented as mean ± SD (n = 2 or 3, independent replicates). Statistics were 
performed by Student’s t-test (* p < 0.05). All treatment groups had significantly higher 







DRUG-FREE MACROMOLECULAR THERAPEUTICS INDUCE 





 A new drug-free nanotherapeutic approach for B-cell malignancies was 
developed. Exposure of B-cells to an anti-CD20 Fab'-morpholino oligonucleotide1 
(MORF1) conjugate decorated the cell surface with MORF1; further exposure of the 
decorated cells to multivalent polymer-oligonucleotide2 conjugates (P-MORF2) resulted 
in CD20 clustering at the cell surface with induction of apoptosis. In this chapter, we 
evaluate this concept in primary chronic lymphocytic leukemia (CLL) cells isolated from 
10 patients. Apoptosis and cytotoxicity were observed in eight samples, including two 
samples with the 17p13 deletion, which suggested a p53-independent mechanism of 
apoptosis induction. When compared to an anti-CD20 monoclonal antibody (mAb), the 
nanotherapeutic showed significantly more potent apoptosis-inducing activity and 
cytotoxicity. This was due to the multivalency effect (8 binding sites per polymer chain) 
of our design in comparison to the divalent mAb. In summary, we have developed a 
novel and potent therapeutic system against CLL and other B-cell malignancies with 
1With kind permission from Springer Science+Business Media this chapter is adapted from the 
following publication: Drug-free macromolecular therapeutics induce apoptosis of patient chronic 
lymphocytic leukemia cells. Drug Deliv Transl Res. 2014; 4(5–6): 389–394. 
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significant advantages over conventional chemo-immunotherapy. 
 
5.1 Background 
 B-cell malignancies are prevalent cancers worldwide.1 Crosslinking of CD20 
receptors at the surface of B-cells initiates apoptosis.2–4 Based on this mechanism, we 
designed a therapeutic system composed of two hybrid macromolecules: (1) a conjugate 
of the Fab' fragment of anti-CD20 1F5 monoclonal antibody (mAb) with a morpholino 
oligonucleotide MORF1; (2) a linear N-(2-hydroxypropyl)methacrylamide (HPMA) 
copolymer grafted with multiple copies of the complementary oligonucleotide MORF2 
(P-MORF2).5 Exposure of a B-cell non-Hodgkin lymphoma line (Raji) to the anti-CD20 
Fab'-MORF1 conjugate decorated the cell surface with MORF1. Further exposure of the 
decorated cells to P-MORF2 resulted in MORF1/MORF2 hybridization, which initiated 
CD20 crosslinking and triggered apoptosis in vitro and in vivo.5 In this design, the 
morpholino oligonucleotide pair serves as a physical crosslinker to cluster CD20 antigens 
at the cell surface. Extracellular hybridization of MORF1/MORF2 translates into innate 
biological responses, i.e., apoptosis. This “drug-free macromolecular therapeutic” 
involves no cytotoxic drug, and the individual parts of the system do not have apoptosis-
inducing activity. The two nanoscale conjugates (Fab'-MORF1 and P-MORF2) can be 
administered consecutively (for pretargeting approaches) or as a premixture. 
 Here, we evaluated the efficacy of drug-free macromolecular therapeutics on 
primary chronic lymphocytic leukemia (CLL) cells isolated from patients. We 
hypothesized that this CD20 receptor crosslinking system is cytotoxic to CLL cells and 
could constitute a new nanomedicine for CLL and other B-cell malignancies. 
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5.2 Materials and Methods 
5.2.1	  Patient Samples and Treatments 
 Peripheral blood mononuclear cells were isolated from 10 untreated CLL patients 
(clinical details summarized in Table 5.1). All samples expressed dim CD20, a typical 
phenotype of CLL. Specimens were collected after informed consent under a protocol 
approved by the University of Utah Institutional Review Board. Cells were suspended in 
RPMI-1640 medium (Sigma, St. Louis, MO) supplemented with 10% fetal bovine serum 
(Hyclone, Logan, UT). Incubation was carried out at 37 °C in a humidified atmosphere 
with 5% CO2. Cells were treated with Fab'-MORF1 and P-MORF2 (at equimolar 
MORF1/MORF2 concentrations), either consecutively (1 h interval) or as a premixture (1 
h, 37 °C). Fab'-MORF1 and P-MORF2 were prepared as previously described.5 
 
5.2.2	  Cytotoxicity and Apoptosis Assays 
 In all experiments, an anti-CD20 mAb (1F5)6 hypercrosslinked with a goat anti-
mouse (GAM) secondary antibody (KPL, Gaithersburg, MD) was used as a positive 
control (molar ratio 1F5:GAM = 2:1). Untreated cells were used as negative controls. All 
experiments were conducted in duplicate or triplicate wells. 
 
5.2.2.1	  Cytotoxicity 
 Viability of cells was determined by Trypan blue staining	   at the indicated time 
points. Alternatively, cells were stained with propidium idodie (PI) and the percentage of 




5.2.2.2	  Annexin V Binding 
 Two hundred thousand cells were suspended in 0.4 mL medium for different 
treatments. Cells were harvested at the indicated time intervals, washed twice with PBS 
prior to staining by propidium iodide and FITC-conjugated annexin V. Staining was 
performed following the RAPIDTM protocol provided by the manufacturer (Oncogene 
Research Products, Boston, MA). 
 
5.2.2.3	  Caspase-3 Activity 
 Two hundred thousand cells were suspended in 0.4 mL medium for different 
treatments. Cells were harvested at the indicated time intervals and washed twice with 
PBS. A PhiPhiLux® kit was used to assay caspase-3 activity using the manufacturer’s 
protocol (OncoImmunin, Gaithersburg, MD). 
 
5.2.2.4	  TUNEL Assay 
 One million cells were suspended in 0.5 mL medium for different treatments. At 
the indicated time points, cells were fixed with 1% paraformaldehyde in PBS (1 h, 4 °C) 
and permeabilized in 70% ethanol overnight at -20 °C. An Apo Direct TUNEL kit was 
used to assay apoptosis using the manufacturer’s protocol (Phoenix Flow Systems, San 
Diego, CA). 
 
5.2.3	  Cell Cycle Analysis 
 Cells were washed twice with PBS after the indicated treatments and 
permeabilized in 70% ethanol overnight at -20 °C. Cells were stained with an excess of 
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PI in PBS, and DNA content was determined by flow cytometry. 
 
5.2.4	  Statistical Analysis 
 All experiments were at least duplicated. Data are presented as mean ± standard 
deviation (SD). Differences were considered significant for p values < 0.05 using the 
Student’s t-test. 
 
5.3 Results and Discussion 
 To evaluate the potential of drug-free macromolecular therapeutics for the 
treatment of chronic lymphocytic leukemia (CLL), cells from 10 patients were obtained 
(Table 5.1). As shown in Table 5.1, these patients fell into different prognostic categories, 
including 2 with the 17p13 deletion. 
 The isolated cells were treated with conjugates Fab'-MORF1 (58.5 kDa; 
equimolar MORF1/Fab') and P-MORF2 (P: 136 kDa; 8 MORF2 per chain), either 
consecutively or as a premixture. The experimental conditions and results of apoptosis 
and cytotoxicity assays are summarized in Tables 5.2 and 5.3, respectively. Results 
showed that both treatment regimens (consecutive and premixed) effectively induced 
apoptosis of CLL cells. Data from 8 patient samples (P1, P2, P4, P6-P10) showed 
significantly higher apoptotic and/or cytotoxic indices in the nanomedicine groups when 
compared to the nontreated cells. A trend of apoptosis induction was also observed in P3 
and P5; however, the changes with the latter samples were not statistically significant. 
Interestingly, the treatment showed activity against the two samples with the 17p13 
deletion (P7 and P8). Deletions of 17p are associated with the loss of one allele of P53 
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and portend a worse prognosis.7 Our results suggest that apoptosis induction by drug-free 
macromolecular therapeutics is p53-independent. It has been reported that the CD20-
crosslinking-mediated B-cell death is a distinct pathway that can bypass mitochondria 
and caspase activation, which could be an advantage in the treatment of chemoresistant 
malignancies.8 This indicates that what we propose has significant advantages over 
conventional chemo- and radiotherapy approaches, especially for high-risk patients with 
the 17p deletion whose disease is particularly difficult to treat. More mechanistic studies 
are needed to further elucidate the pathway(s) leading to apoptosis induction by drug-free 
macromolecular therapeutics. 
 In our experiments, an anti-CD20 mAb hypercrosslinked with a goat anti-mouse 
secondary Ab was used as a positive control in order to reproduce the function of 
immune effector cells.9 This control partly reproduces the therapeutic efficacy of anti-
CD20 mAbs that are used in the clinic (e.g., rituximab). Our drug-free macromolecular 
approach is more effective at apoptosis induction in CLL cells than the mAb control. As 
shown in Tables 5.2 and 5.3, five patient samples (P1, P2, P6, P7 and P9) showed 
significantly higher apoptotic and/or cytotoxic indices in the nanomedicine group when 
compared to the positive control (mAb + 2° Ab). This was likely due to multivalency of 
the P-MORF2 conjugate (8 binding sites per chain) in comparison to the divalent mAb.	  
Our lab10,11 and others12, 13 have previously shown that the multivalency of anti-CD20 
constructs can increase binding affinity and apoptosis-inducing efficiency by several fold, 
when compared to their monovalent or divalent counterparts. We have also reported that, 
in addition to valence, the polymer length (i.e., MW) had a positive influence on CD20 
clustering and apoptosis.4 Therefore, it is possible to further improve the efficacy of this 
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design by using a P-MORF2 conjugate with a higher valence and/or a larger polymer 
backbone. For instance, multiblock backbone degradable HPMA copolymers can be 
synthesized.14–16 This approach can produce P-MORF2 with substantially increased MW 
and valence. 
 We evaluated apoptosis and cytotoxicity from multiple aspects: plasma membrane 
rupture (Figures 5.1A–5.1E), caspase-3 activation (Figure 5.1F), and genomic DNA 
fragmentation (Figures 5.1G and 5.1H). Results consistently showed that the designed 
nanomedicine was effective at inducing apoptosis in CLL cells. In contrast, single-
component treatments with either Fab'-MORF1 or P-MORF2 alone failed to induce 
apoptosis (Figure 5.1E), confirming the necessity to crosslink CD20 in order to trigger 
apoptosis. The effects of the nanomedicine were dose- (Figure 5.1B) and time-dependent 
(Figures 5.1C, 5.1D and 5.1G). In some cases, the mAb does not demonstrate apoptosis-
inducing activity, e.g., in P1, P3, P6 and P8 (as shown in Table 5.2 and Figure 5.1B), 
whereas the nanomedicine is effective. This observation suggests a higher potency of 
drug-free macromolecular therapeutics when compared to mAb treatment. 
 The field of CLL therapy has entered a period of significant change with the 
recent approval of two agents, ibrutinib and idelasilib, targeting the Bruton tyrosine 
kinase and phosphatidylinositide 3-kinase-δ, respectively.17 Mechanistically, both targets 
are related to the B-cell receptor signaling pathway. The drug-free nanotherapeutic 
approach constitutes yet another novel therapeutic approach. It induces apoptosis in the 
malignant cells without the need for cytotoxic compounds or immune system activation. 
It will be interesting to determine whether this strategy synergizes with the new, targeted 
agents. Furthermore, the proposed two-step (consecutive) approach allows the use of 
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pretargeting18,19 For example, the timing of administration of P-MORF2 can be optimized 
in individual patients based on pharmacokinetics and biodistribution of Fab'-MORF1, in 
order to enable more efficient treatment while limiting potential side effects associated 
with off-target binding. We have currently validated this concept in mice bearing B-cell 
lymphoma xenografts (see Chapter 4). With the use of an optimized time lag, a two-step 
pretargeting approach was employed to achieve favorable tumor-to-tissue accumulation, 
which resulted in significantly improved in vivo anticancer efficacy. 
 In summary, we have developed a novel and potent drug-free nanotherapeutic 
approach for the treatment of CLL and other B-cell malignancies. This approach has 
significant advantages over current cytotoxic therapies and immunotherapies. The clinical 
development of our strategy will likely contribute to the ongoing revolution in the 
treatment of these diseases. 
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Figure 5.1  Drug-free macromolecular therapeutics induce apoptosis of patient CLL cells. 
(A) Representative flow cytometric analysis of cells exposed to different treatments and 
stained by propidium iodide (PI) and FITC-labeled annexin V. Nontreated: cells in 
culture medium; Consecutive: Fab'-MORF1 (0.5 µM) followed (1 h later) by P-MORF2 
(0.5 µM; MORF2-eqv.).	   Incubation time was 20 h. Data from patient sample #2. (B) 
Dose-dependent apoptosis induction. Percentage of early apoptotic cells (annexin V+/PI−) 
was quantified by flow cytometry. mAb + 2° Ab: 1F5 mAb followed (1 h later) by goat 
anti-mouse secondary Ab; Consecutive: Fab'-MORF1 followed (1 h later) by P-MORF2; 
Premixed: premixture of Fab'-MORF1 and P-MORF2. Incubation time was 30 h. Data 
from patient sample #8. (C) Time-dependent apoptosis induction. Fab'-equivalent 
concentration was 0.5 µM (applied to D-H). Data from patient sample #6. (D) Time-
dependent cytotoxicity as determined by PI binding. Data from patient sample #6. (E) 
Cell viability as determined by Trypan blue staining. Incubation time was 20 h. Fab'-
MORF1: single-component control at 0.5 µM; P-MORF2: single-component control at 
0.5 µM (MORF2-eqv.). Data from patient sample #1. (F) Representative flow cytometric 
analysis of cells exposed to different treatments and stained by FITC-labeled anti-active 
caspase-3 Ab. Incubation time was 6 h. Data from patient sample #10. (G) Apoptosis as 
analyzed by TUNEL assay. FITC-labeled anti-bromodeoxyuridine (BrdU) Ab stains 
apoptotic cells. Data from patient sample #6. (H) Cell cycle analysis. Cells were 
permeabilized and stained by PI to measure DNA content. SubG1 phase represents 
apoptotic cells. Incubation time was 30 h. Data from patient sample #7. In B-E and G, 
data are presented as mean + SD (n = 2 or 3). Statistics in E and G, unless otherwise 
indicated, were performed by comparing each group with nontreated (** p < 0.005; * p < 





































aSex Rai Stage 
bIgVH 
Mutation CD38 ZAP70 
FISH 
Cytogenetics 
P1 83 F I n/a neg n/a n/a 
P2 76 M I M neg n/a 13q− 
P3 52 M I U neg pos normal 
P4 80 F II n/a pos n/a ts12 
P5 67 M I n/a neg pos 13q− 
P6 59 M II U neg pos 13q− 
P7 72 M I U n/a pos 17p−/11q−/ts12 
P8 60 M I U neg pos 17p−/13q− 
P9 49 F 0 n/a pos neg 13q− 
P10 72 F 0 U neg int 13q− 
IgVH, immunoglobulin heavy variable chain; ZAP70, ζ-chain-associated protein kinase 70; FISH, 
fluorescence in situ hybridization; n/a, not available; neg, negative; pos, positive; int, intermediate; 
ts12, trisomy 12. 
aM, male; F, female. 

























Time Dose Assay 









P1 20 h 0.5 µM Annexin V 30 ± 0.6 27 ± 2.1 48 ± 9.6 
‡49 ± 3.3 
P2 20 h 0.5 µM Annexin V 27 ± 1.4 37 ± 4.4 
‡52 ± 0.8 ‡58 ± 0.6 
P3 20 h 0.5 µM Annexin V 28 ± 4.6 25 ± 3.6 34 ± 6.8 32 ± 7.9
 
P4 20 h 0.5 µM Annexin V 34 ± 4.6 
†54 ± 5.4 †54 ± 5.9 †59 ± 2.8 
P5 20 h 0.5 µM Annexin V 25 ± 8.9 
40 ± 3.0 38 ± 0.1 38 ± 0.1 
1 µM 39 ± 0.2 43 ± 1.5 40 ± 2.3 
P6 
20 h 0.5 µM Annexin V 
61 ± 2.8 64 ± 0.3 ‡69 ± 1.6 ‡72 ± 2.6 
30 h 59 ± 3.9 †76 ± 0.3 ‡78 ± 0.8 †77 ± 0.7 
20 h 0.5 µM TUNEL 24 ± 2.3 
†31 ± 1.5 †36 ± 9.9 ‡42 ± 4.5 
30 h 39 ± 11.0 †58 ± 1.3 ‡71 ± 1.6 †66 ± 6.2 
P7 30 h 0.5 µM Annexin V 41 ± 1.7 
†52 ± 1.4 ‡66 ± 0.3 ‡62 ± 1.1 
P8 30 h 0.5 µM Annexin V 15 ± 1.4 
17 ± 0.8 23 ± 6.0 22 ± 3.3 
1 µM 16 ± 7.5 †30 ± 7.4 †34 ± 4.7 
P9 48 h 0.5 µM Annexin V 46 ± 7.2 
†77 ± 1.0 ‡82 ± 0.1 †78 ± 2.8 
P10 6 h 0.5 µM Caspase-3 10 ± 0.1 17 ± 4.2 
†23 ± 3.5 †21 ± 4.6 
†Significantly higher than nontreated (p < 0.05; Student’s t-test). 



































Time Dose Assay 









P1 20 h 0.5 µM Trypan Blue 38 ± 0.3 
†60 ± 1.3 ‡69 ± 1.9 ‡71 ± 2.1 
P2 20 h 0.5 µM Trypan Blue 59 ± 5.3 
†88 ± 5.0 †82 ± 5.4 †91 ± 0.9 
P4 20 h 0.5 µM 
Trypan 
Blue 52 ± 6.0 63 ± 4.6 76 ± 7.1 
†76 ± 3.9 
PI 49 ± 1.1 53 ± 6.0 †60 ± 2.8 †61 ± 1.3 
P6 20 h 0.5 µM PI 60 ± 1.8 60 ± 2.5 
‡68 ± 0.6 ‡70 ± 3.0 
30 h 63 ± 3.1 †75 ± 0.3 ‡78 ± 0.4 †78 ± 1.8 
P7 30 h 0.5 µM PI 22 ± 6.8 43 ± 2.5 ‡52 ± 1.1 †45 ± 0.7 
P9 48 h 0.5 µM PI 44 ± 0.2 †67 ± 1.4 †69 ± 0.3 †66 ± 0.1 
†Significantly higher than nontreated (p < 0.05; Student’s t-test). 














 Adverse side effects and resistance remain major clinical obstacles for cancer 
chemo-immunotherapy. This dissertation proposes a nanomedicine approach that is 
“drug-free” and “immune-independent” to tackle these problems simultaneously. This 
approach utilizes multivalent cell surface receptor crosslinking constructs to trigger 
apoptosis of cancers specifically and effectively. The designs of two therapeutic 
platforms have been shown. In the first design, multiple targeting moieties (Fab' 
fragments) are tethered to a synthetic polymer for direct apoptosis induction (Chapter 2). 
In the second design, the treatment is two-step. First, cancer cells are marked for death by 
a pretargeting dose; then, the therapeutically active, multivalent effector is administered 
(Chapters 3–5). This two-step strategy allows optimization of the therapy for individual 
subjects. We have shown in a mouse model that the optimized therapy is more 
efficacious than rituximab, a clinically used immunotherapy drug for B-cell lymphomas 
(Chapter 4). This is striking evidence that the anticancer efficacy of receptor-
crosslinking-mediated apoptosis alone may be superior to immunotherapy. We have also 
demonstrated the potential application on other diseases such as leukemias (Chapter 5).  
1This chapter is adapted from the following publication: T.-W. Chu and J. Kopeček. Drug-free 
macromolecular therapeutics – a new paradigm in polymeric nanomedicines. Biomater Sci.	  2015; 3(7): 
908–922. Adapted by permission of The Royal Society of Chemistry. 
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 One of the most important features of drug-free macromolecular therapeutics is 
the lack of low-MW cytotoxic compounds and, thus, the absence of nonspecific 
toxicities. The apoptosis induction is highly specific against the targeted cells, which will 
likely result in a better adverse effects profile when compared to conventional chemo- 
and radiotherapies. The mechanism of receptor crosslinking is unique. For instance, the 
CD20-clustering-mediated B-cell death has been identified as a distinct pathway that can 
bypass mitochondria and caspase activation, which offers the opportunity to treat 
chemoresistant malignancies.1 Besides the drug-free feature, other favorable aspects of 
our design are: (1) the immune-independent feature addresses the concern of mAbs 
nonresponiveness or resistance; (2) multivalency of the polymer conjugates has potential 
to improve therapeutic performance; (3) as mentioned above, the proposed two-step 
treatment is suitable for pretargeting. 
 Distinct from mAb-based immunotherapy, drug-free macromolecular therapeutics 
directly induce apoptosis in diseased cells without the need for immune activation. 
Successful treatment with mAbs requires FcR-expressing immune effector cells 
(macrophages, neutrophils, natural killer cells, etc.) to recognize the Fc region of ligated 
antibodies and trigger immune responses such as ADCC or CDC.2,3 However, a common 
clinical failure of immunotherapy is the inactivation of these effector mechanisms.4,5 For 
instance,	   many rituximab nonresponders harbor polymorphism in the IgG FcR gene, 
which leads to the inability of effector cells to hypercrosslink mAbs that are bound to the 
surfaces of B-cells.4 In the drug-free design, we used synthetic effectors to reproduce and 
enhance the function of immune effector cells. High-fidelity biorecognition pairs are 
introduced externally to replace the Fc–FcR binding. This approach may benefit patients 
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who do not respond to immunotherapies, which constitute about half of all B-NHLs.6 In 
addition, the Fab' conjugates (without Fc) are used for pretargeting. This is advantageous 
because various reported mechanisms attributed to the mAb resistance are directly or 
partly mediated by the Fc–FcR recognition, for example, CD20 downregulation,7,8 
internalization,9,10 and “trogocytosis” (shaving of receptors from cell surfaces by 
macrophages).11 The designed Fc-independent apoptosis induction may circumvent these 
mechanisms, resulting in a potential to target mAb-resistant diseases. Michel and Mattes 
have shown that the 1F5 mAb/CD20 complex becomes noninternalizing when the Fc 
region of the mAb is removed.10 This observation further strengthens our point of view. 
Moreover, mAb therapies may “over-activate” the immune responses, which results in 
adverse side reactions, e.g., hypersensitivity due to complement activation that requires 
discontinuation of treatment and administration of corticosteroids.12 These side effects 
are sometimes fatal (e.g., cytokine storm13 and rituximab-associated lung injury14,15). In 
contrast, our direct apoptosis induction strategy does not rely on immune functions; this 
may ease such concerns. We have demonstrated that, at equivalent doses, the 
MORF1/MORF2 hybridization-mediated drug-free design possesses superior or 
comparable anti-lymphoma efficacies to type I anti-CD20 mAbs (see Chapters 4 and 5). 
These data suggest significant advantages of the drug-free therapeutics paradigm over 
conventional immunotherapies. Mechanistic studies to compare drug-free 
macromolecular therapeutics with Type II mAbs (e.g., obinutuzumab), which may also 
induce direct apoptosis,16,17 will provide further evaluation of the clinical potential. 
 Several previous platforms for CD20 crosslinking and apoptosis induction of B-
cells have been developed.18–24 One strategy is to construct multivalent mAbs or 
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polymer-mAb conjugates. For instance, multimeric rituximab bound to activated 
dextran18 or lipid nanoparticles19 have been synthesized. In Chapter 2, we describe 
multivalent HPMA copolymer – anti-CD20 Fab' conjugates, which successfully induced 
apoptosis of malignant B-cells in vitro. The advantage of such approaches18–22 is the more 
straightforward one-step treatment, likely resulting in better patient compliance. 
However, due to the large size of the antibodies or their fragments, it is difficult to 
synthesize such constructs with high valency (due to steric hindrance). This undesirable 
feature may severely limit the therapeutic efficiency. We have attempted to increase the 
valency by synthesizing branched HPMA copolymer backbones.20 A small amount of 
tetraethyleneglycol dimethacrylate was used as the crosslinker, and copolymers with high 
polydispersity were produced. Consequently, fractionation was required to prepare 
narrowly dispersed copolymers. Other researchers used biological polymers such as 
DNA21 or polypeptides22 as scaffolds to attach antibodies or the smaller size single-chain 
variable fragments (scFv). These polyvalent constructs indeed achieved better efficacies 
than their monovalent counterparts. However, one fundamental difference between these 
single-treatment designs and the “binary system” is that the binary systems have the 
advantage of performing pretargeting. Previously our laboratory has designed and 
developed a pilot “binary” anti-CD20 drug-free macromolecular therapeutic system using 
a pair of pentaheptad peptides (CCE and CCK) that formed antiparallel coiled-coil 
heterodimers as the biorecognition moieties.23,24 When compared to this previous design 
using peptides, the MORF oligos clearly demonstrated faster binding kinetics as well as 
more efficient self-assembly (equimolar MORF1/MORF2 reached binding saturation in 
vitro), therefore resulting in superior apoptosis induction and in vivo anti-lymphoma 
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efficacy (see Chapter 3, Table 3.1). This is because the individual peptide sequences do 
not have a pronounced secondary structure at the physiological pH.25 Fab'-CCE and P-
CCK interact first via hydrophobic and electrostatic interactions, and then, the 
oligopeptides fold into a strong antiparallel coiled-coil heterodimer. Therefore, we aimed 
to identify a biorecognition pair that would bind efficiently at the 1:1 molar ratio. 
Morpholino oligonucleotides were selected due to their fast hybridization, excellent 
binding affinity and stability in plasma, as well as water-solubility.26 
 The results of our study warrant further clinical evaluation of the morpholino 
oligonucleotide mediated drug-free therapeutic system. The selection of the CD20 target 
in this system is validated by extensive prior clinical experience; anti-CD20 “B-cell 
depletion” therapy has been used in the clinic for over 15 years. Before translation to the 
clinic, potential toxicity and/or immunogenicity of the conjugates needs to be carefully 
studied. Note that, here, the preclinical evaluation was performed in SCID mice. It is 
important to follow up immunogenicity studies using immunocompetent animals. 
Properly designed in vivo toxicity experiments with dose escalation also need to be done. 
In addition, in the proposed system, Fab' from a mouse mAb (1F5) is used; therefore, in 
humans, these foreign, murine-derived protein fragments may trigger immune responses, 
e.g., production of anti-mouse antibodies and the associated allergic or hypersensitivity 
reactions. In the future, such issues can be further addressed by producing the 1F5 mAb 
with humanized amino acid sequences or by directly switching to other humanized anti-
CD20 mAbs (ofatumumab, veltuzumab, etc.). 
 In summary, drug-free macromolecular therapeutics constitute a new paradigm of 
polymer-based nanomedicines that are free of toxins and immune activation. Cell surface 
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biorecognition of hybrid nanomaterials translates into innate biological responses, i.e., 
apoptosis. The apoptosis induction is direct (without the help of effector cells) and 
specific (targeted to certain receptors) and suitable for the design of precisely pretargeted 
nanotherapies. This novel approach has significant advantages over conventional chemo-, 
radio-, and immunotherapies. These promising perspectives warrant further developments 
within the same pipeline and may stimulate other designs. Here, we suggest potential 
future directions and provide supporting literature for each direction: 
• Targeting moieties: peptide ligands identified by combinatorial methods,27,28 
oligosaccharides,29,30 and oligonucleotide aptamers.31,32 An aptamer for the B-cell 
receptor has been identified.31 Bifunctional nucleic acids can be produced that 
contain aptamers (targeting moieties) and crosslinkers (binding motifs) on each 
end of one molecule.32 
• Binding motifs: different sequences and lengths (e.g., longer motifs with spacers 
may result in less steric hindrance of binding33), other types of binders such as 
peptide nucleic acids (PNA),34,35 locked nucleic acids (LNA),31,36 and 2'-O-
methyloligoribonucleotides (2'-OMe-RNA).36 
• Polymer backbones (or other carriers): liposomes,37 carbon nanotubes,38 or 
genetically engineered biopolymers (e.g., polypeptides,22 poly-DNA21). Mobility 
and biodistribution of carriers should be characterized. Flexible backbones are 
generally preferred for receptor crosslinking. 
• Different diseases: CD20 crosslinking and B-cell depletion can be used for 
autoimmune disorders such as rheumatoid arthritis,39 multiple sclerosis,40 and 
systemic lupus erythematosus.41 The same approach can potentially be used for 
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antirejection treatment of organ transplants, e.g., rituximab is used off-label for 
kidney transplant recipients.42 
• Cell receptors: potentially any non- or slowly internalizing cell surface antigen 
can be a target, such as CD45 (T-cell, B-cell, macrophage),43 death receptor 4 
(breast and colon cancers, etc.),44 prostate stem cell antigen (prostate cancer),45 
and carcinoembryonic antigen (many tumor types, but not on normal cells).46,47 
The crosslinking of these antigens can induce cell apoptosis. 
• Other directions: crosslinking two different receptors simultaneously to achieve 
synergistic effects (e.g., CD20/CD40,48 CD20/FGFR3,49 CD37/CD20 or 
CD37/CD1937), and designed as a switch for ON-OFF regulation of cellular 
events.44,50 
 For further translation into the clinic, the drug-free therapeutic approach will 
ultimately require validation and confirmation in properly conducted clinical trials, as 
well as carefully designed in vivo biocompatibility/toxicity studies. For applications in 
cancer, the tumor penetration capability of each of the therapy components shall be 
evaluated. It will be interesting to compare the mobility of the nanosized therapeutic 
conjugates with that of the immune effector cells, which have limited penetration into 
solid tumors. In conclusion, we anticipate more designs and research in this exciting new 
field of polymeric nanomedicines. 
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